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Monocytes consist of classical, intermediate, and non-classical monocytes. In 
haematological malignancies, such as multiple myeloma and acute myeloid leukaemia, 
monocytes are affected by both the disease itself and the treatment patients receive. The 
overall aim of this thesis was to explore monocyte subpopulations in clinical settings of 
haematological malignancies by (i) elucidating the important pre-analytical factors to 
properly identify the subsets, (ii) monitoring monocyte regeneration after stem cell 
transplantation in patients with haematological malignancies, and (iii) investigating the 
effects of immunomodulatory drugs on metabolism and cytokine secretion. 
 We demonstrated that K2EDTA, ACD-A, and Li-Heparin blood sampling tubes 
perform similarly regarding the distribution of monocyte subpopulations. In contrast, 
both the monocyte concentration and relative values could be significantly affected by 
choice of blood sampling tubes and decreased sample volume. Our results demonstrate 
that monocytes regenerate very early after stem cell transplantation, before the 
normalisation of other cell populations. This is true for multiple myeloma patients, as 
well for patients with other haematological malignancies, mainly acute myeloid 
leukaemia. The immunomodulatory drugs thalidomide, lenalidomide, and 
pomalidomide, which are therapeutically important in haematological malignancies, 
altered monocyte metabolism, especially when cells were cultured with LPS. 
Lenalidomide had a stronger effect on monocyte metabolism than the other two drugs. 
Furthermore, all three drugs decreased TLR4-induced mediator release, with the 
strongest effect for pomalidomide, whereas lenalidomide, and especially, thalidomide, 
had weaker effects.  
In conclusion, carefully standardizing blood sampling procedures is important to further 
develop monocyte analysis as a clinical tool, and the associations between monocyte 
subset variations and various diseases suggest additional studies should be conducted to 
clarify whether the analysis of monocyte subsets should be incorporated into routine 
clinical handling. IMiDs can alter monocyte metabolism and communication, but the 
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1. INTRODUCTION  
The theoretical background of this thesis is focused on cell-mediated immunity, 
especially on monocytes, and two haematological malignancies, acute myeloid 
leukaemia (AML) and multiple myeloma (MM). 
1.1. THE IMMUNE SYSTEM - A HOST DEFENSE SYSTEM  
The immune system is a complex and interactive network of surface barriers/organs, 
immunoregulatory soluble mediators (e.g., enzymes, histamine, antibodies, cytokines, 
and soluble adhesion molecules) and immune cells [1]. Additionally, the immune 
system is a part of fundamental physiological processes, including development, 
reproduction, and wound healing, and it is important in regulating metabolism and 
functions of the central nervous system and cardiovascular system [1-6].  
The immune system can be divided into innate immunity and adaptive immunity [1, 6], 
but there are multiple interactions between these two systems. The innate immune 
system is crucial for the early detection of foreign invaders and is the first line of 
defence; it also alerts and shapes the adaptive immune system, which involves the 
antigen-specific reactivity of B and T lymphocytes [6]. 
1.1.1. The innate immune system  
The innate immune system can be divided into surface barriers, immunological soluble 
mediators, and cellular components. The plasma components include the complement 
system [7], acute phase proteins (e.g., C-reactive protein, CRP) [8, 9], and cytokines 
[10], including chemokines [11, 12]. The cellular innate immune system [13-15] 
consists of leukocytes, such as polymorph-nucleated granulocytes (e.g., neutrophils, 
basophils, and eosinophils), mast cells, monocytes, macrophages, dendritic cells, natural 
killer (NK) cells, and NK T-cells (NKT). The cells of the innate immune system express 
germ-line-encoded receptors called pattern recognition receptors (PRRs) that bind 
specifically to highly conserved pathogen-associated molecular patterns (PAMPs) only 
present on microorganisms. PAMPs are typical constituents of microbial cell-wall 
components, nucleic acids or metabolic products. PRR-PAMP ligations activate the 
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Figure 1. Illustration of the immune system’s essential components. A) Immunocompetent cells (adapted from 
[16]). B) Pattern recognition receptors (PPR), which are key players in maintaining homeostasis and organism 
defence (adapted from [17]). C) The general immunoglobulin structure. Each immunoglobulin molecule consists 
of two heavy (i) and two light (ii) chains. Both types of chains contribute to the hyper-variable antigen-binding 
region (iii), and the fragment antigen-binding (Fab) component includes both these hypervariable regions. The two 
heavy chains also form a constant part, referred to as the constant or complement-binding Fc region (iv) (adapted 
from [18]). Abbreviations: DAMPs, damage-associated molecular patterns; PAMPs, pathogen-associated 
molecular patterns; PRRs, pattern recognition receptor; ILCs, innate lymphoid cells; MAIT, mucosal-associated 
T-cell; MDSC, myeloid-derived suppressor cells; NKT, natural-killer T-cells.  
innate cell. Endogenous danger molecules, called damage-associated molecular patterns 
(DAMPs), are released or expressed by stressed, damaged, or dying cells, such as uric 
acid, mitochondrial DNA, extracellular ATP, heat-shock proteins (HSPs), amyloid β, 
and S100 molecules, for example, S100A8, also known as myeloid-related protein-8 or 
MRP-8, and S100A9, also known as MRP14, as well as serum amyloid A (SAA), high-
mobility group box 1 protein (HMGB1), and extracellular matrix proteins [19, 20]. 
DAMPs can activate the innate immune system by interacting with PRRs (see Figure 
1b). An overview of the four PRR classes’ important characteristics and the 
corresponding PAMPs and DAMPs are presented in Table 1. The PRRs-
PAMPs/DAMPs cause innate cell activation by initiating signalling through various 
downstream pathways [17, 21, 22]. For example, membrane-bound TLR4 is one out of 
the ten TLRs (TLR1–TLR10) identified in humans and can bind to, and thereby become 
activated by, for example, lipopolysaccharide (LPS), a PAMP expressed by gram-
negative bacteria [21]. Endogenous DAMPs, such as high-mobility group box-1 protein 
(HMGB1), heat-shock proteins (HSPs), histones, and extracellular matrix components 
(e.g., hyaluronic acid and biglycan), can act as TLR4 agonists [21]. 
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Table 1. The four classes of pattern-recognition receptors (PRRs) and their corresponding PAMPs and 
DAMPs. Only some examples within each class are shown (for a comprehensive overview, see reference [17]). 
 









TLR2-2 Peptidoglycan (bacteria) 
Lipoarabinomannan (mycobacteria) 
TLR4 Lipopolysaccharide (LPS) (gram-negative bacteria) 
Fungal mannans (Candida species) 
Envelope proteins (respiratory virus) 
TLR5 Flagellin (flagellated bacteria) 






Fungal mannans (e.g., Candida species) 
Mannose-
binding lectin 
Repetitive oligosaccharides (bacteria and fungi) 
NLRs 
NOD1 Muramyl tripeptide peptidoglycans (gram-negative bacteria) 




RIG-I Short double-stranded dsRNA (e.g., paramyxoviruses) 
MDA5 Long double-stranded dsRNA (e.g., flaviviruses) 
Abbreviations; NLRs, nucleotide-binding oligomerisation domain (NOD) leucine-rich repeat-containing 
receptors; RIG-I helicase receptors, retinoic acid-inducible gene I protein helicase receptors; MAD5, melanoma 
differentiation-associated protein 5. 
TLR4 initiates downstream signalling through the adaptor proteins myeloid 
differentiation primary-response 88 (MyD88) and TIR-domain-containing adaptor-
inducing IFNβ (TRIF) [21]. Both MyD88 and TRIF recruit and activate mitogen-
activated protein kinases (MAPKs) and IκB kinase (IKK), leading to the activation of 
the transcription factor activator protein-1 (AP-1) and nuclear factor κB (NFκB), 
respectively, with the subsequent expression of proinflammatory cytokines [21]. TRIF 
also recruits and activates another cellular kinase, TNF receptor-associated factor 
(TRAF) family member-associated (TANK)-binding kinase 1 (TBK1), leading to the 
synthesis of type I interferon (IFN-I) by activating transcription factor IFN regulatory 
factor 3 (IRF3) [21]. The co-receptor CD14 increases LPS responsiveness by binding 
LPS and promoting LPS transfer to TLR4 [12]. CD14 is either membrane-bound or 
soluble (sCD14) [23]; it can bind several PAMPs and DAMPs (e.g., LPS, peptidoglycan, 
polyinosinic-polycytidylic acid, and DNA) and transfer them to the correct TLR or non-
TLR (e.g., the purinergic P2X7 receptor for ATP) [23].  
Inflammasomes are multimolecular complexes and, when activated, trigger the caspase-
1-dependent proteolytic activation of the inflammatory cytokines IL-1β and IL-18. The 
formation of inflammasomes is initiated a plethora of signals associated with pathogens, 
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sterile inflammation, and metabolic dysfunction and result in the activation of caspase-
1. This leads to the proteolytic activation of IL-1β and IL-18. IL-1β signals through the 
receptor IL-1R. Examples of inflammasomes are NLR3 inflammasome [24, 25]. In 
summary, PAMPs/DAMPs’ ligation to PRRs causes the activation of innate immune 
cells, illustrated by the TLR4 example. A brief overview of the innate cells and some of 
their important effector functions are presented in Table 2. 












• Degranulation, cytokine production/release 
• Neutrophil extracellular traps (NETs/NETosis) 




Eosinophils • Degranulation, cytokine production/release 
• 'Amateur' antigen-presenting cells  
[29, 30] 
 
Basophils • Degranulation (i.e., IgE) 
• 'Amateur' Antigen-Presenting Cells 
[29, 31] 
 
Mast cells • Release of cytokines and mediators that contribute to increased 
vascular permeability and chemoattraction of innate immune cells 
• Migration and cytotoxic responses by T lymphocytes  
• Mast cell extracellular traps (MCETs) 








• Antigen-presenting cells 
• Cytokine production/release 
• Tissue repair 








 M-MDSC  
 E-MDSC 
• Production of immunosuppressive mediators such as indoleamine 







• Professional antigen-presenting cells (APCs)  








• Production of cytokines and inflammatory mediators  
• Professional antigen-presenting cells (APCs) 
[40, 41] 
ILCs family 
 NK cells 
 LTi 
 ILCs1-3 
• Secretory lysosome exocytosis (e.g., perforin)  
• Cytotoxic activity 




Abbreviations: MDSC, myeloid-derived suppressor cells; PMN-MDSC: polymorphonuclear MDSC; M-
MDSC: monocytic MDSC; E-MDSC: early-stage MDSC. pDCs, plasmacytoid DCs; cDCs, conventional DCs, 
mDCs: DCs derived from monocytes. ILCs, innate lymphoid cells; LTi, lymphoid tissue-inducer cells; NBH, B-
cell-helper neutrophils.  
Notably, PRR expression (e.g., TLRs) is not limited to innate immune cells; they also 
seem to be expressed by cells of the adaptive branch of the immune system [44, 45] and 
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can be activated by endogenous or natural ligands, as will be discussed later in this 
thesis. 
The effector functions of innate cells include (i) receptor-mediated endocytosis, 
phagocytosis, macro-pinocytosis for the clearance of microbes, molecular degradation, 
and the presentation of antigenic peptides in a complex with MHC (the latter are 
described in more detail in Section 1.1.2); (ii) degranulation and the extracellular release 
of  cellular contents to eliminate the pathogen (e.g., anti-microbial mediators); (iii) the 
secretion of ‘nets’ interlaced with anti-microbial mediators to capture and prevent 
microbial spread (NETosis, ETosis); (iv) the lysosomal exocytosis of, for example, 
perforin; and finally, (v) cytokine release (e.g., IL-6) to induce acute-phase proteins, 
such as C-reactive protein, the stimulation of antibody production, as well as effector T-
cell development [1, 6, 28, 31, 32, 46].  
1.1.2. The adaptive immune system: T-cells and B-cells 
The inflammatory environment induced by innate immune responses will stimulate cells 
of the adaptive branch of the immune response (B- and T-cells) to proliferate and 
differentiate into cells with a range of functions appropriate for the existing challenge. 
B- and T-cells are derived from multipotent hematopoietic stem cells in bone marrow. 
B-cells differentiate and mature within the bone marrow, while T-cell precursors 
localise to the thymus for the final stages of their maturation. Both these adaptive 
lymphocytes display antigen receptors that result from the recombination, random 
insertion, deletion, and substitution of germline-encoded gene segments, thereby 
securing the diversity of antigen receptors [47]. The repertoire of expressed antigen 
receptors allows B- and T-cells to recognise foreign antigens. This self–nonself 
discrimination is a key feature of adaptive immunity; both B- and T-cells undergo tightly 
controlled and regulated stages during their maturation to secure central tolerance, and 
these steps include clonal deletion/selection, receptor editing, and genetic recombination 
(for a more detailed description, see [48-50]).  
A typical feature of adaptive immune responses is that the effector response occurs later 
than the innate response due to the need for antigen-specific activation, leading to cell 
proliferation and differentiation before the effector response can occur [6]. Furthermore, 
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adaptive immunity involves the ability to remember previous infections, as both T- and 
B-cells produce long-term memory cells capable of responding faster if re-infection with 
the same agent occurs [51, 52]. However, the dogma that immunological memory is 
exclusive to the adaptive immune system has been challenged by evidence that innate 
immunity may also involve retaining memories of previous events (i.e., trained 
immunity) [53]. 
Products of the major histocompatibility complex (MHC) gene bridge the innate 
and acquired immune response: There are two primary classes of major 
histocompatibility complex (MHC) molecules: MHC classes I and II. The main task of 
professional antigen-presenting cells (i.e., dendritic cells [DCs], macrophages, B-cells 
and thymic epithelial cells) is detecting and presenting peptides (i.e., short protein 
fragments resulting from their intracellular degradation). Molecules encoded by the 
MHC gene binds and present self and foreign peptides at the cell surface for recognition 
by specific antigen receptors on T lymphocytes [54].  
When receptors recognise pathogens by, for example, TLRs, APCs undergo maturation, 
in which global rearrangements of the endolysosomal system take place [55]. Following 
internalisation by the endocytic pathway, microbial proteins/constituents are transported 
to late endosomal compartments for processing into short peptides, loaded onto major 
histocompatibility complex class II (MHC-II) molecules, and subsequently exported to 
the plasma membrane. Cell surface peptide-MHC-II complexes (p-MHC-II) can activate 
CD4 T-cells and stimulate their differentiation into T-cell subsets (e.g., Th1 and Th2), 
which are essential for the proper activation of cytotoxic T-cells and the differentiation 
of B-cells [55]. 
Following molecular internalisation, DCs may present exogenous peptides on MHC 
class I molecules (MHC-I) and thereby activate naïve CD8 T-cells. This process is called 
cross-presentation. Internalisation, cross-presentation, and subsequent cell surface 
peptide-MHC-I complexes (p-MHC-I) seem important for both the activation of 
antigen-specific cytotoxic T-lymphocytes and the induction of self-tolerance [56]. All 
nucleated human cells, as well as platelets (but not erythrocytes), express MHC class I 
molecules [57]. MHC-I can then present pathogen-derived peptides from intracellular 
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pathogens, thereby enabling cells to alert the immune system to the presence of an 
invader. Pathogen-specific cytotoxic T lymphocytes monitor cell surface MHC class I 
molecules for pathogen-derived peptides and the elimination of infected cells [57]. 
T lymphocytes express the clonal-specific T-cell antigen receptors (TCRs) that 
recognise antigens only on the surface of other cells in the context of MHC class I and 
class II molecules (see above). Circulating immunocompetent T-cells scan MHC 
molecules in search of peptides derived from altered self (e.g., carcinogenic) or foreign 
(e.g., bacterial) proteins. TCRs survey both the intra- and extracellular environment, and 
their recognition of and binding to the peptide-MHC-complex activates T-cells [58]. 
However, bringing together TCRs and the cognate peptide-MHC, often referred to as 
signal 1, is only the start of a successful T-cell activation and response. Additional, 
second costimulatory signals, such as CD28’s binding of CD80/CD86, often referred to 
as signal 2, are also necessary to establish cell-cell contact (i.e., the immunological 
synapse), and another required signal is APC-derived cytokines, often referred to as 
signal 3 (e.g., IL12) [59].  
The T-cell immune system includes several inter-related and interacting T-cell subsets 
[60]. T-cells can be divided into four main classes based on when they left the thymus 
as immunocompetent cells: (i) naïve cytotoxic T-cells (TCR-αβ, CD8+), (ii) naïve 
helper T-cells (TCR-αβ, CD4+), (iii) thymus-derived regulatory T-cells (TCR-αβ, 
CD4+, FoxP3+) [61, 62] and (iv) γδ T-cells (TCR-γδ) [63, 64]. Naïve T-cells can 
differentiate after antigen recognition into various subsets [6, 59, 65] with a variety of 
effector functions. Table 3 gives a brief overview of suggested T-cell subsets, their 
proposed effector functions, and their proposed cytokine secretion profile. The 
cytokines produced by each lineage of mature effector T-cells reinforce their 
developmental program through positive and negative feedback, acting on both naïve 
T-cells and the innate immune system [65, 66].    
As described above, during acute infection, naïve T-cells give rise to effector T-cells 
that subsequently clear the pathogens. With antigen clearance, many antigen-specific T-
cells die, and only a pool of the remaining highly diverse memory T-cells retain the 
capacity to respond to another challenge [58, 67]. Substantial differences between 
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various infections that may depend on the duration of antigen exposure, tissue 
localisation, or distribution of infection have been described [58, 67]. Suggested 
memory cell subsets include effector memory T-cells (TEM), central memory T-cells 
(TCM), and resident memory T-cells (TRM), which differ primarily in their capacity for 
self-renewal, circulation through secondary lymphoid organs, or presence in tissue [58, 
67] 
When activated, T-cells upregulate several chemokine receptors and ligands that 
facilitate their own migration to tissues, as well as the migration of other cells to the 
same compartment, such as dendritic cells [68]. Interferons also induce the production 
of CXCL9 and CXCL10 by DCs and stromal cells, resulting in inducing T-cells to 
upregulate CXCR3s, which are highly expressed in many memory T-cells. This allows 
rapid migration, independent of antigens, toward infected cells in outer T-cell areas and 
into lymph nodes’ subcapsular sinus in response to infection. Hence, memory cells are 
recruited more quickly to APC compartments than naïve T-cells after infection [68].  
Our overview of T-cell functions is far from complete, but taken together, these 
observations illustrate that the T-cell population includes a large number of interacting 
T-cell subsets with many different effector functions and different roles in the regulation 
of inflammation and immunity. The various subsets mediate their regulatory functions 
through cytotoxicity, the release of pro- or anti-inflammatory soluble mediators with 
direct effects on the function/proliferation/differentiation/maturation of other 
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p-MHC-I IL-12 Tc1 • Releases perforin and granzyme, 
inducing apoptosis of infected cells. 
• Destroys virally-infected or malignant 
cells. 
• Produces TNF-α, INF-γ, (TC1).  
[69, 70] 





Th1 • Helps B- and Tc-cells.  
• Activates macrophages. 
• Produces IFN-γ, lymphotoxins, IL-2, 
and TNF-α. 
 
IL4 Th2 • Stimulates eosinophils, basophils, and 
mast cells. Stimulates B-cells to 
produce IgE and IgA.  
• Releases IL-4, IL-5 and IL-13, TNF-α, 





Th17 • A proinflammatory T-cell subset. 





Th9 • Supports CD4+ T-cell expansion and 
survival; recruits mast cells. 
• Produce IL-9 
[73] 
 Tfh • In follicles of the spleen and tonsils. 
Major B-cell helper cell. 
• Produce IL-4. 
[74] 
TGF-β Th3 • Seems to have a role in maintaining 
thymic Tregs in the peripheral immune 
compartment by the secretion of TGF-
beta 
[75] 
IL10 iTreg/TR1 • Anti-inflammatory and 
immunosuppressive cells; cytotoxic 
effects. 
• Produce IL-10. 
[76] 
tTreg p-MHC-II   The atrophied thymus attempts to balance the 
defective negative selection by relatively 
enhancing tTreg cell generation to maintain 










• Perforin and granzyme-dependent 
mechanisms 
• Cytokine profile IFN-γ, TNF-α, IL-17, 
RANTES, and CXCL10 
[63, 77] 
Abbreviations: tTreg, thymus-derived regulatory T-cells; p-MHC-I, peptide in complex with MHC class I; p-
MHC-II, peptide in complex with MHC class II; ULBPs, UL16 binding proteins. *The presence of APC-mediated 
cytokines is often referred to as signal 3. 
B (bursal or bone marrow-derived) lymphocytes express clonally diverse cell surface 
immunoglobulin (Ig) receptors. B-cells develop in the bone marrow from hematopoietic 
precursor cells and their development involves a continuum of stages [78, 79]. Early B-
cell development in the bone marrow includes the rearrangement of immunoglobulin 
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gene segments to secure clonogenic diversity; VH, DH, and JH rearrangements of the 
heavy chain (H-chain), along with VL-JL rearrangements of the light chain (L-chain) 
gene segments [78]. The final stage of early B-cell development in bone marrow is the 
formation of IgM molecules that are expressed on the cell surface. The developmentally 
intermediate and heterogeneous population of B-cells are termed transitional [80] or 
immature B-cells [78], and they leave the bone marrow and migrate to the spleen, where 
they finalise their development by differentiating into naive, follicular, or marginal zone 
B-cells [78]. Naïve cells circulate through peripheral blood and lymphoid tissues and 
die within days if they do not encounter a cognate antigen [81, 82]. 
Mature splenic marginal-zone B-cells can respond rapidly to T-cell-independent 
antigens and develop into short-lived plasma cells [80], a process thought to be 
supported by innate cells, such as B-cell helper neutrophils (NBH cells) [27, 78, 83, 84]. 
After being presented with T-cell-independent antigens, marginal-zone B-cells migrate 
from the marginal zone to bridging channels and undergo a proliferation burst and 
differentiation to make loci of plasma blasts. This proliferative burst may be a 
requirement for plasma cell differentiation [84]. The plasma cells from this response do 
not always undergo a class switch (i.e., the remain IgM-expressing) and may be short-
lived [80]. Additionally, the antibodies produced seem to be directed toward less 
complex antigens (e.g., polysaccharides, lipids), have lower affinity and have undergone 
less somatic hypermutation [80].  
The majority of mature B-cells are follicular B-cells [80], located in the lymphoid 
follicles of the spleen and lymph nodes, where they participate in T-cell dependent 
antibody responses [80]. Follicular B-cells encountering antigen and T-cell help can 
become (i) short-lived plasma cells, or they can enter into a germinal centre response in 
which (ii) long-lived antibody-secreting plasma cells and (iii) memory B-cells are 
generated. Both of these last two subsets provide protection against reinfection. 
Germinal centres are formed around follicular DCs [85]. The regulation of germinal 
centre responses is complex and involves assistance from T follicular helper (Tfh) cells 
and regulation by Foxp3+ T follicular regulatory (Tfr) cells [85]. The T-cell-dependent 
activation of B-cells induces the somatic hypermutation/class-switch machinery, thus 
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changing the affinity of the B-cell receptor and isotype (e.g., IgM to IgG, IgA, or IgE) 
[80, 86].  
The first line of defence against re-infection is pre-existing protective antibodies 
secreted by long-lived plasma cells (i.e., constitutive humoral memory). If constitutive 
memory is insufficient, pathogen-experienced memory B-cells are quickly reactivated 
to produce antibodies (i.e., reactive humoral memory), which is the second line of 
defence. The reactive humoral memory response is faster, of greater magnitude, and 
consists of antibodies of switched isotypes and higher affinity compared to the primary 
antibody response [52]. Several pathways to B-cell memory exist, and heterogeneity 
among memory B-cells is based on their produced Ig isotype [52]. Human B-cell 
functions are regulated by IL-21R/STAT3 signalling, and the threshold of STAT3 
activation required for differentiation seems to be lower in memory compared to naïve 
B-cells. This last observation suggests that STAT3 is an intrinsic difference in the 
underlying mechanism of differentiation between naive and memory B-cells [87]. 
Stemness, longevity, and robust responsiveness are among the key characteristics of 
memory B-cells, and these cells make effector cells upon re-encountering pathogens 
while maintaining the memory state. IgG+ memory B-cells seem to have a greater 
predisposition to differentiate towards plasma cells than IgM+ memory B-cells, possibly 
reflecting that the IgM+ memory B-cell compartment comprises more stem cell-like cells 
and class-switched memory B-cells (e.g., IgG+ memory cells), corresponding to a more 
committed progenitor cell. This may be similar to memory CD8+ T-cells [52, 88].  
Complement receptor 2 (CR2) on follicular DCs seems to be essential for the survival 
of IgG+ memory B-cells, while B-cell receptor signalling seems to be essential for 
IgG1+ memory, and T-bet or RORα (transcription factors) are essential for the survival 
of IgG2a+ or IgA+ memory B-cells, respectively. Vaccinations and infections are known 
to produce stable IgG+ memory B-cell populations in humans; for example, one study 
detected IgG1+ memory B-cells specific for the influenza strain causing the 1918 
pandemic in circulation 90 years after primary exposure [52, 89]. Furthermore, memory 
CD8+ T-cells maintain mitochondrial mass, providing these cells with a bioenergetic 
advantage during reactivation [52]. 
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Antibodies were discovered more than 100 years ago, but the question of how they 
obtain their diversity was not answered until the 1970s with the detection of somatic 
hypermutation. The most ancient class of antibodies are IgM; the transmembrane form 
defines B-cells, and after B-cell stimulation, IgM is released into plasma as pentameres 
[90]. Other human Igs are IgA (dimer), IgG, IgD, and IgE [90, 91]. The T-cell-dependent 
activation of B-cells induces the somatic hypermutation/class-switch machinery, thus 
changing the affinity of the B-cell receptor and isotype (e.g., IgM to IgG, IgA, or IgE) 
[80, 86]. The general structure of Igs is two light chains and two heavy chains with an 
antigen-binding variable region and a constant region, as illustrated in Figure 1C; 
characteristics of the various immunoglobulins are summarised in Table 4. 
Table 4. Secreted Igs families and general characteristics (adapted from [18]). 
Family FcR Subclasses Characteristics 
Molecular 





  Primary response Pentamer  Serum Yes 
IgD Fcδ   Homeostasis Monomeric Serum, low No 











IgE FcεR   Allergic response Monomeric Serum, low No 




1.2. THE MONOCYTE SYSTEM AND ITS HETEROGENEITY 
Monocytes are large mononuclear cells of the innate immune system and often described 
as highly plastic cells with the ability to function as both precursor and effector cells 
[92]. Monocytes constitute approximately 5–10% of peripheral blood leukocytes in 
healthy humans [93]. Monocytes are separated from granulocytes and lymphocytes in 
automated cell analysers based on their larger size, as well as their non-lobular nucleus 
and smaller/different granules when compared to granulocytes. Monocyte parameters 
used in routine clinical practice are their concentration in peripheral blood (absolute 
numbers), the percentage of monocytes among circulating leukocytes (relative values), 
and the monocytes-to-platelets ratio (MPR) [94], but the latter is not in clinical use in 
Norway.  
 
- 13 - 
 
Monocytes and monocyte subsets can also be identified based on CD14 expression 
(discussed in Section 1.1.1), a cell surface co-receptor for LPS [23, 95], and whether 
they express Fc-gamma receptor IIIa (CD16a); see Section 1.2.3 for further subset 
definitions. CD16a (FcγRIIIA) consists of (i) two extracellular Ig-like domains that bind 
to IgG, (ii) a transmembrane domain that associates with adaptor proteins containing an 
immunoreceptor tyrosine-based activating motif (ITAM) and induces downstream 
intracellular signalling, and finally, (iii) a short intracellular domain [96]. CD16a 
associated γ-chains are essential for signalling and stable expression, as well as targeting 
the receptor on the monocyte cell membrane [96]. Humans seem to express two 
FcγRIIIa (CD16a) allotypes that differ in a single amino acid residue at position 158; 
the isoform with valine at this position has high affinity for the IgG1 Fc domain, while 
phenylalanine, at the same position, results in low affinity [97]. CD16a seems to be 
important for antibody-dependent cellular phagocytosis and antibody-dependent 
cellular cytotoxicity by human monocytes [98]. 
Immunophenotyping circulating monocytes is now used in routine clinical practice for 
the detailed characterisation of circulating monocytes, especially for the diagnosis of 
monocytic leukaemias (i.e., chronic myelomonocytic leukaemia [CMML] and 
monocytic variants of acute myeloid leukaemia) [99]. 
1.2.1. Monocyte development from hematopoietic stem cells in bone marrow  
The development and differentiation of monocytes are called monopoiesis [100-105]. 
One model of monopoiesis indicates that monocytes develop from a lineage-committed 
bone marrow progenitor referred to as the common monocyte progenitor [94, 102, 104, 
105]. Another model based on murine studies suggests that distinct monocyte subsets 
arise from two independent pathways [100, 105]. This development uncertainty is 
probably also reflected by [106] uncertainty regarding the expression of various 
differentiation markers in the different steps of monopoiesis [94, 102, 107]. Common 
monocyte progenitors seem to express receptors for the cytokine macrophage-stem cell 
factor (M-SCF-R), and their development and survival seem to depend on M-SCF [108]. 
Other early monocyte markers seem to include CD64, CD11c, cytoplasmatic 
cyLysozome, cyCD68, CD36, and CD35 [109-111]. Mature monocytes typically 
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express CD300e, CD312, CD45, CD11b, HLA-DR, and CD14 [110, 111]. Both 
immature (e.g., CD64high CD14negative) and mature (e.g., CD300ehigh) monocytes express 
CD62L, and CD62Lpositive monocytes are mainly detected in blood and bone marrow, 
whereas CD62L− monocytes are most abundant in lymph nodes and the spleen [112].  
 
Figure 2. Models of monopoiesis. Model A: Monocytes differentiate from a common monocyte progenitor 
(cMoP), which arises from a common myeloid progenitor (CMP). Classical monocytes differentiate into either 
monocyte-derived macrophages, tissue-monocytes, non-classical monocytes via intermediate monocytes, or 
monocyte-derived dendritic cells, and non-classical monocytes are suggested to differentiate into macrophages 
(illustration adapted from [107]. Model B: Monocytes arise from both monocyte-DC progenitors (MDPs) and 
granulocyte-monocyte progenitors (GMPs) and provide heterogeneous populations of non-classical monocytes 
and monocyte-derived macrophages. Only classical monocytes differentiated from MDP via cMoP may 
differentiate into monocyte-derived DC (illustration adapted from [100]). Classical and non-classical monocytes 
are both suggested to contribute to monocyte-derived macrophages and monocyte-derived dendritic cells. The 
progenitor monocyte subset may contribute to specific subsets of either macrophages or dendritic cells [36]. 
Abbreviations: ESC, embryonic stem cell; MP, Monocyte-committed progenitors, GP, Granulocyte progenitor; 
cDC, conventional dendritic cells; pDC, plasmacytoid dendritic cells. 
Murine studies suggest that differentiation into common monocyte progenitors is 
followed by differentiation in bone marrow into classical monocytes with subsequent 
conversion into intermediate monocytes (i.e., an intermediate state), followed by 
conversion into non-classical monocytes [113]. This is also supported by in vivo studies 
in humans [114, 115]. Computational models suggest that 1% of classical monocytes 
are converted into non-classical monocytes during homeostasis, which is consistent with 
a model where classical monocytes are either converted into non-classical monocytes 
via the intermediate stage and enter tissues or the lymphatic system or undergo apoptosis 
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[114, 115]. Non-classical monocytes may be close to senescence, and this may 
contribute to their pro-inflammatory phenotype. They also have other signs of 
senescence, such as altered miR-146 (a microRNA precursor) expression [116-120]. 
However, current data cannot exclude the existence of a linage-restricted progenitor that 
differentiates directly into non-classical monocytes. 
Monocytes as precursor cells: Monocytes, dendritic cells, and macrophages are all 
mononuclear phagocytotic cells, and monocytes were previously regarded as precursors 
that give rise to tissue macrophages and dendritic cells [121, 122]. Recent evidence 
indicates that there exist distinct monocyte subsets with different genetic, epigenetic, 
transcriptional, and metabolic arrangements committed to becoming macrophages and 
DCs [94]; this process is different from the previous theory that monocytes 
differentiated into macrophages or dendritic cells in response to an inflammatory 
environment [94]. However, monocytes are recruited to sites of inflammation and gain 
phagocytic functions, as well as phenotypic characteristics similar to dendritic cells and 
macrophages, leading to difficulty separating monocyte-derived cell subsets from other 
phagocytes [123]. Monocytes are also shown to preserve their monocyte-like phenotype 
within tissues [94, 123].  
Animal studies suggest that during a steady-state, classical monocytes replenish resident 
peripheral monocyte-derived cells [124, 125]; these monocytes also show the highest 
migration in response to CCL2, CCL8, and CCL7 [126] and have a half-life in the 
circulation of less than one day in humans [115]. Monocytes are recruited to inflamed 
tissues at high rates, where they attract other immune cells by secreting cytokines and 
antimicrobial factors [127]. Monocyte migration studies have not detected any 
significant heterogeneity among intermediate monocytes or differences between 
intermediate and non-classical monocytes [128]. In contrast, intermediate and non-
classical monocytes seem to have a distinct (i.e., slower) migration pattern when 
compared to classical monocytes. 
Monocyte-derived dendritic cells: Conventional DCs seem to be distinct cellular 
lineages from monocytes and originate from a separate precursor cell (Figure 2) [107, 
129]; however, monocyte-derived DCs may be generated by culturing monocytes in the 
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presence of granulocyte macrophage-colony stimulating factor (GM-CSF) and IL-4. 
This generates immature DCs that differentiate further into mature DCs by TNF-α 
stimulation [36, 130]. Transcriptomic analyses suggest that dermal CD14+ DCs, 
intestinal CD103-CD172a+ DCs, and ‘inflammatory DC-expressing CD1c, CD1a, and 
CD14 are monocyte-derived cells [121, 131-134]. 
Monocyte-derived DCs may also invade tissue not normally maintained by monocyte-
derived cells, and not only the skin and intestine [36], where they contribute to the 
control of immune response [135], are able to enhance Th2 cell response, and express a 
high variation cytokines (e.g., CCL-1, CCL-10) [136]. 
The exact contribution of monocyte subsets to monocyte-derived DCs during 
inflammation is unclear [36]. However, examples of increased numbers of CD16+ 
monocytes during inflammation have been associated with increased numbers of 
monocyte-derived DCs [137], and functional differences among monocyte-derived DCs 
generated from different subsets have been reported (e.g., more potent immune 
responses from DCs derived from classical monocytes and better immune tolerance 
from DCs generated from non-classical monocytes) [138-140]. It is suggested that 
CD16+ monocytes differentiate into alternative dendritic cells with poorer antigen-
presenting function [140] and are more likely to induce T regulatory cells [141].  
Monocyte-derived macrophages: Tissue-resident macrophages seem to originate from 
either embryonic precursors or differentiate from extravasated monocytes, which are the 
origin of several macrophage populations, such as Kupffer cells and splenic 
macrophages (Figure 2, panel A) [36, 94, 102, 107]. Macrophages are well adapted to 
their environment, obtain organ-specific functionalities, and contribute to the 
maintenance of tissue homeostasis, and the differentiation, proliferation, and function 
of macrophages are controlled by growth factor colony-stimulating factor CSF-1 and 
IL-34 [36].  
Monocytes are capable of renewing macrophages and are associated with the slow 
replacement of embryonic macrophages in tissues, and monocyte-derived macrophages 
then obtain transcriptional similarities to embryonic macrophages, although some of the 
epigenetic, transcriptional, and functional difference are maintained [94]. Classical 
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monocytes are suggested to be continuously recruited to maintain local macrophage 
populations in homeostasis in some tissues, such as the intestine [142].  
As with monocyte-derived DCs, there are reports of functional differences among 
monocyte-derived macrophages. Murine studies suggest that monocyte heterogeneity 
may underlie macrophage heterogeneity. The two main monocyte subsets in mice are 
suggested to give rise to either proinflammatory (M1) or anti-inflammatory 
macrophages (M2), each associated with a specific monocyte subset [100], suggesting 
monocytes may differentiate into distinct macrophages with different capacities to drive 
inflammatory responses or promote tissue repair, pre-determined by the subset of the 
progenitor monocyte [36]. Non-classical monocytes are suggested to be the source of 
wound healing macrophages [143], although the contribution of CD16+ monocytes in a 
steady state to the macrophage population is unclear [144]. Furthermore, these two 
macrophage phenotypes (M1 and M2) are regarded as being transient and occurring 
along a spectrum [145, 146], and several other factors seem to influence or drive 
monocyte-derived macrophage polarisation, including platelets [147], IL-4 [148], and 
microRNA [146].  
The monocyte subsets also appear to function as macrophage precursors in different 
pathological conditions; for example, during infection, classical monocytes will rapidly 
invade tissue and generate macrophages with little tissue repair capacity [149, 150]. 
However, without infection, except, for example, during cardiac pressure overload, the 
preferential recruitment of non-classical monocytes/macrophages in cardiac tissue is 
observed [151]. The selective recruitment of specific monocyte subsets seems to be 
context-dependent and based on the nature of the challenge [152].  
Monocyte-derived endothelial cells: Monocytes may also differentiate into endothelial 
cell-like cells [153]. CD16+ monocytes exposed to tissue factors showed increased 
expression of VE-cadherin, von Willebrand factor (VWF), and eNOS, while blocking 
β1-integration inhibited this effect [153]. 
Monocyte-derived multinucleated giant cells: Monocyte-derived macrophages are 
also able to fuse and form multinucleated giant cells, such as osteoclasts and 
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Langerhans’ cells [36, 154]. These macrophages arise from monocytes differentiated in 
the presence of M-CSF and the receptor activator of the NF-κB ligand (RANKL) [36]. 
Langerhans cells are proinflammatory and formed in response to infection, and 
osteoclasts reside in the bone marrow and are important in bone homeostasis [154]. 
Although long believed a source of osteoclasts, it was confirmed when fluorescently 
labelled monocytes were recruited from circulation to the bone surface and 
differentiated locally into osteoclasts [155]. There are also reports of osteoclasts 
contributing to inflammation and immune responses [156].  
Monocytes are also able to fuse into multinucleated giant cells in response to foreign 
material, such as medical implants [154]. The molecular mechanisms responsible for 
forming multinucleated giant cells are unknown, but the development of foreign-body 
giant cells and Langerhans’ cells seem to be initiated by different cytokines [154]. 
Multinucleated cells can reabsorb mineralised tissue, such as bone; they bind and then 
degrade the various matrix components by secreting acid, followed by a cocktail of 
different proteolytic enzymes [36].  
Classical monocytes have the highest propensity to differentiate into osteoclasts [157], 
although they may shift to intermediate and non-classical monocytes, as reported in 
patients with psoriatic arthritis, a chronic type of inflammatory arthritis characterised by 
severe bone erosion [157]. This is an indication that the intrinsic properties of isolated 
monocytes generate distinct osteoclasts rather than altered cytokine levels in the 
inflammatory environment [36]; for example, IL-17A decreased the osteoclasts 
formation of intermediate monocytes, however the bone resorption was not affected by 
Il-17A treatment of intermediate monocytes [158]. Intermediate monocytes are 
suggested to be more likely to fuse into multinucleated giant cells and be precursors of 
osteoclasts [159, 160]. The elevated number of CD16+ monocytes, especially 
intermediate monocytes, seem to play a critical role in osteoclastogenesis during 
inflammation, which may explain the observed osteoclast-associated bone loss in 
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1.3. THE HETEROGENEITY OF MONOCYTE EFFECTOR CELLS 
1.3.1. Monocyte subpopulations and heterogeneity 
Several studies have shown that monocytes are heterogeneous; for example, they show 
differences in tetraspanin (membrane protein family) expression, the capacity to form 
multinucleated giant cells, phagocytic responses, cytokine secretion, and cellular 
migration, as well as cell surface receptor expression [94, 128, 160-164]. Monocytes are 
typically classified into the three subsets: classical (CD14++CD16-), intermediate 
(CD14++CD16+), and non-classical (CD14+CD16+) [34, 115, 164-172]. However, the 
detailed definition of each cell subset of each monocyte subset remains a matter of 
debate (see Table 5 for more detailed descriptions). The following sections will 
summarise some of the heterogeneity among monocytes reported in the literature.  
Classical monocytes constitute the majority of circulating monocytes, usually 80–90% 
of peripheral venous blood monocytes [164]. Previously, data have suggested 
heterogeneity among intermediate monocytes [126, 173]. However, very recently, high-
dimensional mass cytometry data identified one intermediate subset [174], but this 
finding suggests there is some heterogeneity among classical monocytes [174].  
Single-cell RNA sequencing studies have shown that classical and non-classical 
monocytes form two separate clusters. On the other side, intermediate monocytes 
formed two clusters, in addition, some intermediate monocytes were included into the 
classical or non-classical monocyte clusters; this study strongly suggests that 
intermediate monocytes are a very heterogeneous group [173]. The first intermediate 
monocyte cluster was characterised by the expression of genes important to the 
regulation of proliferation, differentiation, and trafficking, such as MAX dimerisation 
protein 1 (MXD1), CXCR1, CXCR2, and vascular non-inflammatory molecule 2 
(VNN2). The second intermediate monocyte cluster expresses genes important to 
cytotoxicity (e.g., PRF1, GNLY, and CTSW), in addition to the classical monocyte gene 
[173].  
Recently, based on high-dimensional mass cytometry, the existence of eight human 
monocyte subsets were reported. Three subsets were found to fall within the non-
classical monocyte population, while four subsets belong to the classical monocytes, 
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and interestingly, intermediate monocytes clustered together into one subpopulation 
[174]. 
Table 5. A selection of recently published papers on the topic of monocyte subsets and markers. 
Monocyte subsets Markers of identification Ref. 
Inflammatory monocytes (iMo)  
Patrolling monocytes (pMo)               
Immunosuppressive monocytes 
(M-MDSC)  






CD11b+ CD14+ CD124+ PD-L1+ CCR2+ HLA-DR-  
 
CD14+ Dectin1+ CD36+ TLR4+ GM-CSF-R+ NOD+ 
Undefined in humans. Defined in mice. 






Classical monocytes            
Intermediate monocytes           
Non-classical                               
CD33high, CD86+/high, CD64+, HLA-DR+, CCR2high  




Classical monocytes                            
Intermediate monocytes                         
Non-classical                                  
CD300ehigh CD14high CD16negative 
CD300ehi CD14hi CD16+ 
CD300ehi CD14low/- CD16+ 
 
[111] 
Classical monocytes                            
Intermediate monocytes                         







*There is a great variation in the overall antibody panel and gating strategy applied, but all the studies identified 
monocyte subsets by CD14 and CD16 expression.  
1.3.2. Monocytes as effector cells 
Monocytes are key innate cells involved in eliminating invading bacteria, virus, fungi 
and, protozoa by, for example, phagocytosis and antibody-dependent cellular 
cytotoxicity (ADCC), and they perform important immunoregulatory functions through 
their cytokine/mediator release and antigen presentation [94, 103, 161, 162, 177]. As 
with other innate cells, monocytes detect PAMPs and DAMPs through PRRs like, for 
example, TLRs. These receptors dimerise after ligation and thereby activate the TLR-
MyD88-NF-κB signalling pathway and induce pro-inflammatory or anti-inflammatory 
responses, which depend on the monocyte subset being involved [22]. Table 6 
summarises important features of monocyte subsets as effector cells. 
Phagocytosis is a process involved in the (i) ingestion and elimination of pathogens and 
(ii) the elimination of apoptotic cells, and it is important in (iii) tissue homeostasis [178]. 
The phagocytic response can be categorised into two main categories: (i) pathogen 
killing and digestion and (ii) antigen processing and presentation [178].  
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Table 6. Monocyte subsets as effector cells: A brief summary of important findings. The comparisons are 
to other monocyte subsets. 
CD16- versus CD16+ Monocytes References 
CD16- monocytes are suggested to be migratory, while CD14lowCD16+ are patrolling monocytes. [103, 127, 
179] 
CD16+ monocyte numbers are increased in the blood of patients with systemic infections, implying 
they play an important role in the immune system’s rapid defence against pathogens.  
[180, 181] 
Antibody-mediated cellular cytotoxicity (ADCC) seems CD16-dependent. [98] 
CD16+ seems more efficient in activating T-cells than CD16- monocytes. [103] 
CD16+ expresses higher levels of CX3CR1, supporting the idea that they migrate and adhere more than 
CD16− monocytes to fractalkine/CX3CL1-secreting endothelium.  
[182, 183] 
                                Classical monocytes  
Migration Migrate to CCL2 and CCL3 gradients.  [183, 184] 
Chemokine 
receptor 
Express higher levels of CCR1, CCR2, CCR5, CXCR1, and CXCR2 and lower 
levels of CX3CR1. 
[161, 184, 
185] 
Phagocytosis Differences in the phagosomal environment of the three monocytes subsets; 




Entry into tissue and lymph nodes causes the upregulation of MHC class II 
expression. Show the largest increases in MHC class II expression in response to 
IFNγ, GM-CSF, and IL-4. Probably able to cross-present cell-associated antigen to 





Secrete pro-inflammatory molecules (e.g., IL-6, IL-8, CCL2, CCL3, and CCL5). [161, 177] 
 Efficient in producing ROS  [177] 
                               Intermediate monocytes  
Chemokine 
receptor 
Chemokine receptors, they express more CCR5 than classical monocytes and this 
likely accounts for their high susceptibility to HIV-1 infection  
[182, 184, 
191] 
Phagocytosis The intermediate monocytes seem to be the most efficient phagocytic subset with 
regard to CD16- and the complement-dependent phagocytosis of antibody-
opsonised pathogens. 
[162] 
 Differences in the phagosomal environment; intermediate monocytes have a 
phenotype between alkaline/acidic phagosomes. 
[186] 
APCs Express the highest levels of antigen presentation-related molecules in steady-state [161, 188] 
Mediator 
Secretion 
Secrete TNF-α, IL-1β, IL-6, and CCL3 upon TLR stimulation.  [161, 177, 
192] 
 Suggested as the main producers of IL-10 upon TLR stimulation.  [193] 
                                  Non-classical monocytes  
Chemokine 
receptor 
Express high levels of CX3CR but low CCR2 levels. [184, 185, 
194] 
Phagocytosis Differences in the phagosomal environment: non-classical monocytes had more 
acidic phagosomes 
[186] 
 A Slan+CXCR6+ intermediate subset showed to migrate towards CXCL16 as well 
as had increased efferocytosis capacity 
[174] 
APCs Similar HLA-DR, DQ, and DP expression to classical monocytes but no observed 




Antagonize classical monocytes and promote neutrophil adhesion at the endothelial 
interface via the secretion of TNF-α.  
[128] 
 Do not reach the classical monocyte production levels of pro-inflammatory 
cytokines.  
[163] 
 Are activated by viruses and immune complexes through the TLR7-TLR8-MyD88-
MEK pathway to release TNF-a, IL-1b, CCL-3, and CCL-4. 
[116, 177, 
195] 
 Involved in wound healing processes.  [196] 
Phagocytic responses can be initiated by PRRs or through complement activation and 
antibody-mediated FcγR receptors [162, 197]. Classical and intermediate monocytes are 
suggested in the literature to be the most effective phagocytic cells, whereas non-
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classical monocytes seem less effective [161, 162, 198]. Intermediate monocytes also 
seem to be the most efficient phagocytic subset with regard to CD16 (FcγRIIIa) and the 
complement-dependent phagocytosis of antibody-opsonised pathogens [162]. Further 
heterogeneity within the phagocytosis process for monocytes was supported by recent 
observations indicating differences in the phagosomal environment between the three 
monocytes subsets [186]. Classical monocytes and neutrophils exhibit alkaline 
phagosomes, while non-classical monocytes have more acidic phagosomes, and 
intermediate monocytes have a phenotype between the two [186]. 
Antibody-dependent cellular cytotoxicity (ADCC) is the mechanism by which Fc 
receptor-expressing effector cells recognise and kill antibody-coated target cells. 
Monocytes are suggested to be involved in antibody-mediated cellular cytotoxicity, 
which is CD16 (FcγRIII) dependent; this process seems to require cell-cell contact 
through β2 integrins and is mediated through the release of TNF-α [98]. Additionally, a 
recent study found that slan+ (6-Sulfo LacNAc, the carbohydrate modification of P 
selectin glycoprotein ligand 1) monocytes, but not CD14+ monocytes, increased in 
number and displayed highly efficient rituximab-mediated antibody-dependent cellular 
cytotoxicity almost equivalent to that exerted by NK cells [199]. 
Monocytes secrete a wide range of cytokines, including several chemokines, such as 
IL-6, Il-8, Il-1β, IL-1ra, and TNF-α [116, 163, 200-203]. TNF-α is released by all three 
monocyte subsets [163, 193, 203], whereas classical monocytes secrete higher levels of 
IL-6 and IL-1β than the two other subsets [163]. The intermediate monocyte subset 
releases both anti-inflammatory (e.g., IL-10) and pro-inflammatory cytokines, such as 
TNF-α and IL-1β. Both CD16+ monocyte subsets release high levels of TNF, CCL-3, 
CCL-4, CCL-5, IL-6, IL-8, and IL-1 [116]. See table 7 for an overview of some of the 
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Table 7. An overview of important cytokines released by normal monocytes and their effects on other cells. 
Cytokine*                        Some important features Ref. 
Chemokines  
CCL1  
Chemoattractant. Associated with a distinct form of M2 monocyte activation, which participates in the 





Chemoattractant and the key monocyte-attracting chemokine; regulates monocyte migration and 





Chemoattractant. Proinflammatory activities. Negatively regulate the proliferation of hematopoietic 
stem/progenitor cells. Induce the differentiation of monocytes to osteoclasts. Possible role in 


















Chemoattractant. Recruit and activate neutrophils. Role in inflammation, angiogenesis, tumorigenesis, 





Chemoattractant. Th1 response; Th1, CD8, and NK trafficking. [144] 
Interleukins  
IL1β 
Induces hematopoiesis and pro-inflammatory cytokines. When released from bone marrow plasma cells, 
induces IL-6 production from marrow stromal cells, activates B- and T-cell differentiation into Th17. 
Induces Breg cells in mouse spleen and mesenteric lymph nodes. 
[217, 
218] 




Inducer of antibody production, CD8+ cytotoxic T-cell differentiation; CD4+T-cell differentiation toward 
Th17 and myeloid cell development. Regulation and induction of acute-phase proteins in hepatocytes. 
Activates B-cells and the production of IgG, IgM and IgA. Hematopoiesis. Involved in 
osteoclastogenesis and bone reabsorption. In vivo; synovial fibroblast proliferation and cartilage 









Anti-inflammatory master regulator. Regulates and suppresses the expression of proinflammatory 
cytokines during the recovery phase of infection, which consequently reduces the damage caused by 
inflammatory cytokines. Has an immunosuppressive effect through APC or directly on T-cells. 
Suppression of IgE production and induce IgG. 
[218, 
220] 
Other mediators  
MMP9 
Controls the access of monocytes and T-cells to the vascular wall. Participates in pathological 
remodelling processes that involve inflammation and fibrosis. Enhances elastin degradation and induces 




Important for host defence, initiates the pro-inflammatory response, and limits the duration of the 
response. Modulates multiple signalling pathways with wide-ranging downstream effects, including 
immunometabolism in monocytes. Promotes nitric oxide, necrosis, cytotoxicity, and expression of 
matrix metalloproteinases (MMPs). Increases MHC expression, activates macrophages, enhances 




*Released cytokine levels in supernatant for the listed cytokines was evaluated in Article IV 
Monocytes as antigen-presenting cells: Experiments in mice indicate that monocytes 
seem important to the induction and regulation of CD4+ Th1 [190], Th2 [136], and Th17 
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[136, 226], as well as CD8+ T-cell [227] responses (reviewed in [127]). CD16+ 
monocytes are suggested to be more efficient T-cell-activating cells than classical CD16- 
monocytes [103]. MHCs are important molecules, presenting antigens to T-cells. When 
comparing monocyte subsets, intermediate monocytes show the highest expression of 
MHC class II molecules, (HLA-DR, -DQ and -DP, and HLA-DM), and the lowest ratio 
of class II-associated invariant chain peptide (CLIP) and MHCII (the CLIP:MHC class 
II ratio) [188]. High cell surface expression of CLIP can be viewed as an indicator of 
less effective antigen presentation [188, 228], and these results imply this subset 
presents other peptide/MHCII complexes efficiently [188].  
Additionally, the intermediate monocyte subset seems to be heterogeneous regarding 
the expression of HLA-DR (HLA-DRhigh and HLA-DRmid populations) [126], 
supporting the hypothesis that the intermediate monocyte subset is a heterogeneous 
group. In contrast, classical monocytes show the largest increase in MHC class II 
expression in response to IFNγ, GM-CSF, and IL-4 [188], whereas all subsets show 
decreased HLA-DR levels when exposed to IL-10 [188]. Taken together, these 
observations suggest intermediate monocytes are the most efficient constitutive antigen-
presenting monocyte subset, whereas the classical subset becomes more important in 
response to inflammation. 
Monocytes contribute to immunosurveillance and tissue repair: Immuno-
surveillance is the process whereby abnormal (neoplastic) cells are detected and 
destroyed. CD16+ monocytes are suggested to be especially important for 
immunosurveillance of the central nervous system [229] and within cancer 
immunosurveillance [230, 231]. In an ‘injury niche’, the tissue microenvironment emits 
signals to recruit and instruct cells of the inflammatory system to program repair and 
inflammation resolution. Although heterogeneous populations of monocytes (CD16- 
and CD16+) are recruited from circulation in (i) vascular remodelling, (ii) muscle repair, 
and (iii) bone repair [232], the non-classical monocyte subset (CD16+) seems to be 
especially important for tissue repair [143, 195, 233, 234].  
Trained innate immunity and monocytes: A body of evidence indicates that innate 
immune cells can mount (i) acute response to eliminate invading microbes or 
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transformed self-cells, (ii) innate adaptive memory responses (i.e., long-term responses), 
or (iii) immune tolerance [53, 235-238]. Currently, the concept of innate memory is a 
matter of debate and was recently suggested to be better described as adaptive but 
transient phenotypes not within the concepts of ‘memory’ as we know it from antigen-
specific adaptive cells (T- and B-cells) [239]. This is somewhat in contrast to the view 
that trained innate immunity involves the full haematopoietic system (myelopoiesis) 
[240, 241]. However, innate memory (trained immunity) is suggested to exist in 
monocytes, macrophages, NK cells, and neutrophils [242, 243], and recently, in 
dendritic cells [244]. Additionally, a possible role for non-immune cells in harbouring 
long-lasting immunological memory has been suggested [242].  
Enhanced monocyte reactivity upon a second encounter has been suggested for 
microbial particles (e.g., Candida albicans, a fungal pathogen, β-glucan, a component 
of the fungal cell wall, Bacille Calmette-Guérin, the BCG vaccine, and peptidoglycan, 
a component of the bacterial cell envelope [53, 245, 246], as well as for DAMPs, such 
as oxLDS, oxidised lipid droplets, HSP90, and S100A4) [247-250].  
Trained monocytes are suggested to originate from inflammatory monocytes [94, 240, 
241, 247]. Enhanced reactivity upon a second encounter in monocytes is associated with 
specific cell signalling pathways and metabolic and epigenetic rewiring [53, 94, 236, 
237, 251, 252]. The signalling pathways identified to be involved in the induction of 
trained-monocytes include [241] (i) the dectin-1/AKT/mTOR/HIF-1α signalling 
pathway, with the subsequent secretion of IL-6, IL-1β, and TNFα [94, 245], and (ii) the 
NOD2/NF-kB pathway, with the subsequent secretion of IL-6 and TNFα [246]. 
Epigenetic reprogramming associated with trained immunity in monocytes includes 
monomethylation at histone H3 lysine 4 (H3K4me1), trimethylation (H3K4me3), and 
acetylation at H3 lysine 27 (H3K27ac) [252]. Metabolic reprogramming associated 
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1.4. IMMUNOMETABOLISM, MITOCHONDRIA AND MONOCYTES 
Immunometabolism: Cellular metabolism serves three major functions: (i) generating 
energy (ATP) by catabolism, (ii) producing building blocks (termed biosynthesis or 
anabolism), and (iii) modulating cellular signalling (e.g., via mitochondrial activity) 
[253]. Activated immune cells have an increased demand for nutrients, but the type of 
nutrients needed is dependent on the functional requirements and the type of 
immunocompetent cell [253], as well as the pathogen and the tissue microenvironment 
[253]. The antimicrobial activities of immunocompetent cells seem to require specific 
metabolic programs, termed immunometabolism [240, 253-258]. 
Immune cells require energy (i.e., ATP) to survive [253]. ATP is preferably generated 
using glucose; however, it can also be generated via the use of lipids or amino acids 
[253, 259]. In glycolysis, glucose is turned into pyruvate, or lactate, within the 
cytoplasm. Pyruvate is transported to the mitochondria and subsequently converted into 
acetyl coenzyme A. Within the mitochondria, acetyl coenzyme A enters the 
tricarboxylic acid cycle, which produces electron carriers (e.g., NADH). Finally, NADH 
donates electrons to an electron transport chain that leads to the production ATP [253, 
260]. Decreased ATP production increases AMP levels and thereby causes a shift from 
an anabolic to a catabolic state to sustain a high ATP/ADP ratio, while an increased 
AMP/ATP ratio activates AMPK (AMP-activated protein kinase), which decreases 
mTOR (rapamycin) activity and favours autophagy and the supply of nutrients to 
mitochondria [261]. Thus, the modulation of cellular metabolism will alter intracellular 
signalling and thereby influence the functional characteristics of cells. Additionally, 
extracellular ATP is part of the immune system; it is released during hypoxic conditions 
by necrotic cells, activated immune cells, and endothelial cells, acting as a pro-
inflammatory ‘danger’ signal for innate cells, as a costimulatory signal to T-cells. At 
low concentrations, ATP has anti-inflammatory properties [262, 263]. For instance, in 
monocytes, ATP is released after stimulation with PAMPs, which induces IL-1β and IL-
18 secretion in an autocrine manner [264]. 
Mitochondria have been described as an especially central component of the immune 
system [265, 266]; mitochondrial DNA acts as a DAMP, and the mitochondrial outer 
 
- 27 - 
 
membrane is a platform for the NLRP3 inflammasome [266]. There exist several known 
signal transduction pathways between the cell and its mitochondria [267]: (i) calcium 
influx to the mitochondrial matrix and bursts of Ca2+ into the cytosol, (ii) mitochondrial 
production of reactive oxygen species (ROS), and (iii) alteration of the availability of 
Krebs cycle intermediates, such as acetyl-Coenzyme A, succinate, fumarate, and α-
ketoglutarate [261].  
Monocyte activation is associated with metabolic modulation. TLR4/LPS stimulation is 
often used as a model of acute monocyte activation and results in unique metabolic 
reprogramming [253, 268-271], with the upregulation of glycolysis and fatty acid 
synthesis and suppression of oxidative phosphorylation [271]. However, metabolic LPS 
effects seem to be dose-dependent. The suppression of oxidative phosphorylation seems 
to be linked to the induction of tolerance by higher LPS concentrations, whereas lower 
LPS doses associated with monocyte activation may increase both glycolysis and 
oxidative phosphorylation [272-275]. 
The glycolytic pathway is vital for monocyte function and monocyte-derived cells’ 
differentiation and functions (see Table 8): (i) the glycolytic pathway influences 
monocyte differentiation into macrophages and dendritic cells [261, 276-278]; (ii) 
glycolysis is upregulated in monocytes in response to infection and is important for 
effector functions [279-281], and the Akt-mTOR-HIF-1-α pathway seems especially 
important [268, 276-278]; (iii) trained monocytes are mainly glycolytic [94, 245, 282].  
Fatty acid oxidation plays a role in regulating the inflammatory properties of monocytes 
[94]. In glucose-deprived monocytes, oxidative metabolism has been found to be fuelled 
mainly by fatty acids, and they show comparable levels of cytokine production, 
migration rates, and phagocytosis during LPS activation as when glucose is present. 
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Table 8. Overview of findings reported in some published articles.  
Description of findings  Ref. 
The glycolytic pathway influences monocyte differentiation into macrophages. Glycolysis 
inhibitors affect the expression of essential genes for macrophage differentiation and 
retained plasticity of macrophages. 
[276] 
Monocyte-derived CD137L-dendritic cells show higher glycolysis rates and Akt-mTOR1 
activity than immature DCs. Glycolysis is vital for the expression of most co-stimulatory 
molecules and the secretion of inflammatory cytokines. Inhibition of mTORC1 after the 
induction of immature moDCs or CD137L-DCs differentiation always blocks the 
differentiation of DCs 
[277] 
The TLR4 activation of human monocyte-derived DCs seems to stimulate glycolysis and 
increased glucose consumption and lactate production 
[278] 
Monocytes upregulate genes involved in glycolysis in response to C. Albicans infection. C-
type lectin signalling seems to trigger glycolysis when challenged by pathogens, and both 
glycolysis and the pentose phosphate pathway are then required for ROS production/ 
[279] 
Monocytes in Chagas patients are mainly glycolytic, and monocyte glycolysis determines 
CD8+ T-cell functionality . 
[280] 
CD14+ monocytes from rheumatoid arthritis patients express IL-1β, TNFα, IL-6, IL-27, 
CXCL10, and CXCL11,  and are highly glycolytic, with increased expression of HIF1α, 
HK, and PFKFB3, which is mediated by STAT3.  
[281] 
Amino acid transporter SLC7A5 and mediated amino acid uptake in monocytes influence 
cytokine production, and inhibition of SLC7A5 is associated with the downregulation of 
glycolysis during LPS activation. 
[284] 
In Β-Glucan-trained monocytes, the induction of Dectin-1-Akt-mTOR-HIF-1-α leads to a 
shift toward glycolysis, as well as increased lactate production and TNF-α production. 
[245] 
There are scarce data available regarding the metabolic profile of monocyte subsets, 
namely classical, intermediate, and non-classical monocytes. Pathway analysis suggests 
differences in metabolic gene signatures, whereas classical monocytes express higher 
levels of genes involved in carbohydrate metabolism, priming them for anaerobic energy 
production. Non-classical monocytes express higher levels of oxidative pathway 
components and show higher mitochondrial routine activity [196]. 
Reactive oxygen species (ROS) are molecules containing oxygen (e.g., peroxides, 
superoxide, hydroxyl radical, singlet oxygen, and alpha-oxygen), produced in all aerobic 
cells generated during, for example, mitochondrial oxidative metabolism. Intermediate 
monocytes show higher mitochondrial ROS production than the other monocyte subsets 
in malaria patients, although similar ROS levels have been reported for intermediate and 
non-classical monocytes [116, 285]. Classical monocytes show lower levels of ROS 
production [116]. 
The induction of trained immunity requires specific, complex metabolic modulations 
[240, 253, 286], possibly also at the hematopoietic progenitor level [287, 288]. 
Metabolites are suggested to play a part in the epigenetic programming of trained 
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immunity by acting as cofactors for enzymes, such as methylases, methyltransferases, 
and histone deacetylases [94].  
Trained monocytes seem to exhibit impaired oxidative phosphorylation and lactate 
production, as well as disrupted tricarboxylic acid cycles at the citrate and succinate 
levels [94]. Citrate is withdrawn for fatty acid synthesis, while succinate activates HIF-
1α and consequently upregulates the expression of several pro-inflammatory cytokines, 
mainly IL-1β and TNF-α [94, 245].  
Immunometabolism is a complex field, and this overview regarding monocyte 
immunometabolism is far from complete. For some recent reviews, see [94, 106].  
1.5. MULTIPLE MYELOMA 
Multiple myeloma is a malignancy characterised by uncontrolled plasma cell 
proliferation, driven by intrinsic genetic abnormalities and extrinsic stromal cell support 
and usually detectable by monoclonal protein in blood or urine [289].  
1.5.1. Epidemiology and classification of multiple myeloma 
Multiple myeloma is the second most common hematologic malignancy and accounts 
for 1% of all cancers [289, 290]. The median age at the time of initial diagnosis is 70 
years; only 35-40% of patients newly diagnosed with the disease are below 65 years of 
age, while approximately 25% are 65–74 years, and 35–40% are above 75 years of age 
[291]. Monoclonal gammopathy of undetermined significance (MGUS) refers to the 
detection of monoclonal immunoglobulin without any symptoms or signs of disease; it 
seems to be present in 2–3% of the population above 50 years of age and is associated 
with an annual risk of 1% for transformation into multiple myeloma.  
Soldering multiple myeloma is characterised by the presence of monoclonal 
immunoglobulin in blood samples, increased (i.e., > 10%) plasma cells in bone marrow, and 
the absence of myeloma-related organ impairment. The overall risk of progression to 
multiple myeloma is approximately 10% per year for the first 5 years after diagnosis, 
3% for the next five years, and thereafter, 1% per year [292, 293]. Globally, multiple 
myeloma was responsible for approximately 100,000 deaths with an age-standardised 
death rate of 1.5 per 100,000 in 2016, and between 1990 and 2016, myeloma incidence 
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rates increased by 126% [294]. MGUS, smouldering myeloma, and multiple myeloma 
has a slight male predominance [295-297]. African Americans have a higher prevalence 
than European Americans, but the two groups have similar transformation rates [298]. 
These observations suggest that genetic factors contribute to the development of 
multiple myeloma.  
Multiple myeloma is usually characterised by bone marrow infiltration by abnormal 
plasma cells and is, thus, a bone marrow malignancy for most patients. The detection of 
circulating plasma cells in myeloma patients is usually associated with aggressive 
disease and reduced survival [299]. Studies of Ig gene sequences have shown extensive 
somatic hypermutation without interclonal variation, suggesting that multiple myeloma 
arises from postgerminal B-cells [300] and resembles memory B-cells [301]. However, 
malignant plasma cells seem to differ between patients; the analysis of CD19 and CD81 
expression in newly diagnosed myeloma patients reveals that a majority have malignant 
plasma cells with an immunophenotype similar to fully differentiated plasma cells, 
whereas, for a minority of patients, plasma cells have a phenotype similar to less 
differentiated stages [302, 303].  
1.5.2. The plasma cell population in multiple myeloma  
A recent study of disease heterogeneity used single-cell RNA sequencing and observed 
extensive subclonal structures for 10 out of 29 patients. They also used this technology 
to identify rare malignant plasma cells in asymptomatic patients with early disease and 
patients with minimal residual disease after previous antimyeloma therapy [303]. Thus, 
clonal heterogeneity seems to be relatively common, and this heterogeneity (including 
genetic heterogeneity) seems to be reflected in the gene expression profiles. 
A more detailed study of the plasma cell phenotype was performed by Robillard et al. 
[304]. They report that the predominant myeloma plasma cell immunophenotype lacks 
CD19 expression but shows increased expression of either CD56 or CD28. This is 
different from normal bone marrow plasma cells, which have high levels of CD19 alone 
or CD19 together with CD28/CD56. However, normal bone marrow also includes 
plasma cells that express one or both of CD28 and CD56 without CD19, or are 
completely devoid of all three surface markers. These observations clearly illustrate the 
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polyclonal heterogeneity of the normal bone marrow plasma cell population [304], 
whereas myeloma patients have a clonal bone marrow plasma cell population. The 
differential stage of this clonal plasma cell population may even have a prognostic 
impact regarding progression-free and overall survival rates. The presence of less 
mature plasma cells seems to be associated with an adverse prognosis, and later 
chemotherapy may represent a selection pressure with the preferential proliferation of a 
myeloma clone representing a distinct differentiation stage that is different from the 
initial majority of myeloma plasma cells [302]. Such myeloma plasma cell dynamics 
will usually favour the dominance of a less mature plasma cell phenotype compared to 
the dominant phenotype in the initial cell population 
Development and progression of multiple myeloma: Multiple myeloma is 
characterised by the proliferation of abnormal plasma cells secreting a monoclonal 
immunoglobulin, also referred to as monoclonal protein or M protein [289, 305, 306]. 
The most important complications, also referred to as end-organ damage, are renal 
failure, bone marrow failure, especially with anaemia and, possibly, other cytopenias, 
hypercalcemia, and bone disease leading to skeletal pain and, possibly, pathological 
fractures. The therapeutic intention for most myeloma patients is disease stabilisation 
rather than a cure; as will be described below, this is also true for younger patients below 
65–70 years of age who receive autologous stem cell transplantation [307-311]. The 
indications for treatment will usually be the development of end-organ complications. 
Multiple myeloma can be preceded by MGUS [297] or solitary plasmacytoma [289]. 
MGUS can be a non-IgM, IgM, or light chain type [289]. The M-component should 
generally be below 30 g/L; for the light chain MGUS, the free light chain ratio is 
abnormal with increased levels of the involved light chain [289]. The number of clonal 
plasma cells in the patient’s bone marrow should be <10%, and there should be no end-
organ damage, soft tissue plasmacytomas, or evidence or lymphoproliferative disease or 
circulating plasma cells. [295]. The overall annual progression rate of non-IgM MGUS 
is 1% [289]. Finally, patients with MGUS have an increased risk of fractures, and there 
is an increased prevalence of MGUS among osteoporosis patients [312]. 
 
- 32 - 
 
Solitary plasmacytomas are localised to bone or soft tissue, and they are defined as 
biopsy-proven monoclonal plasma cell lesions without evidence for end-organ damage, 
clonal plasma cells, or less than 10% clonal cells in the bone marrow [289]. The 3-year 
progression rate to multiple myeloma is 10% for plasmacytomas without clonal plasma 
cells in the bone marrow, 60% for bone plasmacytomas, and 20% for soft tissue 
plasmacytomas [289].  
MGUS has progressed to either smouldering multiple myeloma or multiple myeloma 
when bone marrow plasma cells exceed 10% [289, 313]. Smouldering myeloma is 
defined by the following two criteria [289]. First, serum IgG or IgA exceeds 30 g/L, 
urinary monoclonal protein exceeds 0.5 g/24 hours, or clonal bone marrow plasma cells 
are 10–60%. Second, the absence of myeloma-defining events or amyloidosis is 
required [313]. Smouldering multiple myeloma has a 10% overall annual risk of 
progression to multiple myeloma, but this risk varies considerably between patients. The 
following factors are associated with an increased risk of progression [314-318]:  
• A high percentage of bone marrow plasma cells. 
• A highly abnormal serum free light chain ratio is associated with a high risk of 
progression in some studies. 
• Increasing paraprotein levels or the presence of Bence-Jones proteinuria at the time 
of diagnosis. 
• Circulating plasma cells. 
• Immunoparesis with hypogammaglobulinemia. 
• The genetic abnormalities t(4;14), del17p, +1q24, and hyperploidy. 
• Increasing skeletal lesions. 
More detailed criteria for progression have been defined for several of these risk factors, 
and prognostic models based on two or three of these factors have also been developed 
[289, 317].  
The definition of multiple myeloma is generally based on (i) bone marrow plasma cells 
exceeding 10–60%, (ii) biopsy-proven bone or extramedullar plasmacytoma and either 
one end-organ damage (i.e., at least one of the four; hypercalcemia, renal insufficiency, 
anaemia or bone lesion) or at least one biomarker of malignancy (i.e., a bone marrow 
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plasma cell percentage of at least 60%, a highly abnormal free light chain ratio, or more 
than one skeletal lesion). More detailed diagnostic criteria for each of these 
events/biomarkers have been defined [289].  
Equilibrium between osteoblastic and osteoclastic activity is skewed from normal bone 
maintenance toward bone loss during myeloma progression, and myeloma-induced 
osteolysis is caused by a disease-driven increase in osteoclastic activity [319, 320]. 
The disease will often start as a single or a few plasma cell tumours and later progress 
with the development of new osteolytic lesions [321, 322]. For some patients, the 
development of aggressive plasma cell leukaemia will be the final event [321, 323]; 
malignant plasma cells then migrate into circulation and cause a ≥ 20% increase in 
circulating plasma cells with a risk of generating plasmacytomas at new locations 
outside the bone marrow [324].  
A recent study described a possible role of the NLRP3 inflammasome and its 
downstream cytokines in the development of myeloma [325]; such a role in myeloma 
pathogenesis for the cytokine network and immunocompetent cells has also been 
suggested by immunogenetic studies [326]. These observations further suggest that 
immunocompetent cells, immunogenetic factors, or both are involved in the 
pathogenesis of multiple myeloma.  
As described, above ≥10% clonal bone marrow plasma cells, along with one or more 
events attributed to the underlying plasma cell proliferative disorder, are diagnostic 
criteria for multiple myeloma. The other events are end-organ damage, an 
involved:uninvolved serum free light chain ratio of ≥100, more than one focal (e.g., 
skeletal) lesion on MRI examination, or clonal bone marrow plasma cells higher than 
60% [289].  
1.5.3. End organ damage in multiple myeloma: diagnostic criteria and 
indications for disease-stabilising treatment  
End organ damage events in multiple myeloma include hypercalcemia, renal 
insufficiency, anaemia, and bone lesions [289]. First, hypercalcemia is defined as serum 
calcium values at 0.25 mM/L above the upper-normal limit or above 2.75 mM/L. 
Second, renal insufficiency is defined as creatinine clearance less than 40 mL/minute or 
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serum creatinine values higher than 177 mM/L. Third, anaemia is defined as 
haemoglobin values at least 20 g/L below the lower normal limit or below 100 g/L. 
Finally, bone lesions are defined as one or more osteolytic lesions detected on skeletal 
radiography, computed tomography (CT), or positron emission tomography (PET)-CT 
[289]. 
The standard recommendation is that patients with ≥ 60% plasma cell involvement on 
marrow examination should be diagnosed and treated as having multiple myeloma 
irrespective of whether the CRAB criteria are fulfilled [289]. The reason is that 90% of 
these patients will progress to symptomatic disease within two years, and the median 
time to progression is only 7 months [289]. The percentage of plasma cells can then be 
based on bone marrow aspirate or biopsy examination, and if there is a discrepancy, the 
higher of the two values should be used [289]. The prognostic importance of the high 
bone marrow plasma cell percentage was first demonstrated in a small study [327] but 
was confirmed [327, 328].  
Genetic abnormalities in multiple myeloma: Many myeloma patients show clonal 
heterogeneity with multiple subclones early in the disease, and this heterogeneity may 
reflect genetic heterogeneity [329, 330]. Certain abnormalities are regarded as primary 
or disease-initiating (e.g., translocations involving the IgH locus), whereas other 
abnormalities are regarded as secondary events associated with disease progression 
[331]. A wide range of genetic abnormalities has been detected in myeloma patients. 
First, translocations involving the immunoglobulin heavy chain gene (IgH) on 
chromosome 14q32 have been detected in up to 65% of patients [318, 330]. The two 
most common translocations are t(11:14) and t(4:14), while t(14:16) is less frequent 
[332]. Second, several chromosomal deletions have been detected in myeloma cells; the 
single most important abnormality is del17p13, which is associated with shorter survival 
and an adverse prognosis [333]. Finally, hyperdiploidy is detected in up to 60% of 
patients. The most important clinical characteristics of common genetic abnormalities 
are summarised in Tables 9 and 10 [314, 315, 329, 334].  
An important question is whether the prognostic impact of a certain abnormality is 
influenced by the biological or genetic context in the myeloma cells or whether a factor 
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has a prognostic impact only if the patient receives a certain type of treatment. This 
question has been addressed for t(11;14), which has been regarded as a standard risk 
prognostic marker based on studies before the introduction of current therapies [335]. 
This study included 365 patients with t(11;14). These patients were compared with 730 
matched control patients; 132 of the controls had non-(11;14) translocations, and 598 
had no translocation. The median overall survival for these three patient subsets was 74, 
50, and 104 months; these differences were statistically significant when excluding 
patients with the adverse 17p abnormality, for patients younger than 65 years of age, 
and patients receiving the present novel agent-based induction. However, the overall 
survival for patients with t(11;17) was reduced by advanced age, the presence of the 17p 
abnormality, and an advanced disease stage. This example illustrates that the prognostic 
impact of defined genetic abnormalities may be modified by the clinical or genetic 
context, as well as the overall situation of the patient, reflected in the International 
Scoring System (often referred to as ISS, based on serum β2-microglobulin and albumin 
serum levels), but in this case, the type of treatment did not seem to have a major impact. 
A recently published Revised-ISS system incorporates genetic abnormalities into the 
prognostic evaluation of newly diagnosed myeloma patients and is based on the original 
parameters: β2-microglobulin and albumin, the karyotype (i.e., the presence of genetic 
abnormalities), and serum lactate dehydrogenase levels [336]. This should be regarded 
as a simple and updated prognostic classification system suitable for routine clinical 
practice.  
Another important question is whether the efficiency of certain antimyeloma drugs 
depends on the general clinical and biological context (i.e., the overall evaluation, as 
reflected in the Revised-ISS) or is mainly dependent on certain clinical factors and, 
especially, certain genetic abnormalities. This question has been addressed for the 
amplification of chromosome band 1q21. One study found that treatment including 
thalidomide improves the survival of patients lacking 1q21 amplification but not 
patients with the 1q21 amplification [337]. Another study reported that proteasome 
inhibitors, as well as immune-modulatory drugs (IMiDs), did not improve survival for 
patients with amplification 1q21, but these drugs were able to improve outcomes for 
myeloma patients with other abnormalities [338]. 
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Table 9. The prognostic impact of selected genetic abnormalities in multiple myeloma [317, 318].  
Abnormality 
Frequency in newly 
diagnosed myeloma 
Prognostic impact 
del17p13 5-15% • The most important single marker. 
• Negative prognostic factor or treatment based on 
proteasome inhibitors and IMiDs, but pomalidomide 
may be more effective. 
t(4;14) 15% • Adverse prognosis, both with regard to progression-
free and overall survival. Proteasome inhibitors can 
improve survival. Adverse prognosis for all IMiDs. 
t(11;14) 20% • Favourable prognosis. 
t(14;16) 2-3% • Conflicting results, but a negative impact has been 
described in certain studies. 
Gain 1q21 
Del(1p32) 
30-40% • Gain: Adverse prognosis both with regard to 
progression-free and overall survival both for 
proteasome inhibitor and ImiD-based therapy. May be 
directly implicated in resistance to bortezomib. 
• del1p32: Adverse prognosis. 
Hyperdiploidy or 
odd chromosomes 
60% • Hyperdiploidy usually consists of numerical gains but 
with a few structural changes; usually relatively good 
survival, but the impact differs between abnormalities. 
The prognostic impact differs even between trisomies; 
trisomy 21 impairs but trisomy 3 and 5 seem to improve 
overall survival. 
• Standard prognosis unless associated with a 
documented negative prognostic markers. 
• May neutralise the adverse impact of del17 or t(4;14). 
Number of genetic 
abnormalities 
 • Shorter survival of patients with combined del(13q14) 
or del(1p32) abnormalities, decreased survival when 
two adverse abnormalities are present. 
To conclude, karyotyping should be regarded as an important tool for the prognostic 
evaluation of multiple myeloma patients, but it should only be a part of this evaluation, 
combined with other prognostic parameters. Genetic analyses may also become 
increasingly important to guide antimyeloma therapy in future clinical practice.  
Diagnostic tools in multiple myeloma: Detailed recommendations for tools used in the 
diagnosis and monitoring of multiple myeloma were recently published [318]. These 
recommendations are based on the classification systems and biological characteristics 
described above. Among the most important recommendations are (i) the use of both 
bone marrow smears and biopsies to estimate the percentage of plasma cells in bone 
marrow, (ii) the use of an extended flow cytometric panel to distinguish between 
normal/reactive and monoclonal plasma cells, (iii) the use of karyotyping for extended 
prognostic evaluation, and (iv) the use of the Revised-ISS for prognostic evaluation. 
Guidelines for skeletal evaluation by imaging are also given [339, 340]. Although 
several studies suggest the analysis of gene expression profiles in malignant plasma cells 
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can be used for prognostic subclassification possibly in combination with the Revised-
ISS [341-343], the guidelines do not recommend the use of this parameter for the 
diagnosis or monitoring of myeloma patients in routine clinical practice.  
Table 10. Associations between genetic abnormalities and survival in a study [314] of 351 patients with 






Genetic abnormalities   
t(4;14) 28 months* 105 months* 
t(11;14) 55 months 147 months 
Trisomies alone  34 months  
del17p 24 months  
Other abnormalities 55 months  
No detectable abnormality Not reached   
All patients  135 months 
   
Defined risk groups   
1. High risk: del17p, t(4;14) 28 months 51 months 
2. Intermediate: trisomies 34 months 77 months 
3. Standard-risk: t(11;14), t(14;16), t(14;20), 
trisomy+IgH translocations. 
55 months 86 months 
4. Low-risk: No cytogenetic abnormalities detected Not reached 112 months 
   
* Significantly different from t(11;14). The study included 154 patients (43.9%) with trisomies, 127 (36.2%) with 
IgH translocations, 14 (4%) with both trisomies and IgH translocations, 53 (15.1%) with no detected abnormalities, 
and 3 (0.9%) with monosomy13/del(13q) alone. The patients with IgH translocations included 57 patients with 
t(11;14), 36 with t(4;14), 11 with musculoaponeurotic fibrosarcoma (MAF) translocations and 23 with other or 
unknown translocation partners. The patients were included in the period of January 1991 to June 2010. A total of 
219 patients showed progression during the observation period. The median period of follow-up was 82 months, 
and the patients’ median age was 63 years at the time smouldering myeloma was diagnosed. The risk groups were 
defined based on the observations in the present study. 
Treatment of multiple myeloma patients: Several drugs are now available or are in 
late clinical trials for the treatment of multiple myeloma, including second-generation 
proteasome inhibitors and IMiDs, monoclonal antibodies, histone deacetylase 
inhibitors, checkpoint inhibitors, and small molecules, have been included in a large 
number of drug combinations [344]. The treatment landscape and patient survival rates 
have changed over the past two decades, and patients now have improved median 
survival of 8–10 years [344]. A complete review of this complex scientific field is 
outside the scope of this thesis, as the focus is on the use of IMiDs in the treatment of 
multiple myeloma 
Autologous stem cell transplantation in the treatment of multiple myeloma: 
Autologous stem cell transplantation is currently considered the standard of care for fit, 
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newly diagnosed myeloma patients [344]. It was previously considered for patients 
below 65 years of age but is now also considered for fit elderly patients [344]. In elderly 
patients, one should consider reducing melphalan conditioning therapy and performance 
status, comorbidity should be carefully considered before the final decision is made. 
Pretransplant induction therapy usually consists of 3–6 cycles, the goal of which is to 
achieve disease control and decrease symptom severity, allowing successful stem cell 
collection [344]. The European guidelines state that the current standard should be a 
three-drug bortezomib-based combination, and most of these regimens include a steroid 
as the second drug [344]. The third drug was previously a conventional cytotoxic drug, 
such as doxorubicin or cyclophosphamide. However, the third drug can also be an IMiD; 
thalidomide was initially used, but lenalidomide seems to be more effective at achieving 
complete remission. However, a major concern when combining bortezomib with 
thalidomide or doxorubicin is the risk of thromboembolism [345]. The importance of a 
deep response provides the rationale for choosing a regimen with a strong antimyeloma 
effect and acceptable toxicity. The second-generation proteasome inhibitor carfilzomib 
has also been tried in combination with a steroid and either thalidomide or lenalidomide. 
This combination seems to achieve a complete remission rate of 18–24%. Despite these 
more recent results, the European guidelines conclude that standard treatment is a 
combination of bortezomib, a steroid, and IMiD or chemotherapy. 
The recommended conditioning therapy is melphalan 200 mg/m2; this dose is reduced 
to 100–140 mg/m2 for patients with renal failure, and a reduction should also be 
considered for patients above 65 years of age [344]. Conditioning regimens that include 
novel agents have only been investigated in single-arm studies [344]. Double 
transplantation should be considered for patients with high-risk disease [344]. The 
European guidelines recommend single transplantation to be considered for standard-
risk patients with a response to the induction treatment better than a very good partial 
response [344].  
Posttransplant consolidation therapy can be considered to increase the quality of the 
response [344]. Similar to the induction phase, the combination of a second-generation 
proteasome inhibitor and IMiD can be considered for maintenance therapy. Another 
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alternative is to use the original induction treatment. Consolidation can be administered 
in 2–3 cycles of a three-drug regimen [344].  
Maintenance therapy has also been investigated. The optimal maintenance therapy 
should prolong remission without reducing the patient’s quality of life and should not 
increase the development of multi-resistance or reduce overall survival [344]. The 
European guidelines recommend lenalidomide or thalidomide for two years or until 
progression; bortezomib is an alternative for high-risk patients [344]. Multiple 
retrospective studies have shown that continued chemosensitivity and remission 
duration after the first autotransplantation are the two most important prognostic factors 
for long-term disease stabilisation after salvage autotransplantation [344]. Several 
studies have also demonstrated that salvage transplantation is safe and has acceptable 
toxicity, and even a third transplantation may be possible for some patients [344]. The 
European guidelines recommend considering salvage transplantation after the first 
relapse in patients who have a minimum duration of remission of at least 18 months 
after the first autotransplantation; this cutoff can be extended to 24 months for patients 
receiving consolidation or maintenance therapy [344]. The patients should then receive 
pretransplant induction therapy with a triple combination, possibly including IMiD.  
Allogeneic stem cell transplantation in multiple myeloma: The role of allogeneic 
stem cell transplantation is controversial in multiple myeloma, but the available studies 
suggest it could be considered for young patients with high-risk disease, who usually 
experience poor outcomes and easily develop chemoresistance [344].  
First-line treatment of patients who cannot receive stem cell transplantation: 
Several therapeutic alternatives are possible for patients who are elderly or otherwise 
unsuitable for autologous stem cell transplantation [346]. One alternative is a 
thalidomide-based regimen (i.e., melphalan combined with prednisolone and 
thalidomide) or thalidomide in combination with cyclophosphamide and 
dexamethasone. However, major problems with both regimen are thromboembolic 
events and infections [345]. Lenalidomide- and carfilzomib-based regimens have also 
been suggested. Thus, IMiDs can also be considered part of the first-line treatment for 
these patients.  
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Treatment of relapsed multiple myeloma—alternatives to salvage 
autotransplantation: These patients should generally receive treatment with triple-
drug combinations [347]. A wide range of combinations has been investigated in clinical 
studies, including the following combinations: 
• Patients experiencing their first relapse after discontinuing treatment may receive 
treatment with triple combinations, including carfilzomib or daratumumab [348].  
• Frail patients experiencing their first relapse after discontinuing treatment may be 
treated with ixazomib, lenalidomide, and dexamethasone or, alternatively, 
elotuzumab, lenalidomide, and dexamethasone [348]. 
• Patients experiencing their first relapse on maintenance therapy may also be treated 
with triple-drug combinations, similar to patients with relapse after discontinuation 
[347, 348]. 
• Patients experiencing a lenalidomide-resistant relapse may be treated with triple 
combination therapy: daratumumab, bortezomib, and dexamethasone [348]. Such 
patients may also respond to pomalidomide-based regimens [349, 350].  
• An intensive regimen based on a proteasome inhibitor, IMiD, dexamethasone, and 
combinations of conventional cytotoxic drugs followed by autologous stem cell 
transplantation has been suggested [348]. Daratumumab or anthracycline-based 
regimen may be a less toxic alternative for patients with advanced or aggressive 
disease [348]. 
• Other combinations with less toxicity suggested for elderly (>75 years of age) and 
frail patients unfit for transplantation are karfilzomib and dexamethasone or 
daratumumab, bortezomib, and dexamethasone [348]. The choice of regimen should 
be based on the treatment received before the development of resistance.  
• Lenalidomide combined with carfilzomib or ixazomib has been tried [348]. 
• It has been suggested that exceptional frail patients may benefit from steroids in 
combination with daratumumab, elotuzumab, or ixazomib, but one should remember 
that high-quality data collected after third-line therapy in elderly patients are 
unavailable [348].  
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• Even low-dose melphalan or cyclophosphamide combined with dexamethasone may 
be an alternative for elderly or unfit patients with advanced disease [348]. 
To conclude, the treatment of patients with advanced disease needs to be individualised; 
many different combinations have been suggested, and IMiDs are included in many of 
these alternatives. Documented resistance, as well as performance status and 
comorbidity, should be carefully considered [351] 
1.6. ACUTE MYELOID LEUKAEMIA  
Acute myeloid leukaemia (AML) is a heterogeneous bone marrow malignancy. Acute 
promyelocytic leukaemia (APL) is an AML variant with specific genetic abnormalities 
and requires specific treatment. In this thesis, we refer to the non-APL variants of the 
disease when we use the term AML. 
1.6.1. The diagnosis of AML 
The diagnosis of AML is usually made by the morphological detection of at least 20% 
immature myeloblasts in the bone marrow, except for AML accompanied by the 
chromosomal abnormalities t(15;17), t(8;21), inv(16), or t(16;16) and certain subsets of 
erythroleukemia [352, 353]. Flow cytometric immunophenotyping to characterise the 
expression of surface and cytoplasmic molecules is used to verify and characterise the 
blasts’ myeloid phenotype in greater detail. Detailed flow cytometric characterisation 
may be used later to evaluate the treatment response by detecting minimal residual 
disease [352, 353]. Flow cytometric analysis is also essential for the diagnosis of AML 
with minimal differentiation, acute undifferentiated leukaemia [353], and acute 
megakaryoblastic leukaemia [352, 353].  
The prognostic evaluation of AML patients: AML patients are usually classified as 
having a favourable, intermediate, or adverse prognosis based on their genetic 
abnormalities [352]. A summary of this genomic classification, according to European 
Leukemia Net (ELN), is presented in Table 11. Favourable prognosis means long-term 
AML-free survival of 60–70%, while intermediate is 40–50%, and adverse is 
approximately 20% long-term survival. Thus, there is a need to identify other 
pretreatment prognostic factors to improve this classification [352]. The genetic 
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classification reflects the risk of chemoresistant leukaemia relapse for patients receiving 
intensive and potentially curative treatment.  
Table 11. The ELN prognostic classification of AML based on karyotype and molecular genetic analysis 




Favourable  • t(8;21)(q22;q22.1); RUNX1-RUNX1T1 
• inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 
• Mutated NPM1 and no FLT3-ITD or Flt3-ITDlow allelic ratio (defined as ratio <0,5*) 
• Biallelic mutated CEBPA 
 
Intermediate  • Mutated NPM1 and mutated FLT3-ITDhigh allelic ratio (ratio ≥0,5*) 
• Not mutated NPM1 and no FLT3-ITD or FLT3-ITDlow allelic ratio* (no adverse 
cytogenetic abnormalities) 
• t(9;11)(p21.3; q23.3); MLLT3-KMT2A (MLL); detection of t(9;11) is decisive if 
rare, high-risk mutations are also detected. 
• Cytogenetic abnormalities not classified elsewhere. 
 
Adverse • t(6;9)(p23;q34.1); DEK-NUP214 
• t(v; 11q23.3); KMT2A (MLL) rearranged 
• t(9;22)(q34.1;q11.2); BCR-ABL 
• Inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2,MECOM(EVI1) 
• -5 or del(5q); -7 -17/abnl(17p). 
• Complex karyotype; defined as ≥3 chromosomal abnormalities but absence of 
t(8;21), inv(16), t(16;16) and t(9;11). 
• Monosomal karyotype, defined as single monosomy (not the loss of X or Y), 
along with at least one additional monosomy or an additional chromosomal 
abnormality other than core-binding factor AML.  
• Non-mutated NPM1 with FLT3-ITDhigh allelic ratio. 
• Mutated RUNX1 or ASXL with no concomitant favourable classification.  
• TP53 mutation (often, concomitant complex cytogenetic abnormalities or 
monosomal karyotype).  
 
* FLT3-ITD allelic ratio defined by ELN as FLT3-ITD/ FLT3-WT. 
Age is also associated with decreased survival, which may, at least partly, be caused by 
the effect of age on the patient’s ability to tolerate chemotherapy, a low frequency of 
favourable cytogenetic abnormalities, and a higher frequency of secondary AML [352]. 
Finally, response to the first induction cycle is also an important prognostic parameter; 
the need for more than one cycle to induce complete haematological remission is 
associated with an adverse prognosis [354]. 
Approximately 60% of AML patients have cytogenetic abnormalities, as certain 
abnormalities show a strong association with myelodysplastic syndrome (MDS) and are 
regarded as a marker for previous MDS [352]. Certain genetic abnormalities detected in 
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MDS are also associated with progression to secondary AML (e.g., del 17p, TP53 gene 
mutation, and mutations in RUNX1, ETV6, EZH2, and ASXL1). Mutated SRSF2, 
EZH2, and ASXL1 can also identify patients with primary myelofibrosis and at high 
risk of developing secondary AML [352, 353]. AML patients with such genetic 
abnormalities indicating a transformed haematological malignancy have an adverse 
prognosis [352]. In contrast, NPM1 mutations, along with CBF 
and KMT2A rearrangements, are highly specific to de novo AML [352]. 
Complex karyotypes occur in 10–12% of patients, are associated with poor outcomes, 
and are defined as the presence of 3 or more chromosomal abnormalities in the absence 
of the favourable abnormalities t(8;21), inv(16) or t(16;16), and t(15;17) [353]. 
Cytogenetic evidence for clonal heterogeneity is associated with a complex karyotype 
and will further aggravate the prognosis [355]. A monosomal karyotype is also 
associated with very low AML-free survival [352]. As stated above, the high frequency 
of unfavourable genetic abnormalities in elderly patients contributes to their decreased 
survival [353]. Patients with genetic abnormalities not classified elsewhere are classified 
as intermediate; this group includes patients for whom an intermediate prognosis has 
been documented and uncommon abnormalities where the prognostic impact is 
unknown [353].  
A large number of mutations has been detected in AML [356]. The prognostic impact 
of NPM1, CEBPA, and FLT3 is generally accepted, whereas the possible impact of 
FLT3 tyrosine kinase domain (TKD) mutations at codons D835 and I836 remains 
controversial [352, 353]. However, other mutations may also have a prognostic impact. 
The ELN classification includes molecular genetic abnormalities that should be part of 
the routine clinical evaluation of AML patients [352, 353], but it is still regarded as 
controversial whether, for example, the detection of a KIT mutation will worsen the 
prognosis of patients with t(8;21) or inv(16)/t(16;16) [352, 353].  
1.6.2. Treatment of acute myeloid leukaemia 
AML can only be cured by intensive chemotherapy, possibly combined with autologous 
or allogeneic stem cell transplantation [352]. This therapy has a relatively high 
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treatment-related mortality but can be used in patients up to 70–75 years of age if they 
do not have severe comorbidity [352].  
Induction therapy: The aim of the initial induction treatment is to achieve disease 
control. The most common induction therapy is an anthracycline (e.g., daunorubicin 90 
mg/m2 daily for 1–3 days) combined with cytarabine infusion for 1–7 days; complete 
haematological remission (i.e., no morphological signs of AML in the bone marrow and 
normal cell counts in peripheral blood) is achieved in 60–80% of younger adults and in 
40–60% of patients older than age 60 [352].  
Consolidation therapy: Additional postremission consolidation is needed to eradicate 
residual disease, and several alternatives exist for this treatment. First, consolidation 
based on repeated cycles with high-dose cytarabine (3000 mg/m2 twice daily on days 1, 
3, and 5) is commonly used for patients younger than age 60 who have a favourable 
prognosis. Second, intensive treatment based on the combination of two or three 
antileukemic agents, usually including cytarabine, is another possibility. The 
consolidation will usually include two or three separate cycles. Third, autologous stem 
cell transplantation can be used for consolidation, especially in patients with a 
favourable prognosis. Finally, allogeneic stem cell transplantation can also be used as 
consolidation. This is the most effective but also the most toxic antileukemic treatment, 
and it is used especially for patients younger than age 70–75 without severe comorbidity 
and with an available suitable stem cell donor (i.e., an HLA-matched related or unrelated 
donor or, if possible, an HLA-identical sibling donor). Allogeneic stem cell 
transplantation is associated with early treatment-related mortality of 10–20%, and there 
is also a risk of later severe morbidity. This therapeutic strategy is used both for AML 
and for other haematological malignancies with a high risk of early chemotherapy-
resistant relapse (e.g., high-risk MDS and high-risk lymphoproliferative diseases).  
New strategies for the treatment of AML: Several new strategies are now available 
for the treatment of AML. First, midostaurin has been added to intensive chemotherapy 
and seems to cause a limited improvement in long-term AML-free survival in patients 
not receiving allogeneic stem cell transplantation [357, 358] Second, gemtuzumab 
ozogamicin (GO) is an antibody-toxin (calicheamicin) conjugate that targets 
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CD33+ AML, and recent studies suggest that adding GO is associated with improved 
relapse-free survival, especially in patients with a favourable prognosis and, possibly, 
intermediate-risk patients [359]. This drug may also be used in elderly patients up to age 
70 [360, 361]. Third, CPX-351 is encapsulated in nanoscale liposomes of cytarabine and 
daunorubicin at a synergistic 5:1 molar ratio; this agent may become useful even for 
high-risk patients and may also be used in elderly patients [362, 363]. Finally, inhibitors 
of mutated IDH are also used in the treatment of this patient subset [364]. 
The possible use of IMiDs in AML: Lenalidomide has been considered for use in 
AML, but it is not a part of the generally accepted treatment protocol [365]. It has been 
tried in combination with conventional intensive chemotherapy and as monotherapy 
after allogeneic stem cell transplantation. As expected, posttransplant treatment was 
associated with increased graft versus host activity [366]. 
1.7. IMUNNEMODULATORY DRUGS 
Thalidomide has beneficial effects against leprosy [367], as well as anti-angiogenic 
effects [368]. The beneficial effect against myeloma was detected two decades ago, and 
both thalidomide and its analogues, lenalidomide and pomalidomide, are currently used 
in myeloma treatment [369-372]. These drugs have antiangiogenic, immunomodulatory, 
anti-inflammatory, and antiproliferative effects [371, 372], and they are typically used 
in combination with steroids or proteasome inhibitors in myeloma treatment [373]. 
IMiDs have contributed to the improved overall survival of myeloma patients over the 
past two decades [374] 
Cereblon is a direct target of IMiDs and has important intracellular effects: 
Cereblon is a molecular target of IMiDs, and the therapeutic effects of IMiDs mediated 
by cereblon were reviewed recently [375]. Lenalidomide and pomalidomide bind more 
strongly to cereblon than thalidomide [376]. The following effects seem to contribute to 
the anticancer effects of IMiDs [375]: 
• Altered expression by c-myc and p21. 
• Lenalidomide binding induces ubiquitination and degradation of the transcription 
factors IKZF1 and IKZF3; both these factors are involved in B-cell maturation.  
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• Degradation of casein kinase 1a; this effect may lead to p53 activation, which seems 
to be a lenalidomide-specific.  
• Altered epigenetic regulation partly mediated by altered JAK-STAT signalling.  
• Altered cell cycle regulation. 
Thus, IMiDs have a common molecular target, but they differ in their binding to this 
target and in the intracellular consequences of cereblon binding. As stated above, they 
probably also have cereblon-independent effects. These differences may explain why 
myeloma patients developing resistance to one IMiD may not be resistant to the 
antimyeloma effects of other IMiDs [349, 350], and it may also explain the differences 
in toxicity profiles between different IMiDs [313]. 
Functional effects of IMiDs mediated via cereblon: Cereblon binding is important to 
several effects of IMiDs, and these effects may contribute to these drugs’ anticancer 
effects [375, 377]: 
• There seems to be dysregulation of various immunocompetent cells in many cancer 
patients (e.g., B-cells, NK cells, T-cells, and dendritic cells), along with an increase 
in the number of immunosuppressive cells (e.g., regulatory T- and B-cells and 
MDSCs; see [369]). Quantitative and qualitative monocyte defects have been 
reported, including the reduced release of proinflammatory cytokines [378-386]. 
IMiDs may improve the balance between effector functions and immunosuppressive 
activity. 
• IMiDs also seem to modulate cell adhesion mechanisms. 
• IMiDs’ antiangiogenic effects are linked to their cytokine modulation, which 
probably plays an important role in their anticancer effects. 
• IMiDs alters epigenetic regulation of gene expression, and such mechanisms seem 
to be important to its cytokine-modulating effects. 
• IMiDs alters oxidative stress with the generation of reactive oxygen species. 
• IMiDs seem to form a complex with damage-specific DNA binding protein 1 
(DDB1) and cereblon [375]; IKZF1 and CK-1α degradation, as well as IL-2 up-
regulation, are cereblon-dependent. The costimulation of proinflammatory cytokine 
release by activated T-cells thus seems to be a cereblon-mediated effect. 
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• Animal models suggest that IMiDs’ therapeutic effect may also be induced through 
a cereblon independent pathway [387], but cereblon seems to be critical to the effects 
of IMiDs on ubiquitination and the stability of cereblon-interacting proteins [388]. 
The cereblon-independent effect seems to contribute to IMiDs’ effects on 
inflammation/immunity. 
• IMiDs can activate caspase-8 and, hence, have pro-apoptotic activity [389].  
Thus, IMiDs have complex intracellular effects, as well as complex effects on 
interactions and communication between cells.  
1.7.1. Anticancer effect of IMiDs – the chronic lymphocytic leukaemia 
experience  
As described in detail in recent reviews, lenalidomide is regarded as a possible 
therapeutic target not only in multiple myeloma but also in other haematological 
malignancies, including AML and chronic lymphocytic leukaemia (CLL) [390-394]. 
The anticancer effects of lenalidomide have been studied in greater detail, especially in 
chronic lymphocytic leukaemia (CLL) [395], and several of the antileukemic 
mechanisms described in these studies may also be relevant to other haematological 
malignancies (Table 12) [152, 360, 376, 396-408]. The most important conclusion from 
CLL research is that IMiDs’ anticancer effects are very complex, which is unsurprising 
considering the complex effects of these drugs on intracellular regulation and 
extracellular crosstalk between a wide range of cells. First, lenalidomide seems to have 
non-cytotoxic, antiproliferative, and direct effects on CLL cells, whereas the 
observation of complete AML remission after lenalidomide monotherapy suggests that 
the drug can also have direct cytotoxic effects on malignant cells. A direct antileukemic 
effect favours the use of lenalidomide to treat various malignancies.  
Second, lenalidomide seems to increase the reactivity of several T-cell subsets, B-cells 
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Table 12. The use of lenalidomide in chronic lymphocytic leukaemia (CLL)— the effect of 
immunocompetent cells and their interactions with leukemic cells. 
 Effects on CLL cells 
 • Lenalidomide has no direct cytotoxic effect on leukemic cells [396], but it has an antiproliferative 
effect by binding to cereblon and, thereby, the induction of p21WAFI/Cip1. This effect is also 
seen in vivo during treatment with lenalidomide 5 mg daily [397]. Cereblon mediates 
antiproliferative effects for both lenalidomide and pomalidomide in malignant cells [376].  
 T-cell effects 
 • Decreased SOCS1 expression in CD4 and CD8 T-cells [398]. 
 • Increased T-cell production of IL2, TNFα, and IFNγ, and this increased T-cell cytokine release is 
induced via cereblon by lenalidomide and pomalidomide [376]. 
 • Increased CD8+ T-cell cytotoxicity. 
 • Pomalidomide activates  RhoA and enhances F-actin formation, and GTPase activation increases 
IL2 release [399]. 
 • Lenalidomide and pomalidomide inhibits FOXP3 positive, CTLA4 positive, and CD25high CD4+ 
T regulatory cell induction and proliferation, as well as inhibit their suppressive effect [400]. 
 • CLL cells cause the global inhibition of CD11a/CD18 (αLβ2)-mediated T-cell migration through 
altered Rho GTPase activation signalling, adhesion, and motility, which is reversed by 
lenalidomide [402].  
 B-cells 
•  • Lenalidomide seems to reverse the humoral immune defect in CLL [403]. 
 NK cells 
 • Increased NK cell cytotoxicity through the enhancement of NK cell immune synapse formation 
[400, 408].  
 • Decreased SOCS1 expression [398]. 
 Monocytes 
 • Lenalidomide inhibits the differentiation of nursing-like cells into an M1 phenotype with the high 
release of CCL2, IGF1, CXCL12, and HGF1 and has the ability to support T-cell proliferation 
[152, 404]. 
 • Pomalidomide activates RhoA, enhances F-actin formation, and increases cell migration [360].  
• Inhibit TLR4-induced cytokine release [400, 404]. 
 Effects on the leukemic cell microenvironment 
 • Decreased VEGF and FGFb release and increased angiopoietin release [405] 
 • Inhibited angiogenesis [405]. 
 CLL-immunocompetent cell interactions 
 • Downregulated PD-1/PDL1 interactions between T-cells and leukemic cells. 
 • Reduced nursing-like cell support to  leukemic cells by downregulating CCL2, IGF1, CXCL12, 
and HGF1 [152]. 
 • Impaired immunological synapse formation is reversed by lenalidomide[401]. 
 • Lenalidomide after immunochemotherapy induces the long-term repair of T-cell immune 
synapses and improves the quality of T-cell responses [402, 406].  
 • Lenalidomide interferes with the expression of the costimulatory molecules CD40, CD80, CD83, 
CD86, and CD40L n CLL cells after in vivo treatment [396]. 
 • Improved response to pneumococcal vaccines [407]. 
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improved functioning through the use of lenalidomide may then enhance autologous 
immune reactivity against malignant cells. Third, lenalidomide alters the bone marrow 
microenvironment, and both AML and multiple myeloma should be regarded as bone 
marrow malignancies supported by nonleukemic stromal cells through local 
angioregulation, as well as the functions of local nursing cells (e.g., monocytes and 
endothelial cells) of bone marrow stem cell niches [409].  
Finally, lenalidomide seems to favour antileukemic contact between immunocompetent 
and leukemic cells; it increases the expression of checkpoint molecules by leukemic 
cells and restores immune synapses. Defects in the formation of immune synapses are 
also observed in other haematological malignancies, such as human AML [409]. 
However, to the best of our knowledge, it is unknown whether lenalidomide or other 
IMiDs alter the AML cell expression of checkpoint molecules. Thus, although intensive 
conventional chemotherapy, as well as autologous and allogeneic stem cell 
transplantation, can alter the immune system and cause posttreatment CD4+ T-cell 
defects, patients receiving intensive chemotherapy have an operative immune system, 
and all immunomodulatory effects of lenalidomide described for CLL patients should 
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2. AIM OF THESIS 
Monocytes are a heterogeneous cell population that can be classified into three main 
subsets. Monocytes are important for immunoregulation and have an important role in 
regulating inflammation, but they are also important for the support of normal cells and, 
possibly, leukemic haematopoiesis. 
 The main aim of this thesis was to explore the potential use of monocyte subset analyses 
in clinical settings, with a focus on haematological malignancies. This was done through 
three objectives: (i) to establish a standardised flow-cytometric method for analysing 
monocyte subset levels in venous peripheral blood, (ii) use this method to characterise 
monocyte reconstitution in patients with haematological malignancies receiving stem 
cell transplantation, and (iii) characterise the effects of IMiDs (i.e., anticancer agents 
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3. STUDY DESIGN, ETHICAL AND METHODOLOGICAL CONSIDERATIONS  
3.1. STUDY DESIGN OF PAPERS I-IV 
The study designs were selected to answer the research questions/aims in our respective 
studies [410]. The study design of papers I and IV are categorised within the concepts 
of basic studies and in vitro experimental studies. Paper I is a method development study 
investigating the improvement of flow cytometry and immunophenotyping 
methodology for monocyte subset characterisation. In paper IV, we investigate the 
cause-outcome relationships between dependent (i.e., cytokines and ECAR) and 
independent (i.e., IMIDs) variables. In contrast, papers II and III are prospective, 
observational longitudinal studies conducted on a cohort of consecutively recruited MM 
and AML patients, with strictly defined criteria for inclusion, and the control cohort 
were individuals recruited from healthy blood donors, matched for age and gender.  
3.2. ETHICAL CONSIDERATIONS 
All studies were conducted according to the Declaration of Helsinki and were submitted 
for review by the Regional Ethics Committee (REK Vest, Bergen, Norway: Paper I: 
2015/1410, 2017/487; paper II: 2017/305, 2013/102; Paper III: 2015/1759, 2017/305, 
2013/102; Paper IV: 2017/305, 2013/635). All samples were collected after written, 
informed consent. None of our research interventions involved a major risk or burden 
to the research subjects. Conventional venous sampling is not associated with a major 
risk or burden, and the sampling of the patients (i.e., AML and MM-patients) and 
healthy blood donors was often done at the same time as the clinical samples. Hence, 
there was no need for an additional needle insertion, only the collection of additional 
blood. Blood collection from subjects with pancytopenia should, however, be carefully 
monitored and minimised. 
3.3. METHODOLOGICAL ASPECTS: THE PRE-ANALYTICAL PHASE 
 In laboratory medicine, pre-analytical concerns include sample collection, blood 
sampling tube additives, and the storage of blood samples [411]. Our findings in paper 
I regarding common pre-analytical [412-415] variables related to the (i) collection of 
insufficient sample volume, (ii) inappropriate sample tube types, and (iii) improperly 
stored samples, were important to the following papers, II–IV, as they helped establish 
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high quality standards and enhance data reproducibility. In our studies, phlebotomists 
collected blood samples in accordance with approved clinical protocols. All the patient 
material and the age- and gender-matched healthy control samples were collected in 
ACD-A anticoagulated blood sampling tubes and processed further within a specified 
time-period (papers II–III). Otherwise, for healthy donors, blood samples were collected 
in Li-Heparin, K2-EDTA or ACD-A (paper I). Blood samples collected at the blood 
bank (papers I–IV) were first drawn into the diversion pouch, also called a sampling 
pouch, for blood collection bags before being transferred into blood sampling tubes 
(papers I–III) and submitted to the standardised flow cytometry protocol, or the blood 
bag was processed into buffy coats (paper IV) before being submitted to monocyte 
enrichment. Using a diversion pouch means that the initial flow of blood was directed 
into a pouch. In addition to serving as a temporary reservoir for whole blood for 
sampling, the redirection was also intended to prevent bacterial contamination from 
entering the primary blood collection bag [416, 417]. To avoid possible clot formation, 
one should collect blood samples from the sample diversion pouch within approximately 
four minutes per the vendor’s recommendations. The standard procedure used by the 
Haukeland University Hospital’s blood bank facility is to collect blood from the pouch 
within one minute. One could argue that there are differences in human blood 
components (e.g., monocyte numbers) when comparing standard blood collection 
procedures to redirection through a diversion pouch. However, to our knowledge, as 
well as in the literature, there are no such differences; the only exception is, perhaps, the 
risk of bacterial contamination. 
3.4. METHODOLOGICAL CONSIDERATIONS: FLOW CYTOMETRY  
Multicolour flow cytometry [418, 419] provides the possibility to inspect populations 
of cells at a single-cell level, allowing cell populations to be separated by morphology 
(scatter properties) and fluorochrome-conjugated antigen-specific antibodies (e.g., 
immunophenotyping) or specific fluorescent dyes (e.g., SYTOX Red Dead Cell Stain 
for cell viability assessment). BD FACS Verse, the applied flow cytometer in this thesis, 
is equipped with three lasers: violet (405 nm with 40 mW optical power), blue (488 nm 
with 20 mW optical power) and red laser (640 nm with 40 mW optical power) and eight 
 
- 53 - 
 
fluorescent detection channels, along with forward scatter (FSC) and side scatter (SSC). 
For papers I–IV, the configuration was set to use all the three lasers; violet, blue, and 
red laser-detected in 2, 4, and 2 channels, respectively (see Table 13).  
Table 13. Overview of fluorochrome-conjugated antibodies used in papers I–IV related to FACSVerse 
configuration and a simplified overview of respective CD expression by human cells. 
Antibody 
specificity 
Fluorochrome Clones Laser PMT 
Filters 
CD marker expressed by 
Anti-CD11b V450 ICRF44 405 nm nn Monocytes, neutrophils, 
natural killer cells, 
granulocytes 
Anti-CD45 V500 HI30 405 nm nn Monocytes, granulocytes, 
lymphocytes 
Anti-CD14 Alexa 488 M5E2 488 nm nn Monocytes, neutrophilslow 
Anti-HLA-DR PE G46-6  488 nm nn Monocytes, DC, B-cells, 
Anti-CD16 PerCPCy5-5 3G8 488 nm nn Monocytes, NK cells, 
Neutrophils 
Anti-CD56 Alexa 647 / 700* B159 640 nM nn NK-cells 
*In paper I, a change in fluorochrome was necessary due to the viability assessment in panel C and the use of 
SYTOX Red Dead Cell Stain. Abbreviations: PMT, photomultiplier tubes 
A standardised daily and monthly clean program was performed on the BD FACS Verse. 
Quality control routines and performance tracking (BD FACSuite™ CS&T research 
beads) indicated the flow cytometer performed well throughout our studies. In addition, 
our samples were run at a medium-to-low flow rate, which prevented a wider core 
stream, minimised data spreading (decreased CV for the population of interest), and 
hence, improved the quality of the data obtained. By applying appropriate compensation 
controls, spillover coefficients were determined and corrected for each experiment, 
taking into the account day-to-day variations. All compensations were performed by 
utilising BD™ CompBead Anti-Mouse Ig and a κ/Negative Control Compensation 
Particles Set. When compensation methods were compared using single-staining and 
beads, the generated compensation matrices were not significantly different from each 
other [420, 421] and had good accuracy in a 12-colour panel [422].  
The selection of fluorochrome and CD-marker panels involves interlocked issues 
and us crucial for good quality data in flow cytometry. For instance, steric hindrance or 
fluorescence resonance excitation transfer between neighbouring fluorochromes (e.g., 
PE and PE-CY7, resulting in false PE-CY7 signals) could be problematic. In our panel 
(see Table 11), we minimised the use of tandem dye-conjugated antibodies. We could 
not, however, avoid the possibility of steric hindrance, as CD45, CD11b, HLA-DR, and 
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CD14 are all markers expressed in abundance and were used for the selection of 
monocytes in our gating strategy. However, in support of our targets and selected gating 
strategy, one recent publication presents optimised flow cytometry panels in which the 
monocyte panel does, indeed, contain anti - CD45, anti - HLA-DR, and anti - CD11 as 
a prerequisite for further monocyte gating (CD14+ and CD16-/+) [423]. However, a more 
simple variant with HLA-DR+ as the only prerequisite was published recently [172]. We 
used a dump channel to avoid contamination by unwanted cell populations. Autessier et 
al. recommend using only one marker per channel to exclude populations when possible 
[422]. Our panel included CD56 for the exclusion of NK cells, which also express CD16 
[165]. Moreover, in our studies, monocytes were sub-divided into three subsets based 
on CD16 and CD14 expression. This classification system has limitations, as CD14 
seems to be expressed in a continuity, leading to subjective gating of the non-classical 
and intermediate subsets. CD16 expression is also changeable, making the identification 
of subsets difficult and impossible after, for example, cryopreservation (paper I). Several 
alternative markers for use in monocyte subset detection have been suggested (see Table 
5).  
The selection of specific antibody clones for the flow cytometry panel was based upon 
conducting an in-depth literature search and selecting the antibody clones most often 
used for the specific antigen of interest. One could argue that using this approach is a 
drawback in our studies. For example, newer and, perhaps, improved antibody clones 
may have been missed, and we cannot be sure that factors (e.g., temperature, ionic 
strength, pH levels, and incubation duration) affecting the antigen-antibody reaction are 
the same in our experiments or that such a selection can be made [424]. However, all 
our selected clones of antibodies are (i) known antibody clones used and published by 
other researchers in the field and (ii) properly titrated by us to find the optimal staining 
index for our experiments and the applied flow cytometer. 
In conclusion, currently, within the flow cytometry methodology for monocyte 
characterisation, there seems to be (i) no agreement in the literature regarding which 
selection/exclusion markers should be used for proper monocyte subset identification 
and, hence, (ii) no agreement on standardising multicolour flow cytometry panels, 
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including, for instance, clones of antibodies and fluorochrome combinations. We have, 
however, taken measures in our studies to avoid several potential pitfalls of flow 
cytometry methodology.  
3.5. METHODOLOGICAL CONSIDERATIONS: EXTRACELLULAR FLUX ASSAY  
High throughput metabolic profiling by Seahorse extracellular flux assays made it 
possible to observe differences between quiescent, activated, and memory immune cells 
[425-427], evaluate the effects of changes in the cellular microenvironment [428-430], 
and assess the capability of drugs to alter metabolic phenotypes [431, 432]. As 
previously outlined, monocytes undergo concentration-dependent metabolic changes 
when activated. For instance, the LPS/TLR4-induced activation of monocytes may 
increase both glycolysis and oxidative phosphorylation [272-275]. Mitochondrial 
oxidative phosphorylation, measured as the oxygen consumption rate (OCR) [433, 434], 
is most likely a contributor to cellular ATP demand during monocyte activation. In paper 
IV, we assess whether immunomodulatory drugs (i.e., IMIDs such as thalidomide and 
analogues) display mitochondrial susceptibility; if they do, oxygen consumption is, thus, 
affected, and extracellular acidification increases accordingly as cells attempt to avoid 
mitochondrial insult through increased glycolytic flux [435].  
XFe96 analysers measure the oxygen consumption rate (OCR) and extracellular 
acidification rate (ECAR) of live cells simultaneously in a 96-well plate format. The 
oxygen consumption rate is an established measure of mitochondrial function, while the 
extracellular acidification rate is an estimate of glycolytic activity under certain 
conditions. 
In the following section, the principle of Seahorse XFe96 is briefly outlined. Pre-
hydrated probes on the sensor cartridge are lowered into the wells of the 96-well plate, 
creating a microchamber in close proximity to the cellular monolayer, allowing 
differences in O2 concentration (OCR: measured as picomol oxygen per minutes, 
pMol/min) and protons (ECAR: milli-pH units per minutes, mpH/min, are measured). 
The sensor cartridge also contains four injection ports that allow up to four stimulants 
or drugs to be injected into the wells of the cell plate in sequential order and the effect 
on OCR and ECAR to be measured in real-time.  
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In paper IV, Seahorse XFe Cell Mito Stress Test Kit as applied to provide information 
on mitochondrial function. Mitochondria are the power plants of cells, producing the 
majority of ATP through oxidative phosphorylation (OXPHOS), which refers to redox 
reactions (substrate oxidation) involving the electron transport chain and ATP synthase 
complexes. The kit contains the following compounds added sequentially in the 
following order through the injection ports: (i) oligomycin, (ii) carbonyl cyanide-p-
trifluoromethoxyphenyl-hydrazon (FCCP), and (iii) rotanon and antimycin A (see 
Figure 3 and its description for details of the reactions). Due to the added compounds, 
OCR was measured through the key parameters of mitochondrial function: (i) basal 
respiration, (ii) ATP production, (iii) proton leak respiration, (iv) maximal respiration, 
and (v) spare respiratory capacity. Simultaneously, ECAR values were measured 
consistently, allowing the calculation of OCR/ECAR ratios.  
 
 
Figure 3. Overview of the Seahorse XF Cell Mito Stress Test. (A) Basal respiration is derived by measurements 
of baseline cellular oxygen consumption, from which non-mitochondrial oxygen consumption is subtracted (see 
E). (B) Oligomycin, an inhibitor of complex V (inhibition of final complex of OXPHOS), is added. The resulting 
decline in OCR is used to derive two parameters: (i) ATP-linked oxygen consumption (respiration), by subtracting 
the oligomycin rate from the baseline cellular OCR, and (ii) proton leak respiration, by subtracting non-
mitochondrial oxygen consumption from the oligomycin rate. (C) Protonophore carbonyl cyanide-
ptrifluoromethoxyphenyl-hydrazon (FCCP), a mobile ion carrier, is added, leading to the collapse of the inner 
membrane gradient, driving the electron transport chain to function at its maximal rate. The maximal respiratory 
capacity is derived by subtracting non-mitochondrial oxygen consumption from the FCCP OCR. (D) Adding two 
inhibitors of the electron transport chain (ECT), antimycin A (a complex III inhibitor) and rotenone (a complex I 
inhibitor), shuts down the electron transport chain function and reveals non-mitochondrial respiration, allowing 
oxygen from the soundings to be accounted for, as it contributes to the OCR. (E) The mitochondrial reserve 
capacity is calculated by subtracting basal respiration from the maximal respiratory capacity. (F) The extracellular 
acidification rate (ECAR) is primarily a measure of lactate production and can be equated to the glycolytic rate 
(i.e., glycolysis), and ECAR is measured simultaneously with OCR in the Seahorse assay. Basal ECAR refers to 
the ECAR measured before the injection of oligomycin. The glycolytic reserve capacity is calculated by 
subtracting the basal ECAR from the oligomycin-induced ECAR. 
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Unlike OCR, ECAR is not unambiguously linked to extracellular acid production. 
Changes in extracellular pH are due to both lactate from anaerobic glycolysis and CO2 
from the Krebs cycle. From glycolysis, glucose is converted into lactate- and H+, and 
from respiration, CO2 export and hydration to H2CO3, leading to dissociation into HCO3- 
and H+. The pentose phosphate pathway also contributes to acidification, and 
experimental conditions allow determining the proportion of acidification between 
glycolysis and respiration. This includes the cell type and substrates provided, and 
acidification may be derived completely from either glycolysis or respiration. ECAR 
only determines anaerobic glycolysis, whereas glycolysis (glucose metabolised to 
pyruvate) includes pyruvate metabolism to acetyl Coenzyme A [436-438].  
Seahorse data normalisation is vulnerable due to, for instance, changes in cell viability, 
mitochondrial density, or protein levels. However, normalisation is commonly achieved 
using either protein assay or cell counting [427, 430, 439, 440]. In paper IV, the values 
were normalised to protein content via BCA assay. One could argue that additional 
measurements of, for example, cell viability or the adjustment of data to cell numbers 
in paper IV would have strengthened data quality. However, to obtain reproducible data 
within the linear detection range of the XFe96 analyser, the following optimisation of 
the assay was performed: (i) titration of monocyte numbers, (ii) titration of oligomycin 
and FCCP concentrations, and (iii) titration of the LPS concentration.  
We analysed a mixed subset of monocytes, and one could, therefore, claim that this 
introduced great heterogeneity to the examined monocytes. However, one could argue 
that isolating monocyte subpopulations based on CD14 and CD16 does not necessarily 
ensure homogeneity [174]. 
In conclusion, the Seahorse XFe cell analyser provides OCR and ECAR values for the 
same sample, while other ways to obtain these parameters may require performing two 
separate assays [441, 442]. The ability to show changes in both OCR and ECAR allow 
investigating the relationship between glycolysis and mitochondrial respiration in live 
cells and is a major advantage of this analysis. In contrast, the ability to identify site-
specific changes (e.g., damage to components of the respiratory chain or anaplerotic 
enzymes) are reduced in this assay [443]. Furthermore, the advantage of XFe96 analysis 
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is that single wells are seeded with relatively few cells, can give information about 
mitochondrial functions, including basal respiration, ATP production, proton leak 
respiration, maximal respiration, spare respiratory capacity, and non-mitochondrial 
respiration, with relatively high throughput.  
Table 14. Overview of the literature: monocytes and the use of seahorse methodology. 
Cells Kit / 
Focus 
Monocyte source and isolation Cell 
number 
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NT* NT* [427] 
*NT, not tested 
Finally, currently, within the Seahorse XFe cell analyser methodology for monocyte 
characterisation of energy metabolism, there seems to be no standardised methodology 
for monocyte subset characterisation (see Table 14 for an overview of the literature). 
The variety of experimental Seahorse XFe conditions used by investigators to measure 
mitochondrial function in monocytes makes comparison amongst studies challenging 
[279, 283, 427, 430, 444-446] 
 
- 59 - 
 
4.1 SUMMARY OF RESULTS  
3.6. ARTICLE I  
Standardisation of sampling and sample preparation for the analysis of human 
monocyte subsets in peripheral blood  
Authors: Ida Marie Rundgren, Øystein Bruserud, Anita Ryningen, and Elisabeth Ersvær. 
Summary of background 
As important immune cells, monocytes are interesting in many clinical settings. 
However, to further develop monocyte analysis as a clinical tool, it is vital to improve 
and standardise sample collection and handling procedures. We aimed to investigate the 
effect of different blood sampling tube anticoagulants, insufficient sample volume, and 
cryopreservation on monocyte subset analysis. 
Summary of study design and methodology  
We analysed the distribution of monocyte subsets in blood sampling tubes with different 
anticoagulants, in insufficient and correctly filled blood sampling tubes, and in fresh and 
cryopreserved PBMC by flow cytometry.  
Summary of results  
We detected no significant differences in the various monocyte subpopulations between 
the different anticoagulated sampling tubes. However, there was a significant difference 
in the percentage of total monocytes between different anticoagulants, also observed in 
the absolute cell count.  
For the K2EDTA samples, no significant differences were detected between the 
differently-filled K2EDTA tubes. For the differently-filled ACD-A samples, we detected 
a significant difference between the two samples of reduced sample volume regarding 
the percentage of total monocytes. For the monocyte subpopulations, a significant 
difference was detected between fresh and cryopreserved PBMCs with respect to the 
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3.7. ARTICLE II  
Circulating monocyte subsets in multiple myeloma patients receiving autologous 
stem cell transplantation – A study of the preconditioning status and course until 
posttransplant reconstitution for a consecutive group of patients  
Authors: Ida Marie Rundgren, Elisabeth Ersvær, Aymen Bushra Ahmed, Anita 
Ryningen, and Øystein Bruserud. 
Summary of background 
Autologous stem cell transplantation (ASCT) is the recommended strategy for managing 
multiple myeloma in patients younger than age 65–70. Monocytes are suggested to be 
involved in the pathogenesis of multiple myeloma, as contributors to multiple myeloma 
bone disease. We monitored the regeneration of monocyte subsets after autologous stem 
cell transplantation.  
Summary of study design and methodology 
Blood samples from multiple myeloma patients who received autologous stem cell 
transplantation were collected at different stages of treatment. All blood samples were 
directly subjected to flow cytometry analysis using a standardised protocol for monocyte 
subset detection. 
Summary of results  
MM patients also showed a wider range of monocyte subsets, both in absolute and 
relative values, compared to healthy controls. We continued by comparing patient 
samples at each collection time point by paired sample analysis. We observed a 
significant reduction in monocytes by conditioning therapy. Unsurprisingly, this was 
also detected in the monocyte subsets, and a further reduction during neutropenia was 
observed. Monocytes also show early regeneration, detected in absolute values, and in 
classical and non-classical monocytes. Monocytes reached normalisation levels before 
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3.8. ARTICLE III  
A pilot study of circulating monocyte subsets in patients treated with stem cell 
transplantation for high-risk haematological malignancies  
Authors: Ida Marie Rundgren, Elisabeth Ersvær, Aymen Bushra Ahmed, Anita 
Ryningen, and Øystein Bruserud.  
Summary of background 
Autologous and allogeneic stem cell transplantation is used in the treatment of high-risk 
haematological malignancies. Monocytes are probably involved in haematological 
reconstitution and posttransplant immunoregulation because they are a part of the bone 
marrow stem cell niche and, therefore, may influence outcomes after transplantation.  
Summary of study design and methodology 
We used a highly standardised flow cytometric method to characterise peripheral blood 
monocyte subset levels at different time points during the treatment of patients who 
received autologous stem cell transplantation.  
Summary of results  
During remission, patients showed a majority of classical monocytes and severe, early 
posttransplant monocytopenia. During the first few days after transplantation (i.e., 
during cytopenia), most of the circulating monocytes showed a non-classical phenotype, 
but later, most showed a classical phenotype. The patients showed a greater variation 
range of classical monocytes during remission and regeneration than healthy controls. 
The total peripheral blood monocyte levels normalised very early, before neutrophil 
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3.9. ARTICLE IV  
Immunomodulatory drugs alter the metabolism and the extracellular release of 
soluble mediators by normal monocytes. 
Authors: Ida Marie Rundgren, Anita Ryningen, Tor Henrik Anderson Tvedt, Øystein 
Bruserud, and Elisabeth Ersvær. 
Summary of background 
Immunomodulatory drugs (IMiD) are used in the treatment of haematological 
malignancies and have direct anticancer effects, but they also have indirect effects via 
cancer-supporting stromal cells. Monocytes are a stromal cell subset whose metabolism 
is modulated by the microenvironment, and they communicate with neighbouring cells 
through the extracellular release of soluble mediators. Toll-like receptor 4 (TLR4) is a 
common regulator of monocyte metabolism and mediator release. Our aim was to 
investigate IMiD’s effects on these two monocyte functions. 
Summary of study design and methodology 
 We compared the effects of thalidomide, lenalidomide, and pomalidomide on in vitro-
cultured normal monocytes activated by lipopolysaccharide (LPS, a TLR4 agonist) or 
cultured in media alone. Metabolism was analysed by the Seahorse XFe 96 cell analyser. 
Mediator release was measured as culture supernatant levels by Luminex. 
Summary of results 
TLR4 was shown to regulate both monocyte metabolism and mediator release. 
Monocyte metabolism was altered by all three IMiDs, especially when cells were 
cultured with LPS, with the strongest effect for lenalidomide. IMiDs also decreased 
TLR4-induced mediator release, with the strongest effect for pomalidomide, whereas 
lenalidomide and, especially, thalidomide had weaker effects. IMiDs alter monocyte 
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4. GENERAL DISCUSSION  
There has been growing evidence of and interest in the possible clinical uses of 
monocyte subsets analyses by flow cytometry for inflammation [447, 448], autoimmune 
diseases [449], infection [100, 450-457], and cancer [458-460]. Monocyte 
subpopulation analyses are also used in the diagnosis of chronic myelomonocytic 
leukaemia [458-460] and may contribute to the prognostic evaluation of patients’ MDS 
[459, 460].  
Monocytes seem to be involved in the development of multiple myeloma bone disease, 
which is characterised by osteoclast activation and the absence of functioning 
osteoblasts, with the final effect being bone resorption [159, 383, 461, 462]. CD16+ bone 
marrow monocytes in myeloma patients have distinct features compared with 
smouldering myeloma and MGUS patients; they overexpress IL21R, which may induce 
osteoclastic differentiation [159, 383, 385]. Activin A is a TGF-β cytokine that 
stimulates osteoclastogenesis; it is derived from bone marrow monocytes and mediates 
the osteoclastogenic effect of IL-3 in myeloma. Non-classical monocytes are a potential 
cytological marker for osteoclast precursors [159, 462]. Lenalidomide enhanced 
differentiation toward dendritic cells of both bone marrow and the peripheral blood 
monocytes of MM patients and increased the chemokine and cytokine production, 
degrading Ikaros, a transcription regulator of hematopoietic cell differentiation, and 
Aiolos, a transcription factor of lymphocyte differentiation [463]. 
Monocytes seem to be important in stem cell mobilisation and the regulation of 
hematopoiesis [409, 464], and they are a part of the bone marrow stem cell niche [465, 
466]. A subset of monocytes characterised by the expression of the Tek tyrosine kinase 
receptor TIE-2 also seems important for the paracrine induction of angiogenesis in 
malignant diseases [467]. Such bone marrow cells have also been detected in various 
haematological malignancies [467]; in these cases, this monocyte subset seems to 
support the growth of malignant cells [467]. Bone marrow monocytes may, thereby, 
support the survival and growth of myeloma stem cells [468]. 
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4.1. MONOCYTE REGENERATION AFTER STEM CELL TRANSPLANTATION 
Patients included in the transplantation studies: In the second study, we investigated 
patients with multiple myeloma receiving autologous stem cell transplantation. The 
European guidelines recommend that cytogenetic analyses and bone marrow biopsies 
should be a part of the routine handling of patients with multiple myeloma [344], but 
unfortunately, these data were unavailable for our patients. However, we emphasise that 
the patients included in paper 2 represent all but one patient admitted for autologous 
stem cell transplantation from a defined geographical area during a defined time period. 
Our study should, therefore, be regarded as population-based and including unselected 
patients; for this reason, it is likely that our patients constitute a representative cohort. 
Our patients were treated largely in accordance with the European guidelines published 
in 2018 after the end of our study; this statement is based on the following data (see 
Section 1.5): 
• Our patients have an expected median age for an autotransplanted patient cohort. 
However, we did not perform transplants in patients older than age 65 at that time, 
whereas the present guidelines state that autotransplantation can be considered for 
older patients. 
• In accordance with the guidelines, our patients receiving a second transplant had not 
received maintenance or consolidation therapy, had a previous posttransplant 
stabilisation lasting for at least 18 months, and received a second transplant in their 
first relapse. 
• The patients were heterogeneous regarding their induction treatment, but we regard 
all regimens to be in accordance with the guidelines, both the drug combinations and 
the number of cycles.  
• The European guidelines state that myeloma patients should achieve better than very 
good partial remission before transplantation; this was not the case for our patients, 
as they reached very good partial remission (17 patients) or partial remission (7 
patients) according to the generally accepted criteria for response evaluation in 
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multiple myeloma [469, 470]. However, we emphasise that all our patients had an 
objective response to the induction treatment.  
• We used standard melphalan conditioning therapy, as recommended. 
• The time until haematological reconstitution was as expected. 
Thus, even though our patient cohort was relatively small and genetic analyses were 
unavailable, we would regard it as representative because our study is population-based, 
and patients were treated in accordance with generally accepted European guidelines.  
We would also regard the allotransplant recipients included in our third study/article to 
be representative even though the cohort was small [352]: 
• We included consecutive and unselected patients planned for allotransplantation at 
the time of initial diagnosis. 
• All allotransplanted patients reached pretransplant remission. 
• All AML and MDS patients received standardised anthracycline/cytarabine 
induction treatment and cytarabine-based consolidation therapy. 
• Although the conditioning therapy differed, we emphasise that we used well-known 
regimens for all patients. 
• The time until haematological reconstitution was as expected.  
However, we only investigated patients transplanted with matched sibling donors for 
high-risk bone marrow diseases, and our observations may, therefore, be representative 
only for this subset of allotransplant recipients. 
Expected immunological reconstitution after autologous stem cell transplantation: 
Immunological reconstitution after autologous stem cell transplantation has been 
reviewed previously, and similar observations have been made in various types of 
patients receiving this treatment [471]. First, the level of circulating B-cells is low for 
3–18 months, and serum immunoglobulin levels (IgM up to 6 months, IgG 12–18 
months, and IgA up to 36 months) are decreased for several months. In vivo antibody 
responses are also reduced for months to years. Secondly, the levels of circulating CD4+ 
T-cells can be low for months to years, whereas CD8+ T-cell levels usually normalise 
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earlier, after 3–18 months. T-cells also show functional abnormalities for 6 months to 
several years. Finally, NK cell levels and functions normalise within a few weeks.  
Patients with early lymphoid reconstitution seem to have a more favourable prognosis 
than patients with late reconstitution (generally evaluated on day +15 or +30 
posttransplant) [472-475]. This prognostic impact of early lymphoid reconstitution 
suggests that early posttransplant events are important for outcomes after autologous 
stem cell transplantation. Future studies should, therefore, clarify whether early 
monocyte reconstitution is important for the early lymphoid reconstitution or whether 
lymphocyte-monocyte crosstalk is important for the prognostic impact of lymphocyte 
levels.  
Expected immune reconstitution after allogeneic stem cell transplantation: 
Although allotransplanted patients have a long-lasting quantitative and qualitative T-
cell effect [476-478], early lymphoid reconstitution reaching a level of at least 0.3 x 
109/L on day +15 and day 30 posttransplant is associated with positive outcomes after 
transplantation and improved survival [479]. Total monocyte counts also showed an 
association with prognosis in this study. In total, these observations suggest that 
immunological or inflammatory events early after posttransplantation are important for 
later outcomes. This hypothesis is supported by several other observations. First, 
pretransplant recipient characteristics are associated with outcomes after 
allotransplantation [480, 481]. Second, donor and graft characteristics are also 
associated with prognosis [482, 483]. Finally, the use of G-CSF therapy to support 
posttransplant engraftment has an adverse prognostic impact, especially for patients 
receiving conditioning therapy, including total body irradiation [484, 485]. 
Experimental studies suggest that irradiation increases the G-CSF responsiveness of 
immunocompetent cells [486]. As discussed in article 3, monocyte levels after 
allotransplantation are associated with prognosis. Based on our present study describing 
the early reconstitution of various monocyte subsets, researchers should investigate 
monocyte subset reconstitution in larger studies to clarify whether differences in early 
monocyte reconstitution are associated with prognosis and whether early monocyte 
targeting should be tried in allotransplant recipients.  
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4.2. THE POSSIBLE USE OF MONOCYTE SUBSET ANALYSES IN FUTURE CLINICAL 
MEDICINE 
Several previous studies have described altered levels of circulating monocyte subsets 
in patients with a wide range of diseases. Some examples of observations in common 
human diseases are given below: 
• Alzheimer’s disease. Animal models suggest that monocyte subsets are altered in 
this disease, with a decrease in the peripheral blood levels of CCR2+ monocytes, 
which seems to have a neuroprotective effect [450, 451].  
• Cardiovascular events. The absolute count of intermediate monocytes seems to 
predict cardiovascular events [452]. Statin-treated coronary artery disease is 
associated with increased non-classical monocytes, whereas acute stroke is 
associated with increased levels of circulating intermediate monocytes [453].  
• Cardiovascular disease and chronic renal failure. Cardiovascular calcification is 
regarded as a predictor of cardiovascular events/disease in patients with chronic renal 
failure; this process of calcification is complex and involves several cells, including 
endothelium, vascular smooth muscle cells, fibroblasts, and 
monocytes/macrophages [454]. Furthermore, the proportion of circulating 
CD14+CD16+ monocytes is abnormally high in both dialysed and nondialysed 
patients with chronic kidney disease [455]. Thus, the intermediate monocyte subset, 
regarded as the most proinflammatory, is also regarded as a cellular marker of the 
chronic inflammation associated with cardiovascular disease and chronic renal 
failure [454].  
• Microbiota. Circulating components derived from the microbiome and metabolites 
modified by bacteria can influence hematopoiesis [100], but to the best of our 
knowledge, it is unknown whether this mechanism can alter the levels of various 
monocyte subsets.  
• Effects of various infections. The associations between infections and altered levels 
of monocyte subsets have been reviewed recently, and for more detailed information 
and additional references, we refer the reader to reference [453]. First, sepsis is 
associated with increased levels of circulating intermediate and, possibly, 
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nonclassical monocytes; this seems to be true both for adults and pediatric patients. 
The same is true for tuberculosis. Second, several viral infections are also associated 
with increased levels of intermediate or nonclassical monocytes, including dengue 
fever and hepatitis B and C.  
• Autoimmune and inflammatory diseases. Increased levels of the intermediate 
monocyte subset have been described in active Chron’s disease, rheumatoid arthritis, 
and asthma [453] 
• Drug effects. Steroids decrease nonclassical monocyte levels but increase classical 
monocytes levels [456]. Whether statins contribute to the increased levels of 
nonclassical monocytes in patients receiving them for coronary artery disease needs 
further studies for clarification [453]. 
• Pregnancy. Variations in monocyte levels observed in pregnancy were reviewed 
recently [457]. Studies of monocyte subset levels in pregnancy have produced 
conflicting results, but patients with preeclampsia have increased peripheral blood 
monocyte counts, increased monocyte-lymphocyte ratios, and at the same time, 
increased levels of the CD14++CD16++ subset but decreased levels of the 
CD14++CD16- monocyte subset.  
Taken together, these examples clearly show that levels of circulating monocyte subsets 
are altered in many human diseases. However, for most of these examples, it is unknown 
whether the altered subset levels have any predictive or prognostic impact, as well as 
whether the therapeutic targeting of abnormal monocyte subset levels is an effective 
strategy in any of these diseases.  
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5.  CONCLUSION AND FUTURE PERSPECTIVES 
There are several clear examples that altered levels of circulating monocyte subsets are 
altered in human diseases, but little is known whether any of these alterations have a 
predictive or prognostic impact. More studies are, therefore, needed to further elucidate 
whether targeting abnormal distributions of monocyte subsets is of potential therapeutic 
value in any of these diseases. Thus, additional studies should be performed to clarify 
whether analysing monocyte subsets should be incorporated into routine clinical 
protocols, especially in patients with infectious, autoimmune, or inflammatory diseases. 
The second important question is whether additional monocyte subsets exist; as 
discussed previously, heterogeneity has been reported for all three monocyte 
subpopulations, and a more thorough biological characterisation of circulation 
monocyte populations in various diseases is needed.  
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A B S T R A C T
Introduction: Monocytes are important for innate immunity and include the classical (CD14brightCD16negative),
intermediate (CD14brightCD16dim) and non-classical (CD14dimCD16bright) monocyte subsets. The quantification of
these functionally different subsets in peripheral blood may become useful for diagnosis and follow-up in human
diseases. The aim of the present study was to investigate how different pre-analytical parameters influence
analysis of monocyte subsets in peripheral blood samples.
Methods: We determined relative levels of monocytes and monocyte subsets by flow cytometry of peripheral
blood samples derived from healthy individuals. A gating strategy exclusively extracting viable CD14+ mono-
cytes and focusing on the three monocyte subsets was applied. We investigated the effects of (i) various an-
ticoagulants (i.e. Li-Heparin, ACD-A, K2EDTA), (ii) insufficient filling of blood sampling tubes, (iii) cryopre-
servation. In addition, we analysed expression of the CCR2 chemokine receptor.
Results: The relative numbers of CD14+ monocytes depended on the anticoagulant used, whereas the fraction of
the three monocyte subsets did not. Insufficient filling of blood sampling tubes altered the relative levels of
monocytes out of leukocytes, but not the relative levels of the monocyte subsets. Finally, the fraction of CD14+
monocytes out of isolated peripheral blood mononuclear cells was not significantly altered by cryopreservation,
but the relative percentages of monocyte subsets was altered (similar effects for ACD-A and K2EDTA samples)
and this was observed in correlation to a decreased CD16 expression.
Concluding remarks: Analysis of the monocyte subsets (i.e. classical, intermediate, non-classical) in peripheral
blood samples requires a careful standardization of peripheral blood sampling and pre-analytic handling of the
samples with respect to the anticoagulant used, filling of sample tubes, and cryopreservation of cells prior to
analysis.
1. Introduction
Circulating monocytes (Jakubzick et al., 2017) represent around
10% of peripheral blood leukocytes (Swirski et al., 2009), and following
extravasation they differentiate into macrophages or dendritic cells
(Jakubzick et al., 2017) but they may also differentiate in endothelial
direction (Arderiu et al., 2017). Based on their expression of CD14 (a
cell surface co-receptor for lipopolysaccharide) and CD16 (the low af-
finity IgG receptor) the circulating monocytes can be divided into the
three main subsets, termed classical (CD14brightCD16negative), inter-
mediate (CD14brightCD16dim) and non-classical (CD14dimCD16bright)
monocytes (Passlick et al., 1989; Franca et al., 2017; Ziegler-Heitbrock
et al., 2010; Patel et al., 2017). Classical monocytes normally com-
prise> 90% of the circulating monocytes, release proinflammatory
cytokines like IL-6, are phagocytic and mediate a wide range of re-
sponses to pathogens (Franca et al., 2017; Patel et al., 2017; Mukherjee
et al., 2015; Skrzeczynska-Moncznik et al., 2008; Cros et al., 2010;
Wong et al., 2011; Boyette et al., 2017). In contrast, the intermediate
monocytes seem to release anti-inflammatory cytokines (e.g. inter-
leukin (IL)-10) + and proinflammatory cytokines, e.g. tumour necrosis
factor-α (TNF-α) and IL-1β (Franca et al., 2017; Patel et al., 2017; Cros
et al., 2010; Wong et al., 2011; Boyette et al., 2017). Finally, the non-
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classical subset seems to be involved in tissue repair; their capacity of
cytokine release is less well characterized and they bind viruses as well
as nucleic acids through their expression of Toll-like receptor (TLR) 7
and 8 (Patel et al., 2017; Skrzeczynska-Moncznik et al., 2008; Cros
et al., 2010; Boyette et al., 2017). Monocytes are thus important
members of the innate immune system, they function as im-
munoregulatory cells and animal studies suggest that functional re-
programming through epigenetic mechanisms will induce innate
memory that is important for the defence against infections (Bekkering
et al., 2015; Hamon and Quintin, 2016; Quintin et al., 2012). Taken
together these observations suggest that the possible clinical use of
monocyte subset analysis for the diagnosis and/or follow-up during
treatment of human diseases should be further explored, e.g. for pa-
tients with inflammatory disorders (Rogacev et al., 2012; Williams
et al., 2017), autoimmune diseases (Chara et al., 2015), severe infec-
tions and cancer (Greenberg, 2017; Selimoglu-Buet et al., 2017; Talati
et al., 2017).
Pre-analytical factors may have a major impact on later analyses of
peripheral blood samples (Lippi et al., 2015). Such factors can be col-
lection of insufficient sample volumes, use of suboptimal anticoagulants
or storage of samples (Kalra, 2004; Wallin et al., 2008; Plebani and
Carraro, 1997; Carraro and Plebani, 2007; West et al., 2017). Patient-
associated variables (e.g. fasting, physical exercise, genetic factors and
previous infections) may also influence the results (Appleby et al.,
2013; Da Silva Neves et al., 2015; Crosslin et al., 2013; Kahn et al.,
2016). Such pre-analytical factors are important for quantification of
total monocyte blood counts (Buttarello, 2004), but to the best of our
knowledge their impact on monocyte subset identification and quanti-
fication has only been addressed in two previous studies (Appleby et al.,
2013; Ji et al., 2017), investigating differences between the two an-
ticoagulants K2EDTA and sodium citrate (Ji et al., 2017) and effects of
delayed analysis (Ji et al., 2017) and cryopreservation (Appleby et al.,
2013). Further development of monocyte subset analysis as a clinical
tool will probably require a careful standardization of sampling and
sample handling. In this context, we have investigated in more detail
the effects of pre-analytical factors on the flow cytometric detection
(i.e. relative levels of various monocyte subsets) of circulating mono-
cyte subsets.
2. Material and methods
2.1. Ethical statement and study population
The study was conducted according to the Declaration of Helsinki,
and was submitted for review by the local Ethics Committee (Regional
Committees for Medical and Health Research Ethics, REC West, Bergen,
Norway) (REK 2015/1410, 2017/487). The study was characterized as
a laboratory quality improvement project, and the donor identity was
not registered. Our data contains no information that can identify the
individual sample donors. All donors were healthy adults volunteering
after informed consent (see Supplementary Table 1).
2.2. Blood sampling
Well trained biomedical laboratory scientists performed the vene-
puncture of the antecubital vein for all experiments. For experiment A
(see Supplementary Fig. 1) we standardized the procedure by per-
forming all phlebotomies in the morning and instructed the donors to
eat only a light meal before sampling, and everything was done to
ensure a relaxed and comfortable atmosphere. Blood was collected by a
closed-loop system directly onto K2EDTA (4mL, #367862, BD vacu-
tainer, San Jose, CA, USA, spray dried), Li-Heparin (4mL, #454029
Greiner Bio-one Vacuette®, Kremsmünster, Austria, spray dried) and
ACD-A (9mL,#248,368, BD Vacutainer, San Jose, CA, USA) blood
sampling vacuum tubes from 22 donors. For all subsequent studies (see
Supplementary Fig. 1, experiment B and C) blood sampling was
undertaken at the Blood Bank Services at Haukeland University
Hospital (HUH, Bergen, Norway). We then used a pre-donation sam-
pling bag for blood bags (TERUFLEX blood bag systems, TERUMO BCT,
Lakewood, CO, USA), and blood was thereafter transferred to K2EDTA
(spray dried; 6 mL #456023, Greiner Bio-one Vacuette®,
Kremsmünster, Austria,) or ACD-A (9mL #248368, BD Vacutainer, San
Jose, CA, USA) vacuum collection tubes. Blood sampling tubes were
immediately turned over 6–10 times, incubated at room temperature
for at least 15min but not more than two hours after blood collection
before further processing.
We followed the same highly standardized procedures in all these
experimental studies of freshly isolated cells; for three donors we in-
cluded analysis of cell viability (SYTOX™ Red Dead Cell Stain, Thermo
Fischer Scientific, InvitrogenTM, #S34859) and in all these studies the
viability was very high and the fraction of dead cells considered to be
negligible (data not shown).
2.3. Insufficient blood sample volume
K2EDTA (6mL) or ACD-A (9mL) vacuum collection tubes were
filled with insufficient sample volume (Supplementary Fig. 1, experi-
ment B). Blood was collected in the pre-donation sampling bag for
blood bags as described in Section 2.2; 1.5mL (¼ of correct volume),
3 mL (½ of correct volume) or 6mL (correct volume, 1/1) of whole
blood from 9 donors were drawn into separate K2EDTA vacuum tubes
containing 1.8mg/mL of dipotassium EDTA when filled with correct
volume. Alternatively, 2, 4 or 9mL were drawn into separate tubes
containing ACD-A (8 donors). The resulting ratios of whole blood to
ACD-A were 2:1 (¼ filled), 4:1 (½ filled) and 9:1 (correctly filled, 1/1),
respectively.
2.4. Isolation of peripheral blood mononuclear cells (PBMC),
cryopreservation and thawing
2.4.1. Isolation of PBMC
ACD-A (9mL) or K2EDTA (6mL) blood sampling tubes were col-
lected. Blood samples were diluted 1:2 in 0.9% sodium chloride (9 g/L
# 884239, Fresensius Kabi, Oslo, Norway) and peripheral blood
mononuclear cells (PBMC) collected from the interphase after density
gradient separation (Lymphoprep™ #07801, Stemcell Technologies,
Oslo, Norway, specific density 1.077 g/mL) with centrifugation at
800×g for 30min. Cells were washed twice at room temperature with
0.9% sodium chloride (Fresensius Kabi, Oslo, Norway) by centrifuga-
tion at 400×g for 8min. Cells were resuspended in 10mL of phos-
phate-buffered saline (PBS, Department of microbiology, Haukeland
University Hospital, Bergen, Norway). Approximately 1× 106 cells
were processed for subsequent flow cytometry analysis, while the re-
maining cells were cryopreserved (see Supplementary Fig. 1, experi-
ment C, and immunofluorescence staining protocol in Section 2.5.2.
2.4.2. Cryopreservation and thawing
The cells (1–2.5×107 cells) were suspended in 1 to 2mL RPMI
1640 (#R5886-500ML, SIGMA/Merck KGaA, Darmstadt, Germany)
supplemented with 40% inactivated fetal bovine serum (FBS; #DE14-
801F, LONZA, Basel, Switzerland) and an equal volume of RPMI 1640
plus 20% dimethyl sulfoxide (DMSO, #D2650-100ML, SIGMA/Merck
KGaA, Darmstadt, Germany), for a final DMSO concentration of 10%.
The cells were aliquoted immediately after (1 mL per freezing vial) and
frozen by a controlled rate freezer before vials were transferred to li-
quid nitrogen. Each vial contained 0.5–1.25× 107 PBMC. All samples
were handled by sterile techniques and frozen within 2 h.
After at least 3 weeks of storage, samples were analysed. The sam-
ples were then thawed by hand before RPMI 1640 was immediately
added, samples were thereafter centrifuged and washed once in PBS
(HUH, Bergen, Norway) before being stained for flow cytometry. We
conducted a small-scale study to evaluate the effect of a short recovery
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time post-cryopreservation on CD16 and CCR2 (CD192) expression. For
each of the three healthy donors we collected ACD-A and K2EDTA blood
samples that were prepared for direct flow cytometry and for cryo-
preservation. After thawing the cryopreserved PBMC were both directly
immunostained and seeded at 1×106 cells per well in a 24 well plate
and incubated for 90min at 37 °C in a humidified atmosphere of 5%
CO2. The plate was thereafter left on ice for 5min to release adherent
monocytes. The cells were collected by tilting the plate and rinsing each
well by pipetting the medium from the bottom to the top of the well
several times. Subsequently, the plate was washed once more with cold
RPMI 1640 medium before collection and immunofluorescence staining
of the cell; the collection of cells was controlled by light microscopy of
the wells and detachment of the cells could then be confirmed.
2.5. Flow cytometric analysis of membrane molecule expression
2.5.1. Flow cytometry
All analyses were performed by an 8-parameter BD FACS Verse
equipped with 404 nm, 488 nm and 640 nm lasers. Instrument quality
control was done on a daily basis using BD FACSuite™ CS&T Research
Beads (#650621, BD Biosciences, San Jose, CA, USA). For each run
single stained compensation beads (#552843, BD Biosciences) were
prepared and applied for compensation. Unstained samples served as
gating controls. The concentrations used of each antibody were de-
termined by titration, and for each sample at least 5000 monocytes
based on SSC/FSC properties were counted and analysed by FlowJo
software (Tree Star, Inc., OR, USA). The gating strategy is shown in
Supplementary Fig. 2.
2.5.2. Immunostaining of whole blood samples and PBMC
Whole blood (100 μL) was added to flow cytometry tubes containing
the appropriate antibody mixture and volume; cells were thereafter
incubated for 30min at room temperature in the dark and subsequently
haemolysed according to the manufacturer's instructions (# 55589, BD
Biosciences). Samples were thereafter washed once in 1% BSA
(#10735086001, Roche, Basel, Switzerland) in PBS, centrifuged
(200×g, 5 min) before analysis. Alternatively, the PBMC concentration
was adjusted to 0.5–0.75×106 cells per 100 μL staining buffer (PBS,
HUH, Bergen, Norway) containing 1% BSA (#10735086001, Roche,
Basel, Switzerland) and 10% Octagam (100mg/mL, Octapharma,
Lachen, Switzerland). The cells were thereafter added to tubes con-
taining anti-human antibodies (see Section 2.5.3) and finally incubated
in the dark on ice for 20min before being washed once in PBS with 1%
BSA and analysed by flow cytometry.
2.5.3. Antibody panels
As can be seen from Supplementary Fig. 1 mouse anti-human CD14
(clone M5E2), CD56 (clone B156), and CD16 (clone 3G8, all from BD
Biosciences, San Jose, CA, USA) served as a basis for the monocyte
subset identification in all our experiments. In experiment B and C the
antibody panel included mouse anti-human CD45 (clone HI30), CD11b
(clone ICRF 44) and HLA-DR (clone G46-6, all from BD Biosciences).
K2EDTA blood samples in experiment C included in addition a dead-
viable marker (SYTOX™ Red Dead Cell Stain). The small-scale part of
the cryopreservation study (N=3; evaluation of a recovery time after
cryopreservation and thawing) included staining with and analysis of
mouse anti-human antibodies (all from BD Biosciences) specific for the
following molecular markers; CD192 (CCR2, 48,607, BV421), CD45
(HI30, PerCpCy™5.5), CD16 (3G8, PE-Cy™7) CD11b (D12, BV510),
CD56 (B156, Alexa 700) CD14 (M5E2, Alexa 488) and HLA-DR (G46–6,
PE); but for these studies we also included SYTOX Red Dead Cell Stain
and CountBright™ Absolute Counting Beads (Thermo Fischer Scientific,
# C36950).
2.6. Differential blood count
Differential blood counts were estimated for the K2EDTA and Li-
Heparin blood samples in experiment A (see Supplementary Fig. 1).
Blood samples were then analysed 15–45min after collection by the
ABX Pentra XL 80 hemocytometer (Horiba Medical, Kjeller, Norway).
Quality control sample (ABX Minotrol CRP2, Horiba, Albany, NY, USA)
was applied prior to analysis and at two hours intervals.
2.7. Statistical analyses
All statistical analyses were conducted using IBM SSP statistics 23.
One-way analysis of variance (one way ANOVA) was used with
monocyte subsets as grouping variables and post hoc tests to determine
significance between groups. Paired sample t-test was used instead of
one way ANOVA when appropriate. P-values below 0.05 were regarded
as statistically significant. We did not compare data across the various
experiments; hence, only within-subjects comparisons were performed.
3. Results
3.1. Only the relative levels of total circulating monocytes but not the
relative distribution of the three monocyte subsets differed between ACD-A,
Li-Heparin and K2EDTA samples
We investigated the relative representation of monocytes out of
leukocytes as well as the monocyte subsets for 22 healthy donors when
using three different anticoagulants; K2EDTA, Li-Heparin and ACD-A,
following protocol as described for experiment A (see Supplementary
Fig. 1). The median percentages of CD14+ monocytes of leukocytes
differed significantly between ACD-A (median 4.4%), Li-Heparin
(median 3.9%) and K2EDTA (median 5.8%; p=0.006). In contrast, the
median percentages of the classical monocyte subset (median relative
levels 84.1, 82.6 and 83.1%, ACD-A, Li-Heparin, and K2EDTA, respec-
tively), the intermediate subset (median relative levels 5.5, 4.0 and
4.8%, ACD-A, Li-Heparin, and K2EDTA, respectively) and the non-
classical subset (median 6.5, 6.6 and 6.4%, ACD-A, Li-Heparin, and
K2EDTA, respectively) among total monocytes did not differ when
comparing the three anticoagulants. Results are presented in Fig. 1A.
We also determined the absolute numbers of monocytes as well as
the other leukocyte subsets and platelets when using differential blood
cell counting by an automated hemocytometer (see Fig. 2), and this
analysis showed higher absolute levels of monocytes for the antic-
oagulant K2EDTA (median 0.57×109/L) than for Li-Heparinized
(median 0.43× 109/L, p < 0.0001). The absolute numbers of mono-
cyte subsets, calculated from the differential blood cell count and the
median relative percentages of monocyte subsets from the flow cyto-
metry analysis, indicate higher levels of classical monocytes for the
anticoagulant K2EDTA (median 0.48× 109/L) than for Li-Heparinized
(median 0.39×109/L). This is in contrast to intermediate and non-
classical monocytes, where results indicate equal relative levels irre-
spective of the anticoagulant used (Supplementary Table 2). The ab-
solute numbers for lymphocytes and granulocytes were both within the
laboratory reference ranges for healthy adults (Helse Bergen, 2018),
however, both cell types was statistical significant altered by the use of
Li-Heparin (Fig. 2). By calculating the neutrophil to lymphocyte ratio
(NLR) a declined relationship from mean 1.3 for K2EDTA to 0.99 for Li-
Heparin was observed (p < 0.0001 by paired sample t-test; Fig. 2B).
For the differential blood cell count, the largest difference was observed
for platelets with median level of 254×109/L in K2EDTA samples
versus 143× 109/L in Li-Heparin anticoagulated blood samples
(p < 0.0001).
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3.2. The relative distribution of the monocyte subsets was not altered by a
reduced blood sample volume
We collected blood from healthy adults onto ACD-A (N=8) and
K2EDTA (N=9) anticoagulation tubes; the tubes were filled with either
correct volume (1/1) or reduced volumes, i.e. ½ and ¼ of the correct
sample volume. Samples were further handled as described for ex-
periment B (Supplementary Fig. 1). We compared the percentage of
total CD14+ monocytes among total peripheral blood leukocytes for
tubes filled with either the correct (1/1) volume or ½ or ¼ of the
correct sample volume. For the ACD-A samples, the median percentages
of CD14+ monocytes was 5.7%, 5.2% and 7.2% respectively; these
differences were statistically significant (p=0.044 by One Way-
ANOVA). The same trend was seen for K2EDTA anticoagulated blood
with reduced sample volume (median 4.9% and 5.0% for ½ and ¼
respectively) compared with the correct sample volume (median 6.3%),
but was not statistical significant (Fig. 1B).
We also compared the percentage of classical, intermediate and
non-classical monocyte subsets in ACD-A and K2EDTA samples when
the tubes were filled 1/1 or with reduced volumes corresponding to ½
and ¼ of the correct blood sample volume. The percentage of the
various monocyte subsets did not differ between the various sample
volumes, and this was true both for the ACD-A and K2EDTA samples
(Fig. 1B).
3.3. Cryopreservation of PBMC alters the relative distribution of monocyte
subsets
Cryopreserved PBMC were stored for at least 3 weeks before
thawing and subsequent flow cytometric analysis; ACD-A samples de-
rived from 9 donors and K2EDTA samples derived from 10 donors were
analysed according to Protocol C and a viable/dead marker was
Fig. 1. Effect of pre-analytical variables on the detection of monocytes and various monocyte subsets. Circulating leukocytes in peripheral blood samples from
healthy individuals were studied. The figure presents the results for all three experiments (A, B and C) that are described in Supplementary Fig. 1; the experimental
variables are given to the left in the figure. All the results are presented as box and whisker plots where the vertical line presents the median level, the boxes represent
the upper and lower quartiles (the interquartile range); the two lines outside the box (the whiskers) represent the variation range. In all parts of the figure we present
(from left to right) the results for analysis of CD14+ monocytes among total leukocytes and the percentages of classical CD14brightCD16negative, intermediate
CD14brightCD16dim and non-classical CD14dimCD16bright. The number of individuals tested is indicated to the lower right in each part of the figure. (Panel A)
Anticoagulants. We compared the effects of the three anticoagulants ACD-A, Li-Heparin, and K2EDTA on the analysis of monocytes and monocyte subsets. (Panel B)
Insufficient sample volume in ACD-A tubes (upper, N=8) and K2EDTA tubes (lower, N=9). The tubes were either correctly filled (1/1) or filled with a reduced
volume (½ and ¼ filled). (Panel C) Cryopreservation; monocyte distribution in ACD-A PBMC (upper, N=9) and K2EDTA PBMC (lower, N= 10). Post- and pre-
cryopreservation relative levels are indicated. Statistically significant as P < 0.05 by One Way-ANOVA (Panel A and B) or paired sample t-test (Panel C): p < 0,05:*;
p < 0.01:**; p < 0.001:***.
Fig. 2. Differential blood cell counts from K2EDTA
and Li-Heparin anticoagulated blood. Peripheral
blood samples derived from 22 healthy individuals
were investigated. Panel A indicate the median ab-
solute numbers of platelets, total white blood cells
(WBC), neutrophils, lymphocytes and monocytes
(×109 cells/L). The differential blood cell counts
were estimated by Pentra XL80. All counts except for
the WBC showed a significant difference between
K2EDTA and Li-Heparin blood samples
(***p= 0.0001, paired sample t-test). The data in
panel B are presented as the NLR (neutrophil to
lymphocyte ratio) for 22 healthy donors (X) of
K2EDTA and Li-Heparin blood samples. Horizontal
line indicate median and vertical line indicate the
95% confidence interval. The difference between
K2EDTA and Li-Heparin samples was significant by
paired sample t-test (***p=0.0001).
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included for the K2EDTA blood samples (see Supplementary Fig. 1). The
percentage of CD14+ monocytes among PBMC was not significantly
altered by the cryopreservation; this was true both for ACD-A and
K2EDTA samples (Fig. 1C). In contrast, the percentage of the three main
monocyte subsets among total monocytes was significantly altered after
cryopreservation. For the ACD-A samples the classical monocyte subset
increased from a median relative level of 86.4% before cryopreserva-
tion to 99.9% after preservation (p=0.013, Fig. 1C), whereas the in-
termediate (median 2.4% before preservation) and non-classical
(median 7.7% before preservation) monocyte subsets could not be de-
tected after preservation (p=0.001, Fig. 1C). For the K2EDTA samples
the statistically significant effect of cryopreservation was a decrease of
the non-classical monocyte subset from 5.9% to 1.1% (p=0.001,
Fig. 1C). Finally, remaining adherent cells could not be detected by
light microscopy of the wells after the recovery procedure; this ob-
servation makes selective loss of monocyte subsets due to plastic ad-
hesion to be less likely (data not shown).
Our present study cannot explain our observations when analysing
cryopreserved cells. However, based on the overall results from our
present methodological studies we can conclude that; (i) flow-cyto-
metric studies of monocyte subsets should preferably be done in fresh
samples, (ii) analyses of fresh and cryopreserved cells cannot be directly
compared, and (iii) if cryopreserved cells are analysed this require
careful standardization of the methodology and a very careful inter-
pretation of the observations.
3.4. Only cryopreservation but not different anticoagulants and insufficient
sample volume alters CD16 expression by circulating monocytes
CD16 expression is an important marker for subclassification of
monocytes (Passlick et al., 1989; Ziegler-Heitbrock et al., 2010), and for
this reason the effects of pre-analytical factors on relative CD16 levels
was investigated in more detail. Firstly, we investigated the effects of
the three anticoagulants ACD-A, Li-Heparin and K2EDTA on CD16 ex-
pression for monocytes derived from 22 healthy adults (see Section
3.1). There was no difference between these three anticoagulants with
regard to CD16 (MFI, mean fluorescence intensity) expression (Fig. 3A).
Secondly, differences in sample volumes (see Section 3.2) did not alter
CD16 expression and this was true both when using ACD-A (N=8) and
K2EDTA (N=9) as the anticoagulant (Fig. 3B). Finally, in contrast to
the above described results, cryopreservation and thawing altered CD16
expression (MFI) significantly, and this was seen both when using ACD-
A and K2EDTA as the anticoagulant. For ACD-A a significant decrease
correspond to 40 times whereas for K2EDTA the decrease was only 2
times (Fig. 3C). The additional experiments demonstrated that a short
recovery period after thawing did not have any statistical significant
effect on CD16 expression compared to cryopreserved and direct im-
munostained PBMC (Fig. 3D). However, the absolute numbers indicate
loss of cells after the short recovery period of 90min (see Supplemen-
tary Table 3). This small-scale study also suggests that the MFI of CD14
was doubled in PBMC compared to whole blood for both K2EDTA and
ACD-A samples (see Supplementary Fig. 3).
3.5. Monocyte CCR2 levels decrease due to both PBMC isolation and
cryopreservation
The CCR2 chemokine receptor (CD192) is important for regulation
of monocyte trafficking and has been used to aid classification of the
three monocyte subsets (França et al., 2017). Previous studies have also
shown that cryopreservation of cells seems to reduce the level of var-
ious cell surface molecules (Sasnoor et al., 2003). We therefore in-
vestigated the CCR2 levels in a small-scale experiments (N=3) for
whole blood samples and for PBMC before, immediately after cryo-
preservation and after a post-thawing recovery period. The CCR2 levels
decreased after gradient separation of PBMC and this decrease was seen
for all three monocyte subsets. However, no further decrease was seen
after cryopreservation and CCR2 could be detected mainly for the
classical monocyte subset when investigating cryopreserved PBMC.
This is illustrated in Fig. 4.
4. Discussion
The various monocyte subsets differ in their functions, membrane
molecule expression and disease associations (Wong et al., 2012). It
may therefore be useful to determine the absolute or relative levels of
circulating monocyte subsets as a part of the diagnostic work, evalua-
tion of disease activity or early detection of hematological and/or im-
munological toxicity during treatment. In the present study, we have
therefore analysed how various pre-analytical parameters will influence
the flow cytometric identification of monocyte subsets.
Our analyses were based on gating and thereby separation of viable
blood cells from debris and dead cells using the forward- and side-
scatter area (Supplementary Fig. 2). For PBMC and cryopreserved
PBMC this viable cell gating was combined with a live/dead marker to
identify viable cells only. Selection of monocytes was based on negative
selection using CD56 (excluding natural killer cells, NK-cells) and po-
sitive selection using CD45 (only nucleus-containing hematopoietic
cells), CD11b and HLA-DR (the last two being extensively expressed by
monocytes). The classic, intermediate and non-classic monocyte subsets
were then identified by their expression of CD14 and CD16.
Our blood sampling was carefully standardized. Phlebotomy was
performed using a closed-loop system by routine laboratory personnel.
The blood was harvested onto pre-sampling bags (experiment B and C;
see Supplementary Fig. 1) and the blood from the pre-sampling bags
was added to sampling tubes within 2min and immediately after the
glasses for routine analyses had been filled. Alternatively, for experi-
ment A, we drew the blood directly into the blood sampling vacuum
tubes similar to what was described in a previous study (Ji et al., 2017).
These authors also investigated differences between the two antic-
oagulants K2EDTA and sodium citrate upon monocyte subset identifi-
cation (Ji et al., 2017), but they collected the whole blood first into a
syringe before it was distributed equally to the EDTA and sodium ci-
trate tubes; a methodology that may cause erroneous results due to a
possible contamination of sample tubes with additives from previous
tubes (Cornes et al., 2017).
K2EDTA is today regarded as the anticoagulant of choice for routine
analyses of peripheral blood cells (Ji et al., 2017; Zini and H.
International Council for Standardization, 2014; Bruegel et al., 2015). It
allows the best preservation of blood cell morphology and causes an
irreversibly prevention of clotting (Banfi et al., 2007). Other antic-
oagulants are commonly used in research laboratories including ACD-A
(Melve et al., 2016), CPDA (Citrate Phosphate Dextrose Adenine solu-
tion) (Ersvaer et al., 2015; Bruserud and Lundin, 1987), heparin
(Appleby et al., 2013), and sodium citrate (Ji et al., 2017), but for
several studies detailed information is not given (Boyette et al., 2017;
Chara et al., 2015; Selimoglu-Buet et al., 2017; Talati et al., 2017). We
wanted to characterize and compare the effects of anticoagulants used
in routine clinical practice, i.e. K2EDTA, ACD-A and Li-Heparin.
Our results indicate that the choice of anticoagulant did not have
any major effect on the relative distribution of monocyte subsets.
However, the percentage of total monocytes relative to total leukocyte
counts, as well as the platelet counts decreased significantly, especially
in Li-Heparin when compared to K2EDTA. Previous studies have de-
monstrated that heparin has an effect on platelets consistent with pla-
telet activation (Gao et al., 2011), and the most likely explanation for
the decrease in platelet and monocyte numbers when using Li-Heparin
activation and aggregation of platelets leading to platelet-monocyte
adhesion (Basavaraj et al., 2012). Li-Heparin should therefore be used
with caution in experimental studies of monocyte function. ACD-A is
the preferred anticoagulant used in transfusion medicine services, and
it is reliable with regard to preservation of resting platelets for several
hours without inhibition of their responsiveness (Pignatelli et al., 1995;
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Lei et al., 2009). For the ACD-A blood the lower percent of monocytes
relative to total leukocytes can possibly be explained by adherence of
monocytes to the test tube, but this seems to be a random process that
does not alter the relative levels of various monocyte subsets.
Minimizing blood collection volumes is definitely an advantage,
especially in paediatric patients as well as seriously ill adults, however,
insufficient sample volume is a common pre-analytical error (Kalra,
2004; Wallin et al., 2008; Plebani and Carraro, 1997; Carraro and
Plebani, 2007; West et al., 2017; Xu et al., 2010). To the best of our
knowledge, there are no previously published data on the effects of
insufficiently filling of blood tubes on monocyte and monocyte subset
distribution. We found that ¼ of correct sample volume in K2EDTA
tubes did not alter the total percentage of monocytes relative to total
leucocytes or the relative distribution of monocyte subsets. This is in
accordance with previous studies (Xu et al., 2010), where 1.0mL of
blood in a 4mL K2EDTA tube showed acceptable cell counts. However,
our results suggest that the percentage of total monocytes is affected by
insufficient sampling in ACD-A tubes. A likely explanation is that this is
due to the sample dilution. We did not observe any significant differ-
ences in the distribution of monocyte subsets in any of the incompletely
filled samples. We therefore conclude that sample volumes can be re-
duced to ¼ of correct filling without any effects on the monocyte
subsets percentages, in both K2EDTA and ACD-A anticoagulated sample
tubes.
Separation and cryopreservation of PBMC is a common strategy in
longitudinal clinical studies. The methodological variations between
analyses of different samples can then be reduced both when analysing
several samples from the same patients and when comparing samples
collected from different patients and different time points. Previous
reports suggest that the gradient separation involved in production of
PBMC can alter the relative percentage of monocyte subtypes
(Mukherjee et al., 2015), their phenotype (Mukherjee et al., 2015; Nieto
et al., 2012) and thus may also influence their function (Wong et al.,
2012; Italiani and Boraschi, 2014). In our results, no significant dif-
ferences were observed for CD16-MFI when comparing whole blood
and PBMC, but the MFI of CD14 was doubled in PBMC compared to
Fig. 3. MFI values of CD16+ monocytes derived from healthy individuals; a summary of the results from experiments comparing different anticoagulants, different
sample volumes in the tubes and the effects of cryopreservation (see also Supplementary Fig. 1). The variables in each experiment are indicated to the left in each
figure. All results are presented as the CD16 MFI levels of CD14+CD16+ monocytes. In Figs. A–C the results are presented as box plots with whiskers. Median values
represent the vertical line in the box. The boxes represent the upper and lower quartiles (the interquartile range); the two lines outside the box (the whiskers)
represent the variation range. (A) The anticoagulant experiments (N=22); the results for Li-heparin, K2-EDTA and ACD-A samples were compared. (B) Insufficient
blood sample volumes of ACD-A (N=8) and K2EDTA samples (N=9); sample tubes were either filled with the correct volume (1/1) or with reduced volumes (1/2
or 1/4 of the correct volume). (C) PBMC isolated from ACD-A (N=9) or K2EDTA samples (N=10); the figure shows a comparison of samples analysed after
crypreservation/thawing (upper) and before the cryopreservation (lower). (D) Freshly isolated and cryopreserved PBMC (N=3) a comparison of CD16 expression
for monocytes after cryopreservation/thawing/recovery (IV), after only cryopreservation/thawing (III), staining of freshly isolated PBMC (II) and whole blood
staining (I). Results are presented as box plots where the ends of the box extend to the lowest and highest observations, and median is marked by a vertical line inside
the box. Statistical significant when p < 0.05 by One way-ANOVA with post hoc (panel A, B and D) or paired sample t-test (panel C): p < 0,05:*; p < 0.01:**;
p < 0.001:***.
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whole blood for both K2EDTA and ACD-A samples.
Cryopreservation caused a statistical significant increase in the
amount of the CD14+CD16− classical monocyte subset while inter-
mediate- and non-classical monocytes were reduced in ACD-A samples.
The increase in amount of CD14+ monocytes is probably a result of
relative distribution secondary to a decrease in the amount of CD16+
monocytes after cryopreservation and thawing. In our data the CD14
expression was affected by the methodology as a statistically significant
increase in its expression was observed after PBMC isolation compared
with the observations in the whole blood analyses). However, this in-
creased CD14 expression was not observed after cryopreservation, and
this was true for both anticoagulants investigated. The CCR2 chemokine
receptor (CD192) is important for regulation of monocyte trafficking
and has been used to aid classification of the three monocyte subsets
(França et al., 2017). CCR2 is mainly expressed on the classical
monocyte subset and its expression was significantly decreased when
comparing whole blood samples to (i) freshly separated, (ii) cryopre-
served and (iii) cryopreserved plus recovered PBMC. The CCR2 de-
crease was seen both for monocytes as described previously (Shantsila
et al., 2011) and for all three monocyte subsets and the decrease was
not dependent on the anticoagulant. The previous study by Nieto et al.
(Nieto et al., 2012) suggests that separation-induced internalization is a
Fig. 4. CCR2 expression by monocytes derived from three healthy individuals; an analysis of the total CD14+ monocytes (A) and classical (B), intermediate (C) and
non-classical (D) monocyte subsets. For each of the four analyses (A-D) we compared CCR2 expression of PBMC after cryopreservation/thawing/recovery (IV), after
only cryopreservation/thawing (III), staining of freshly isolated PBMC (II) and whole blood staining (I). Results are presented as box plots where the ends of the box
extend to the lowest and highest observations, and median is marked by a vertical line inside the box. For each donor immunofluorescences staining of K2EDTA and
ACD-A anticoagulated blood samples were examined. The results from statistical comparisons are indicated in the figure (One Way-ANOVA with post hoc):
p < 0.05*; p < 0.01**; p < 0.001***.
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possible explanation for these difference.
We conclude that the detection and estimation of the classical, in-
termediate and non-classical monocyte subsets is not dependent on the
type of anticoagulant, and insufficient filling of sample tubes down to ¼
of the correct volume does not alter the ratios between the various
subsets. In contrast, preparation of PBMC before analysis reduces the
total percentage of CD14+ monocytes while CD14 expression increases.
The expression of CCR2 is reduced in PBMC compared to monocyte
subsets analysed in whole blood, whereas cryopreservation mainly re-
duced CD16 expression and this was not reversed by post-thawing re-
covery. Our data thus indicate that cryopreservation alters the identi-
fication and hence the stoichiometry of the subsets. This alteration can
be due to (i) decreased CD16-expression, (ii) increased CD14-expres-
sion, and/or (iii) a subset selection process due to the methodology
used. It remains whether the non-classical monocytes are selectively
lost during freezing or thawing, or that the expression of CD16 and/or
CD14 is simply altered by the procedure. Our advice based upon our
results are to investigate monocyte subsets in freshly drawn peripheral
blood samples, thereby avoiding PBMC isolation and cryopreservation.
Thus, a careful standardization of sample collection and handling as
well as a detailed methodological description is necessary for studies of
monocytes and monocyte subsets in peripheral blood.
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Circulating monocyte subsets in multiple
myeloma patients receiving autologous
stem cell transplantation – a study of the
preconditioning status and the course until
posttransplant reconstitution for a
consecutive group of patients
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Abstract
Background: Induction therapy of multiple myeloma patients prior to autologous stem cell transplantation
has changed from conventional chemotherapy to treatment based on proteasome inhibitors or immunomodulatory
drugs. We used flow cytometry to analyze total monocyte and monocyte subset (classical, intermediate and non-
classical monocytes) peripheral blood levels before and following auto-transplantation for a consecutive group of
myeloma patients who had received the presently used induction therapy.
Results: The patients showed normal total monocyte concentrations after induction/stem cell mobilization, but the
concentrations of classical monocytes were increased compared with healthy controls. Melphalan conditioning reduced
the levels of total CD14+ as well as classical and non-classical monocytes, whereas intermediate monocytes were not
affected. Thus, melphalan has a non-random effect on monocyte subsets. Melphalan had a stronger effect on total and
classical monocyte concentrations for those patients who had received induction therapy including immunomodulatory
drugs. Total monocytes and monocyte subset concentrations decreased during the period of pancytopenia,
but monocyte reconstitution occurred before hematopoietic reconstitution. However, the fractions of various
monocyte subsets varied considerably between patients.
Conclusions: The total level of circulating monocytes is normalized early after auto-transplantation for multiple myeloma,
but pre- and post-transplant levels of various monocyte subsets show considerable variation between patients.
Keywords: Monocytes, Multiple myeloma, Autologous stem cell transplantation
Background
Multiple myeloma is usually characterized by prolifera-
tion of abnormal plasma cells in the bone marrow and
secretion of monoclonal immunoglobulin [1–3]. Auto-
logous stem cell transplantation is an established part of
early myeloma-stabilizing treatment [4, 5], and the
patients usually develop a quantitative posttransplant
CD4+ T cell defect that lasts for several months [6]. The
posttransplant innate immune system is less well charac-
terized, but early reconstitution of monocytes with
reduced expression of HLA-DR and CD16 together with
reduced cytokine production has been observed [7, 8],
especially decreased release of proinflammatory cytokines
(e.g. IL-6, TNF-α and IL-1β) [8].
Monocytes constitute up to 10% of total circulating
peripheral blood leukocytes in healthy individuals [9];
they can differentiate into macrophages or dendritic cells
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[10] and may also differentiate in endothelial direction
[11]. Furthermore, immunomodulatory drugs (IMiDs,
e.g. lenalidomide) can induce differentiation towards
dendritic cells with modulation of the cytokine profile,
the transcriptional regulation and the accessory cell
functions [12]. Finally, based on the expression of CD14
(a cell surface co-receptor for lipopolysaccharide) and
CD16 (the low affinity IgG receptor) monocytes are now
divided into classical (CD14bright CD16negative), inter-
mediate (CD14bright CD16dim) and non-classical
(CD14dim CD16bright) monocytes [13–15]. Classical
monocytes constitute 90% of the circulating monocytes
in healthy individuals [13, 15, 16].
Monocytes seem to be involved in the development of
myeloma bone disease [17–20] through the release of
soluble mediators that stimulate osteoclastogenesis, and
the presence of non-classical monocytes may be a poten-
tial marker for increased osteoclast precursors [18, 19].
However, monocytes are also important immunoregula-
tory cells, and they are important for the defense against
complicating infections in myeloma patients [21–23].
Several new drugs have become available during the last
decade for the treatment of multiple myeloma, and no
previous studies have investigated the effects of these
drugs on the levels of circulating monocyte subsets
before and following auto-transplantation. In the present
study, we therefore used a highly standardized method-
ology to characterize peripheral blood levels of mono-
cyte subsets in auto-transplanted myeloma patients
receiving pre-transplant induction treatment based on
proteasome inhibitors and IMiDs.
Results
Myeloma patients show decreased concentrations of
circulating total leukocytes prior to high-dose melphalan
conditioning
We first compared the total leukocyte counts in periph-
eral blood for myeloma patients (Table 1, patients 2–18)
and the healthy controls (12 males and 5 females, me-
dian age 51 years). The patients were tested immediately
before high-dose melphalan conditioning, i.e. after initial
induction treatment (see Table 1) followed by stem cell
mobilization/collection based on cyclophosphamide plus
G-CSF. At this time point they showed significantly
decreased total leukocyte counts compared with the
controls (Fig. 1a, p = 0.004), and patients receiving their
first and second auto-transplantation showed a similar
decrease. The decreased leukocyte counts were seen
with both analytical methods (flow cytometry with
counting beads, measurement by clinical hematology
instrument), and the levels measured by these two
methods were significantly correlated (Pearson cor-
relation coefficient 0.963, p-value 0.0001). The total
leukocyte levels prior to melphalan conditioning showed
no association with age, induction treatment (regimen,
number of cycles), response to induction treatment,
circulating CD34+ cell level at the day of harvesting or
duration of posttransplant neutropenia/cytopenia (data
not shown).
Myeloma patients show normal peripheral blood
concentrations of total monocytes but decreased levels of
classical monocytes prior to high-dose melphalan
The preconditioning peripheral blood concentrations of
total CD14+ monocytes did not differ between the 17
myeloma patients (Table 1, patients 2–18) and 17 healthy
controls (Fig. 1a). However, classical monocyte concentra-
tions were then slightly increased (Fig. 1a, p = 0.01)
whereas we could not detect any significant differences
between patients and controls for intermediate and non-
classical monocytes. The three patients admitted for their
second auto-transplantation showed total monocyte and
monocyte subset concentrations within the range for the
patients admitted for their first transplantation (Fig. 1).
Thus, the effect of mobilization/conditioning on circulat-
ing monocytes is a non-random effect mainly affecting the
classical monocyte subset.
The total monocyte concentrations prior to the condi-
tioning therapy showed no association with age, induction
treatment (regimen, number of cycles), response to induc-
tion treatment, circulating CD34+ cell level at the first day
of harvesting or the duration of posttransplant neutro-
penia/cytopenia (data not shown). The same was true for
classical, intermediate and non-classical monocytes except
that pre-harvesting CD34+ cell levels showed significant
correlations to absolute and relative levels of intermediate
(r = 0.78/p = 0.001 and r = 0.75/p = 0.002, respectively) and
non-classical monocytes (r = 0.63/p = 0.017 and r = 0.61/
p = 0.047, respectively.
Myeloma patients are heterogeneous with regard to the
preconditioning monocyte subset distribution/percentage
in peripheral blood
We first compared the relative levels of circulating total
CD14+ monocytes (percentage of total leukocytes) and
the various monocyte subsets (percentage of total mono-
cytes) for 18 newly diagnosed myeloma patients (Table 1,
patients 1–18) and the 17 healthy controls. The precondi-
tioning percentage of CD14+ monocytes among total leu-
kocytes was increased for the patients; this was expected
since total leukocyte levels were decreased whereas the
monocyte concentration was not significantly altered
before melphalan conditioning (Fig. 1b, p = 0.013).
The preconditioning percentages of the classical, inter-
mediate and non-classical monocyte subsets among
CD14+ monocytes did not differ between patients and
healthy controls (Fig. 1b). However, the variation range
was wider for the patients both for the percentage of
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total CD14+ monocytes and the three monocyte subsets.
Firstly, classical monocytes constituted a majority of the
CD14+ monocytes (corresponding to > 70%) both for the
healthy controls and for all except five patients. We also
observed wide variation ranges for the intermediate and
non-classical monocyte subsets; exceptional patients
showed intermediate monocyte levels exceeding 15%
and non-classical monocytes levels up to 40% of the
total CD14+ monocytes (Fig. 1b). Wide variations were
observed both for patients admitted to their first auto-
transplantation and for the four patients admitted to
their second transplantation. The percentages of total
monocytes and monocyte subsets showed no significant
associations with age, induction treatment, response to
induction treatment, CD34+ cell level at the day of har-
vesting or time until posttransplant neutrophil/platelet
reconstitution (data not shown).
The concentrations of circulating CD14+ monocytes
decrease early after melphalan conditioning
We compared the peripheral blood levels of total leuko-
cytes and CD14+ monocytes before the conditioning
therapy (day − 2) and 2 days later immediately before
the autologous stem cell reinfusion (day 0). Ten patients
Table 1 The characteristics of the myeloma patients included in the study
Patient Aged) M-
component









Pretransplant treatment Number of cycles Neutrophils Thrombocytes
1 60–70 IgG MM Second CVD 4 VGPR 5 2
2 60–70 IgG MM CVD 4 VGPR 171,270 4 1
3 60–70 IgA MM Second CVD 4 VGPR 5 3
4 50–60 IgG MM CVD 5 VGPR 32,180 5 5
5 50–60 IgG MM CVD 5 PR 48,635 2 1
6 30–40 LCD CVD (1), KRD (4) 5 VGPR 70,570 5 3
7 60–70 IgG MM VTD (1), CVD (2) 3 VGPR 218,945 4 2
8 60–70 IgG MM CVD 4 VGPR 90,930 4 4
9 60–70 IgA MM CVD 5 PR 42,285 3 3
10 50–60 IgG MM Second PVD 6 PR 5 4
11 50–60 IgA MM CVD 4 VGPR 32,125 5 4
12 60–70 IgA MM Second VRD 4 VGPR 5 2
13 60–70 LCD-L CVD 4 VGPR 60,410 5 4
14 60–70 IgG MM CVD, VTD, VD (3) 5 VGPR 123,190 6 1
15 60–70 IgG MM VCD 4 PR 37,060 8 5
16 60–70 LCD-K RD 4 VGPR 36,010 4 6
17 50–60 IgA-MM CVD 4 VGPR 132,000 4 5
18 60–70 LCD-L CVD (4 before and 2 after harvesting) 6 VGPR 27,690 5 5
19 50–60 IgG MM Second CVD 4 VGPR 5 3
20 50–60 Amyloid-MM IgG-L CVD (3), VTD (1) 4 185,800 4 2
21 40–50 IgG MM CVD (4 before harvesting), VTD (2 after), RD (2 after) 8 VGPR 56,380 4 6
22 50–60 LCD-L Second CVD 4 PR 7 5
23 50–60 IgG MM Second CVD, VTD, VD (4) 6 PR 5 5
24 50–60 LCD-L CVD 4 VGPR 74,800 3 4
25 60–70 LCD-K Second CVD 4 PR 3 2
Abbreviations: CVD Cyclophosphamide, bortezomib (Velcade®), dexamethasone, LCD Light chain disease type lambda (L) or kappa (K), MM Multiple myeloma, PR
Partial response, RD Lenalidomide (Revlemide®) plus dexamethasone, VGPR Very good partial response, VRD Bortezomib, lenalidomide (Revlemide®),
dexamethasone, VTD Bortezomib (Velcade®), thalidomide, dexamethasone
a) Patients undergoing their second auto-transplantation are indicated; the stem cell graft was the same as for the first transplantation for all these patients
b) The peripheral blood concentration of CD34+ cells on the (first) day of harvesting is given; the level is expressed as × 103 cells/mL
c) Neutropenia was defined as the time from the first day of neutrophil peripheral blood concentration ≤ 0.2 × 109/L until the first of three consecutive days with
neutrophils exceeding 0.2 × 109/L or alternatively the first day with neutrophil counts > 10 × 109/L. The duration of thrombocytopenia was defined as the number
of days from the first day of peripheral blood thrombocyte counts below 20 × 109/L until the first day with thrombocyte count above 20 × 109/L without
thrombocyte transfusion
d) The age of patients are grouped
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were available for this paired comparison (Table 1, pa-
tients 7–9, 11–17), and total leukocyte levels were not
altered 2 days after the melphalan infusion (i.e. immedi-
ately before transplantation, see Fig. 2a). In contrast, the
concentrations of circulating monocytes were signifi-
cantly decreased 2 days after the conditioning, and a
similar decrease was observed when total monocyte
levels were analyzed by clinical hematology instrument(-
data not shown) and when using whole-blood staining
for flow cytometric analysis of CD14+ monocytes (Fig.
2b). A comparable decrease was seen for patients receiv-
ing their first and the second auto-transplantation, but
neutrophil levels were increased for many patients (see
below) so that total leukocyte levels were not signifi-
cantly altered.
We finally compared the levels of circulating neutro-
phils, total lymphocytes and thrombocytes (estimated by
clinical hematology instrument) immediately before and
2 days after melphalan conditioning (Table 1, patients
7–9, 11–17). The neutrophil levels 2 days after melpha-
lan were slightly increased (median level 3.6 versus 4.9 ×
109/L, p = 0.06), whereas lymphocyte (median level 1.0
versus 0.2 × 109/L, p = 0.002) and thrombocyte levels
(median levels 225 versus 177 × 109/L, p = 0.002) were
significantly decreased similar to the monocyte levels.
Melphalan conditioning causes an early decrease in the
percentages of circulating classical and non-classical
monocytes whereas the levels of the intermediate subset
are not altered
We compared the peripheral blood percentages of clas-
sical, intermediate and non-classical monocytes at day − 2
pre-transplant (i.e. before conditioning) and day 0 (i.e. be-
fore stem cell transplantation) for 10 patients (Fig. 2c-e;
Table 1 patients 7–9, 11–17). The concentrations of all
three monocyte subsets were decreased for most patients
2 days after the conditioning, but the difference reached
statistical significance only for the classical (Wilcoxon’s
test for paired samples; p = 0.002) and non-classical sub-
sets (p = 0.0039). Thus, melphalan conditioning has a non-
random early effect on circulating monocyte subsets.
However, we observed a wide variation in the percentage
of the various monocyte subsets among total CD14+
monocytes in preconditioning samples (Fig. 1), and wide
variations persisted after conditioning both for the clas-
sical (variation range 41–93%), intermediate (2–48%) and
non-classical (2–51%) monocyte subsets.
The early effect of melphalan conditioning on monocyte
concentrations differs between patients receiving
induction treatment with and without
immunomodulatory drugs
IMiDs can alter the monocyte phenotype [24], and we there-
fore compared the effect of the melphalan conditioning for
patients receiving induction treatment with or without
IMiDs (i.e. thalidomide, lenalidomide, pomalidomide). A
total of 13 patients were included in this analysis. At
day 0 (the day of transplantation) patients receiving
induction treatment including IMiDs showed decreased
concentrations of circulating total monocytes (median
level 0.0023 × 109/L with range 0.001–0.01 versus
0.0061 × 109/L with range 0.003–0.03; p = 0.045) and
classical monocytes (median 0.0022 × 109/L with range
0.001–0.010 versus 0.0057 × 109/L with range 0.0003–
0.016; p = 0.046) compared with patients receiving in-
duction treatment without these drugs). Furthermore,
the absolute and relative levels of total monocytes and
the various monocyte subsets 2 days after the condi-
tioning therapy (i.e. on day 0, the day of transplant-
ation) showed no association with age, response to
induction treatment or levels of circulating CD34+ cells
at the first day of harvesting (data not shown). Finally,
the day 0 pretransplant levels of circulating neutrophils,
total lymphocytes and thrombocytes did not differ be-
tween patients that had received induction therapy with
and without IMiDs (data not shown). Thus, the IMiDs
seem to have a non-random effect on the various
monocyte subsets that becomes detectable after the
melphalan infusion.
The peripheral blood concentrations of all three
monocyte subsets show a further decrease during the
period of severe neutropenia
We investigated the peripheral blood concentrations of
the three monocyte subsets during the period of severe
neutropenia for 8 myeloma patients (Table 1 patients 13,
14, 16, 17, 21–24); for five of these patients we could
compare the levels immediately before stem cell reinfu-
sion with the levels during severe cytopenia (patients 13,
14, 16, 17, 21). As expected the concentrations of all
three monocyte subsets, especially the classical and
intermediate subsets, decreased to low levels during
cytopenia (Fig. 2). In contrast, the relative levels (i.e.
percentage among total CD14+ monocytes) varied dur-
ing pancytopenia when tested 6–8 days after stem cell
reinfusion. All patients showed < 5% intermediate mono-
cytes, whereas classical monocyte levels varied between
8 and 92% (median 62%) and non-classical monocytes
also showed a considerable variation (median 18%, range
3–57%).
Auto-transplanted myeloma patients show expected early
hematological reconstitution
The levels of circulating total leukocytes, neutrophils
and thrombocytes were measured by clinical hematology
instrument) for all our patients. Neutrophil reconstitu-
tion was defined as the first of 3 days with neutrophils
above 0.2 × 109/L. The median time from first day of
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neutropenia (i.e. first day with neutrophils ≤0.2 × 109/L)
until neutrophil reconstitution was 4 days (range 2–9
days). Furthermore, thrombocyte reconstitution was de-
fined as the first out of three consecutive days with
thrombocyte counts above 20 × 109/L in transfusion-
independent patients. The median duration of
thrombocytopenia (i.e. thrombocyte levels below 20 ×
109/L) was 4 days (range 1–6 days). Finally, time to neu-
trophil/thrombocyte reconstitution did not differ be-
tween patients receiving their first or second auto-
transplantation and showed no significant associations
with preconditioning (i.e. day − 2) or pre-transplant (i.e.
day 0) total monocyte levels.
Auto-transplanted myeloma patients show early
monocyte reconstitution
The absolute levels of total monocytes were followed
daily during the period of early hematological reconstitu-
tion for 24 consecutive patients. The median time from
transplantation until the monocyte levels exceeded the
lower normal limit (0.04 × 109/L) was 10 days; the
median monocyte level was then 0.23 × 109/L (range
0.05–0.78 × 109/L). The neutrophil levels at the first day
of monocyte normalization were generally below the
lower normal limit (median 0.5 × 109/L, range 0.1–3.8 ×
109/L), i.e. for 18 patients the neutrophil levels were still
below the lower normal limit. All patients still had
severe thrombocytopenia (median 29 × 109/L, range 13–
38 × 109/L) at the first day of monocyte normalization.
Finally, there was no significant association between pre-
conditioning or pre-transplant total monocyte levels and
time to normalized circulating monocyte levels, and
monocyte normalization did not differ for patients
receiving induction treatment with or without IMiDs
(data not shown).
We compared the absolute and relative levels of vari-
ous monocyte subsets at day + 10/+ 12 posttransplant
with the corresponding preconditioning levels (day − 2);
paired samples were then available only for eight pa-
tients (Fig. 3; Table 1 patients 14, 16, 17, 21–25). This
posttransplant time point corresponds to the initial neu-
trophil reconstitution, but the neutrophil levels were still
below the lower normal limit for six of the eight patients
(median level 0.7 × 109/L, range 0.2–6.8 × 109/L). The
thrombocyte counts for all patients (median 30 × 109/L,
range 20–52 × 109/L) were also below the lower normal
limit. However, even at this early time point only 10–12
days post-transplant most patients showed normalized
absolute (concentration) and relative (percentage) levels
of total CD14+ monocytes as well as the three monocyte
subsets within the pre-transplant variation range.
One of our collaborating local hospitals only investi-
gated peripheral blood neutrophil but not monocyte
counts at the out-patient evaluations; for this reason
peripheral blood monocyte counts were only available at
later time points for 15 patients. The total monocyte
count (normal range 0.04–1.30 × 109/l) was tested early
after neutrophil and platelet reconstitution, and at this
time point (median time 14 days posttransplant, range
14–16) nine patients showed normal and six patients
showed increased counts (median 0.95 × 109/L, range
0.40–2.1 × 109/l). The total monocyte counts tested at a
later time point (median 30 days posttransplant, range
27–39 days) showed increased levels for a minority of
four patients (median level 0.97 × 109/L, range 0.20–
1.78 × 109/L).
Most patients shows disease stabilization lasting at least
2 years after the first transplantation
The posttransplant observation time for patients receiv-
ing their first auto-transplantation was 27–36months
(median 32months). Five patients had disease progres-
sion less than 2 years post-transplant, one patient was
lost from follow-up and all other patients remained in
plateau phase during follow-up. Progression-free survival
less than 2 years showed no association with precondi-
tion (n = 16) or pretransplant (n = 18) total monocyte or
monocyte subset levels or with posttransplant time to
normalized total monocyte levels (n = 24) (data not
shown).
Discussion
Autologous stem cell transplantation is widely used in
the treatment of younger myeloma patients up to 70
(See figure on previous page.)
Fig. 1 The peripheral blood levels of total leukocytes, total monocytes and monocyte subsets; a comparison between healthy controls and
multiple myeloma patients examined after the initial induction chemotherapy and stem cell harvesting with cyclophosphamide plus G-CSF, i.e.
immediately before conditioning high-dose melphalan therapy (pre-transplant day − 2). (a, UPPER FIGURES) We used flow cytometry to estimate
the concentrations of total circulating leukocytes, total CD14+ monocytes and classical, intermediate and non-classical monocyte subset. The
results for 17 patients (Table 1, patients 2–18) were compared with 17 healthy controls (CTR) individuals. Three of the 17 patients received their
second auto-transplantation. (b, LOWER FIGURES) The percentage of circulating CD14+ monocytes among total leukocytes and the percentages
of classical, intermediate and non-classical monocytes among total CD14+monocytes were estimated. The results for 18 patients (Table 1, patients
1–18) were compared with the 17 healthy individuals. Four patients received their second auto-transplantation. In all the figures, black symbols
represent the levels for patients receiving their first auto-transplantation whereas open symbols represent levels for patients receiving their
second transplantation. The Wilcoxon’s test for paired samples was used for statistical analyses and the p-values for statistically significant
differences are indicated in the figure
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years of age [25]. The pre-transplant conditioning ther-
apy has direct anti-leukemic effects, but previous studies
suggest that immune-mediated anti-myeloma activity
may also contribute to the effect of this therapy [26–28].
The lymphoid reconstitution has been investigated in
previous studies [29], but the monocytes are less well
characterized and for many of the previous studies the
induction treatment included conventional cytotoxic
drugs and not proteasome inhibitors or IMiDs. In our
present study, we investigated the levels of circulating
total monocytes and monocyte subsets in auto-
transplanted myeloma patients. Although our study is
relatively small, we observed that the pre-transplant in-
duction and stem cell mobilization by cyclophosphamide
plus G-CSF seemed to have only a minor effect on the
preconditioning monocyte levels even though the con-
centration of total circulating leukocytes was decreased
compared with the healthy controls.
Our present observations will probably not only depend
on the use of IMiDs and proteasome inhibitors in the in-
duction treatment but on the overall clinical and bio-
logical context of our patients. One should emphasize that
the use of cyclophosphamide in stem cell mobilization will
probably influence our results. The same may be true for
our use of posttransplant G-CSF therapy, e.g. through its
effects on systemic metabolic regulation that influence the
metabolic environment of regenerating hematopoietic and
immunocompetent cells [30]. Furthermore, studies in
healthy donors show that G-CSF has a mobilizing effect
on many different immunocompetent cells, including
monocytes [31, 32]. These effects differ between healthy
donors; they will also influence the levels of immunocom-
petent cells in the stem cell grafts and possibly also out-
come in allotransplant recipients. To the best of our
knowledge it is not known whether similar differences
exist for auto-transplanted myeloma patients, and unfor-
tunately we do not have information about graft levels of
various monocyte subsets for our patients.
We analyzed the total number of monocytes by two
different methodological approaches, i.e. by using a
hemocytometer and by using flow cytometry to estimate
the levels of CD14+ total monocytes. Both these analyses
showed that the preconditioning patient levels did not
differ from healthy controls, whereas the levels 2 days
after the conditioning (i.e. immediately before stem cell
reinfusion) were decreased compared with the precondi-
tioning levels. However, the levels of CD14+ monocytes
were lower than the monocyte levels estimated in the
alternative assays, and this difference is probably due to
a random loss of cells during the washing steps.
Our studies included all except one patient from a de-
fined geographic area and during a defined time period;
for this reason it should be regarded as a population-
based study. We could not investigate all patients at every
time point during the treatment. However, we would
emphasize that this was due to practical reasons such as
transfer of patients to their local hospital or long traveling
distance from their home to the transplantation center; it
was not because of the disease, the treatment or develop-
ment of complications. Leukocyte levels show diurnal var-
iations [33–36], and for this reason we sampled the
patients only in the morning, and shipment of samples or
analysis of cryopreserved cells was not possible due to our
standardized methods for handling of the samples [37].
Our present study showed that the preconditioning
patient levels did not differ from healthy controls, i.e.
the myeloma disease itself, the induction treatment and
the stem cell mobilization by cyclophosphamide plus G-
CSF have only minor effects on monocytes except for a
slight increase of classical monocytes. In contrast, the
melphalan conditioning seemed to have a nonrandom
effect of the monocyte subsets before an early reconsti-
tution of all three subsets was observed. However, it
should be emphasized that there is a wide variation
between patients with regard to the effects of the condi-
tioning therapy. A short duration of this monocytopenia
is also suggested by previous studies [7, 8], but our study
is the first to suggest that this is true also for patients re-
ceiving IMiD- or proteasome inhibitor-based induction
therapy and for different monocyte subsets. Further-
more, the studies by Callander et al. [38] suggest that
even though monocyte levels are normalized at day 100
posttransplant, the levels of total CD14+ and
CD14+CD16low/negative classical monocytes are then asso-
ciated with prolonged progression-free survival after
auto-transplantation. Thus, taken together these studies
show that monocyte reconstitution occurs early (according
to our study very early) after auto-transplantation, but
(See figure on previous page.)
Fig. 2 The peripheral blood concentrations of total leukocytes (a), CD14+ monocytes (b), classical (c), intermediate (d) and non-classical (e)
monocytes in auto-transplanted myeloma patients. We estimated the cell concentrations by flow cytometry. The left parts of each panel show a
comparison of peripheral blood levels before versus 2 days after the conditioning melphalan therapy (day − 2 versus day 0; Table 1, patients 7–9,
12–18). The middle parts show a comparison of levels at the time of transplantation (day 0) versus the levels during the period of severe
posttransplant melphalan-induced pancytopenia with neutrophils < 0.2 × 109/L and thrombocyte transfusion dependency (tested 6–8 days
posttransplant; Table 1, patients 14, 15, 17, 22, 24). The right panel show the comparison of peripheral blood levels during the severe
pancytopenia versus the levels during initial hematopoietic and immunological reconstitution (tested 10–12 days posttransplant with increasing
neutrophils > 0.2 × 109/L and thrombocyte transfusion independence; Table 1 patients 15, 17, 18, 22–24). The Wilcoxon’s test for paired samples
was used for statistical analyses and significant p-values are indicated in the figure (ASCT, autologous stem cell transplantation)
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despite this normalization there is still a relatively wide va-
riation between patients and this heterogeneity in monocyte
(subset) levels seems to persist until day 100 posttransplant
and may even have a prognostic impact. The antimyeloma
effect of posttransplant monocyte targeting may therefore
vary between patients and depend on the monocyte subset
profile. IL6 is regarded as a possible target in multiple
myeloma [39]; monocytes constitute a subset of the bone
marrow stromal cells that are regarded as important regula-
tors of both normal and malignant hematopoietic cells [16,
40]. IL6 is released by monocytes, especially classical mono-
cytes, in response to ligation of various Toll-like receptors,
and therapeutic targeting of IL6/monocytes may therefore
be most effective for those patients with high levels of
classical monocytes.
Most of our patients received only 3 or 4 induction cy-
cles before stem cell transplantation, whereas 6 cycles
are now often recommended, especially for patients who
have not received a complete remission [25, 41, 42].
Alternative induction cycles have also been used in other
studies [33, 41, 42], and future studies have to clarify
whether our present results are representative also for
patients receiving additional cycles or alternative induction
treatment.
Fig. 3 The peripheral blood concentrations (a, upper part, n = 6) and percentages (b, lower part, n = 7) of total CD14+ monocytes and classical,
intermediate and non-classical monocyte subsets in auto-transplanted myeloma patients. Monocyte levels were estimated by flow cytometry. We
investigated the levels for a total of eight patients (Table 1, patients 15, 17, 18, 22–24) during initial hematopoietic and immunological
reconstitution (tested 10–12 days posttransplant) when the patients showed increasing neutrophils > 0.2 × 109/L and thrombocyte transfusion
independence). Horizontal lines indicate median values after 10–12 days. The shaded parts of each figure indicate the variation range of the
corresponding peripheral blood levels tested 2 days pre-transplant (referred to as day − 2), i.e. immediately before high-dose melphalan
conditioning therapy. Black symbols represent patients receiving their first auto-transplant, open symbols represent patients receiving their
second auto-transplantation
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Our comparison of induction treatments with and
without IMiDs suggests that the post-conditioning
monocyte concentrations are influenced by the previous
use of immunomodulatory drugs in the induction therapy,
whereas the capacity of stem cell mobilization and re-
sponse to the induction therapy are less important. How-
ever, G-CSF responsiveness (i.e. CD34+ cell mobilization)
was associated with the levels of intermediate and non-
classical monocytes before conditioning therapy.
Previous studies have shown that early posttransplant
lymphoid reconstitution is associated with a favorable
prognosis of auto-transplanted myeloma patients [26–29].
More recent studies suggest that this effect may be due to
early NK cell reconstitution [29]. Even though monocytes
have important immunoregulatory functions, the previous
studies have not investigated whether the early monocytic
reconstitution is required for the prognostic impact of
early lymphoid reconstitution. A recent study of allotrans-
plant recipients suggests that monocytes can mediate
anti-myeloma effects [43], and monocytes derived from
auto-transplanted patients may even be used for immuno-
therapy due to their presentation of myeloma-associated
peptides to the adaptive immune system [44]. Our present
studies thus suggest that a close to normal monocyte
system is present in myeloma patients even early after
auto-transplantation and may then be an immunothera-
peutic target.
Monocytes and macrophages are important members
of the bone marrow stem cell niches that support both
normal and malignant hematopoiesis [40]. IMiDs can
alter the differentiation of monocytes [24], and we there-
fore investigated whether the use of such drugs for
induction therapy was associated with an altered balance
between monocyte subsets later during treatment or
with other differences in hematopoietic reconstitution
between patients. Our present study showed that the
type of induction therapy actually has an influence on
monocytes/monocyte subsets, but this difference was
only detected after additional melphalan therapy in pre-
transplantation (Day 0) samples.
The observation time for our patients was relatively
short (27–35 months) for our patients that received their
first auto-transplantation and a majority of them were
still in a plateau phase. We could not detect any associa-
tions between time to progression (i.e. progression before
2 years posttransplant) and monocyte subset levels/recon-
stitution. However, these data should be interpreted with
great care because the patient cohort is relatively small for
such analyses and the observation time is short and
patients with early relapse are few.
Conclusions
Although our study is relatively small, we observed that
the total level of circulating monocytes is normalized
early after auto-transplantation for multiple myeloma.
However, the levels of various monocyte subsets show
considerable variation between patients. Clinical studies
including larger number of patients and a longer obser-
vation time are needed to clarify whether these differ-
ences are associated with overall survival, time to relapse
and/or frequencies of severe infections.
Methods
Aim, design, characteristics of myeloma patients and
healthy controls
Proteasomal inhibitors and IMiDs are now commonly used
in induction treatment of young and fit myeloma patients
prior to stem cell harvesting and auto-transplantation.
These drugs may thereby influence the pretransplant im-
munological status of the patients and the immunocompe-
tent cells in the stem cell graft. The aim of our present
study was therefore to investigate the preconditioning
status of the monocyte system in myeloma patients treated
with induction chemotherapy based on IMiDs or proteaso-
mal inhibitors, and to characterize the monocyte subset
levels in autotransplanted patients during the early post-
transplant period until hematological reconstitution.
Our hospital is the only center for stem cell trans-
plantation in a defined geographical area of Norway
(Health Region III), and our patients represent all
myeloma patients except one receiving autologous stem
cell transplantation in this area during an 8 months
period. Our study should therefore be regarded as a
population-based study of unselected patients.
The diagnosis of multiple myeloma was based on
generally accepted criteria [1, 45], and induction therapy
was initiated in accordance with generally accepted
international guidelines [45, 46]. The patient characteris-
tics are presented in Table 1. All patients received
premobilization therapy including either a proteasome
inhibitor or an IMiD; this induction treatment was
followed by stem cell mobilization using cyclophospha-
mide plus G-CSF [47, 48]. The stem cell grafts were
cryopreserved in 5% dimethyl sulfoxide and stored in
liquid nitrogen until reinfusion [49, 50]. All patients
were transplanted with at least 6 × 106 CD34+ cells per
kilo body weight, and the median time from start of
induction to transplantation was 16 weeks (range 13–28
weeks). For patients receiving their first auto-
transplantation the grafts had been stored for 3–5 weeks,
whereas for those patients receiving their second trans-
plantation the grafts were stored for at least 2 years. All
patients received conditioning therapy with melphalan
(Fresenius Kabi, Oslo, Norway), 200 mg/m2 administered
as an intravenous infusion 2 days before stem cell reinfu-
sion. They received G-CSF 5 μg/kg from day + 4 post-
transplant until stable neutrophil recovery, i.e. peripheral
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blood neutrophil levels above 0.2 × 109/L for three
consecutive days or exceeding 10 × 109/L.
The normal controls were healthy blood donors; in ac-
cordance with the approved routines at the Blood Bank,
Haukeland University Hospital peripheral venous blood
samples for medical research were donated after written
informed consent.
Blood sampling
Blood samples were drawn in ACD-A (9 mL, #248368,
BD Vacutainer, San Jose, CA, USA) blood sampling vac-
uum tubes. We collected the first patient sample imme-
diately before melphalan conditioning (day − 2). The
second sample was collected 2 days later immediately
before reinfusion of the peripheral blood stem cell graft
(day 0). The third sample was collected on day + 6 post-
transplant when patients had severe neutropenia (per-
ipheral blood neutrophil counts below < 0.2 × 109/L) and
thrombocytopenia. The last sample was collected on the
first or second day with peripheral blood neutrophil
counts exceeding 0.2 × 109/L (10–12 days posttrans-
plant). The control samples were derived from 17
healthy blood donors (5 females and 12 males, median
age 51 years with range 22–82 years). All samples were
processed at room temperature within 120 min. All
samples were collected between 08:00 and 10:00 am. It
was not possible to get samples from all patients at all
four time points; this was due to either transfer to their
local hospitals after stem cell reinfusion or the patient
was not available for sampling at the indicated time in
the morning.
Flow cytometric analysis
Four mL of ACD-A (9, #248368, BD Vacutainer) antic-
oagulated whole blood and 46 mL of lysing buffer (#
55589, BD Biosciences) were mixed and incubated for
15 min at room temperature. Subsequently, leukocytes
were collected by centrifugation (400×g, 5 min, room
temperature) and thereafter washed in phosphate-
buffered saline with 1% Bovine Serum Albumin (BSA,
Bovine Serum Albumin Fraction V #10735086001,
Sigma-Aldrich/Merc KGaA, Darmstadt, Germany),. The
cells were reconstituted in 200 μL 1% BSA/PBS with
10% immunoglobulin solution (Octagam 100mg/mL,
Octapharma, Lachen, Switzerland). The following mouse
anti-human antibodies were included in the antibody
panel (all from BD Biosciences, San Jose, CA, US): CD14
Alexa 488 (Clone M5E2), CD56 Alexa 647 (Clone B159),
CD16 PerCpCy™5–5 (Clone 3G8), CD45 V500 (Clone
HI30), CD11b V540 (Clone ICRF44 (44)) and HLA-DR
PE (Clone G46–6). The staining procedure and gating
strategy for identification of monocytes and monocyte
subsets has been described in detail in a previous
methodological article [37].
All samples were analyzed by a 10-parameter BD
FACS Verse flow cytometer equipped with 404, 488 and
640 nm lasers. We used BD FACSuite™ CS&T Research
Beads (#650621, BD Biosciences, San Jose, CA, USA) for
regular quality control of the instrument, single-stained
compensation bead samples (#552843, BD Biosciences)
for compensation and unstained samples as gating con-
trols. At least 5000 monocytes were analyzed for each
sample (based on SSC/FSC properties). We used count-
ing beads (Count Bright Absolute Counting beads™, #
C36950, Invitrogen™, Thermo Fischer Scientific, Waltham,
MA USA) when estimating the concentrations of mono-
cytes/monocyte subsets. FlowJo software (Tree Star, Inc.,
OR, USA) was used for analysis of the results.
Analysis of total leukocytes, neutrophils, monocytes and
thrombocytes in peripheral blood
Analyses of peripheral blood levels of total leukocytes
and total monocytes were performed by using accredited
clinical hematology instrument (Laboratory for Clinical
Biochemistry and Hematology at Haukeland University
Hospital).
Statistical analyses
We applied IBM SSP statistics 23 for all statistical ana-
lyses. The Wilcoxon’s rank sum test and the Wilcoxon’s
test for paired samples were used for comparison of dif-
ferent groups and for comparison of paired observations,
respectively. The Pearson’s test was used for correlation
analyses. Differences were regarded as statistically
significant when p-values were below 0.05.
Abbreviation
IMiDs: Immune modulatory drugs
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Abstract: Background and Objectives: Autologous and allogeneic stem cell transplantation is used
in the treatment of high-risk hematological malignancies, and monocytes are probably involved in
hematological reconstitution as well as posttransplant immunoregulation. The aim of our study was
to investigate the levels of circulating monocyte subsets in allotransplant recipients. Materials and
Methods: The levels of the classical, intermediate, and nonclassical monocyte subsets were determined
by flow cytometry. Sixteen patients and 18 healthy controls were included, and the levels were
analyzed during pretransplant remission (n = 13), early posttransplant during cytopenia (n = 9),
and early reconstitution (n = 9). Results: Most patients in remission showed a majority of classical
monocytes. The patients showed severe early posttransplant monocytopenia, but the total peripheral
blood monocyte counts normalized very early on, and before neutrophil and platelet counts. During
the first 7–10 days posttransplant (i.e., during cytopenia) a majority of the circulating monocytes
showed a nonclassical phenotype, but later (i.e., 12–28 days posttransplant) the majority showed a
classical phenotype. However, the variation range of classical monocytes was wider for patients in
remission and during regeneration than for healthy controls. Conclusions: The total peripheral blood
monocyte levels normalize at the very early stages and before neutrophil reconstitution after stem cell
transplantation, and a dominance of classical monocytes is reached within 2–4 weeks posttransplant.
Keywords: monocytes; leukemia; stem cell transplantation; flow cytometry; hematology
1. Introduction
Acute myeloid (AML) and acute lymphoblastic leukemia are both aggressive malignancies
characterized by the accumulation of immature malignant cells in the bone marrow [1,2]. However,
several less aggressive hematological malignancies are also regarded to have unfavorable prognoses
with short expected survival, e.g., the high-risk myelodysplastic syndromes [3] and certain
prolymphocytic leukemia variants [4]. The only or the best possibility for cure for all these malignancies
is intensive conventional chemotherapy, possibly combined with allogeneic or autologous stem
cell transplantation [1]. However, several new and promising therapeutic approaches are now
considered and/or are available for high-risk hematological malignancies, including T-cell targeting
immunotherapy [5,6], new monoclonal antibodies for the treatment of acute lymphoblastic leukemia [7],
modulation of apoptotic regulation with increased proapoptotic activity, or [8] inhibition of intracellular
Medicina 2020, 56, 36; doi:10.3390/medicina56010036 www.mdpi.com/journal/medicina
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signaling, including metabolic targeting [9,10]. These new therapeutic strategies may be used as a part
of the initial treatment to reduce the risk of later relapse and thereby reduce the need for high-toxicity
antileukemic therapy (e.g., allogeneic stem cell transplantation), or they can be used to reduce the risk
of posttransplant relapse [9,11].
The median age for the time of diagnosis is 60–70 years for most hematological malignancies [1],
and the most intensive therapeutic strategies can only be used for relatively young patients without
severe comorbidity [12]. Conventional intensive chemotherapy is usually considered for patients
up to 75–80 years of age [13], whereas stem cell transplantation is usually considered for patients
up to 70–75 years of age [12,14]. However, the use of these most intensive therapeutic strategies in
elderly patients will not only depend on the age, clinical evaluation, and comorbidity score of the
individual patient, but will also differ between institutions. For most patients, stem cell transplantation
is therefore used as a consolidation therapy after they have reached complete hematological remission
(i.e., disease control without morphological signs of leukemia) in response to the initial induction
chemotherapy [1,14]. The strong antileukemic effect of stem cell transplantation is caused by the
intensive conditioning therapy and, especially for allotransplant recipients, antileukemic immune
reactivity mediated by graft immunocompetent cells [15].
Monocytes constitute up to 10% of peripheral blood leukocytes in healthy individuals [16].
They can be differentiated into macrophages and dendritic cells [17], in the endothelial direction [18]
and possibly also in the direction of monocytic myeloid-derived suppressor cells [19,20]. Based on
their expression of the two cell surface receptors CD14 and CD16, monocytes are divided into classical
(CD14brightCD16negative), intermediate (CD14brightCD16dim), and nonclassical (CD14dimCD16bright)
subsets [21–23]. CD16 is a low-affinity IgG receptor that can initiate intracellular signaling, and it is
thereby important for regulation of monocyte cytotoxicity [24]. CD14 is a pattern recognition receptor;
it functions as a co-receptor for Toll-like receptors but has also several functions independent of these
receptors, including transport of inflammatory lipids to induce phagocytosis [25]. Thus, the functional
heterogeneity of various monocyte subsets is reflected by the two molecular markers used for
identification of the three monocyte subsets, and both markers are involved in the regulation of
important phenotypic characteristics through their modulation of intracellular signaling. Classical
monocytes often constitute at least 90% of circulating monocytes in healthy individuals [21,23,26].
The monocyte subset levels during the first 4 weeks posttransplant have not previously been
characterized in detail, but a few studies have investigated later monocyte reconstitution, from day
+28 until day +100 posttransplant. Firstly, both monocytes and neutrophils show early posttransplant
reconstitution [27–29], and total monocyte reconstitution occurs early, both after myeloablative and
reduced intensity conditioning [28]. Total monocyte reconstitution also seems to occur early in patients
receiving haploidentical transplantation for nonmalignant bone marrow disorders [30]. Secondly,
the levels of circulating CD14+CD16+ monocytes (i.e., intermediate and nonclassical monocytes)
after day +30 posttransplant are associated with decreased incidence of chronic graft versus host
disease (GVHD) after allotransplantation [20]. Thirdly, another study described an association between
relatively high levels of classical monocyte (i.e., CD14+CD16−) levels early posttransplant, as well
as improved survival, relapse risk, and transplant-related mortality. These associations seem to be
maintained during the first 100 days posttransplant [31]. The patients included in this last study were
heterogeneous and half of them received umbilical cord blood grafts [31].
The peripheral blood levels of several immunocompetent cells are altered after stem cell
transplantation, and the posttransplant CD4+ T-cell defect can last for months [27]. Our hypothesis
was that the levels of the various circulating monocyte subsets are also altered, especially during the
early (i.e., first 4 weeks) posttransplant period, even though the total monocyte levels normalize at
the early (i.e., before the neutrophil and platelet counts) stages of this period. The immunoregulatory
events during the first weeks posttransplant are important for outcome after stem cell transplantation
(for detailed discussion and additional references see [15]), and our aim was therefore to characterize
circulating monocyte subset levels during this period. We used a highly standardized methodology to
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characterize peripheral blood levels of monocyte subsets for a relatively homogeneous and unselected
group of patients (i.e., all having hematological malignancies with adverse prognosis) receiving
peripheral blood stem cell transplantation. All patients were transplanted after reaching complete
hematological remission, and our studies of circulating monocyte subsets included pretransplant levels
(i.e., after reaching remission), early levels during severe posttransplant pancytopenia, and levels
during hematological reconstitution.
2. Materials and Methods
2.1. Patients and Healthy Controls
The study was conducted according to the Declaration of Helsinki. All samples were collected after
written informed consent (Regional Ethics Committee REK Vest 2015/1759), and the use of biological
material in the present project was also approved (REF Vest 2017/305, 2013/102). Control samples
were derived from 18 healthy blood donors (7 females and 11 males, median age 53 years with range
21–73 years). In accordance with the approved routines at the Blood Bank, Haukeland University
Hospital, peripheral venous blood samples for medical research were donated after written informed
consent. Our hospital is the only center providing intensive antileukemic treatment in a defined
geographical area of Norway, and our patients represent a consecutive group of patients receiving
intensive antileukemic treatment/stem cell transplantation during an eight month period. Our study
should therefore be regarded as population-based.
All our patients received initial chemotherapy to achieve disease control (Table 1, Supplementary
Table S1). Thus, we investigated peripheral blood levels of monocyte subsets for stem cell recipients
who had achieved complete hematological remission, i.e., normal levels of immature/abnormal cells
in the bone marrow judged by light microscopy, peripheral blood neutrophils > 1.0 × 109/L and
peripheral blood platelet counts > 100 × 109/L [1]. One myelodysplastic syndrome (MDS) patient
reached complete remission with incomplete peripheral blood normalization. In addition, patients
with lymphoproliferative disease did not show flow cytometric evidence of minimal residual bone
marrow disease, and imaging studies did not show evidence of residual disease immediately before
stem cell transplantation.
Sixteen patients were included in the various parts of our study (see Table 1, right part), but only
11 of these patients were treated with stem cell transplantation. They were all treated at Haukeland
University Hospital during the period June 2016–June 2017. Patients were transplanted after reaching
complete hematological remission, and they received G-CSF mobilized peripheral blood stem cell
grafts. All our allotransplant recipients received grafts from HLA (human leukocyte antigen)-identical
sibling donors, the same GVHD prophylaxis (cyclosporine plus methotrexate) [32], VOD prophylaxis
(i.e., ursodeoxycholic acid) [32] and pretransplant trimethoprim–sulfamethoxazole treatment, but no
fungal prophylaxis. Five patients were not allotransplanted for the following reasons: because they
had a favorable karyotype (one patient), were unfit for stem cell transplantation (two patients), had a
second relapse before transplantation could be performed (one patient), or had been transplanted at
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2.2. Blood Sampling, Flow-Cytometric Analysis of Monocyte Subsets and Analysis of Peripheral Blood
Leukocytes
Peripheral venous blood was drawn in ACD-A blood sampling tubes (#248368, BD Biosciences, San
Jose, CA, USA). All samples were collected between 08:00 and 10:00 a.m. and were processed at room
temperature within 120 min. Sampling was conducted at the same standardized time interval because
total leukocytes show diurnal variations [33–36]. Four milliliters of the anticoagulated blood and 46 mL
of lysis buffer (#55589, BD Biosciences) were mixed and incubated for 15 min at room temperature.
Subsequently, leukocytes were collected by centrifugation (400× g, 5 min, room temperature) and
thereafter washed in phosphate-buffered saline with 1% bovine serum albumin (BSA, Bovine serum
albumin fraction V, #10735086001, Sigma-Aldrich/Merc KGaA, Darmstadt, Germany). The cells
were reconstituted in 200 µL 1% BSA/PBS with 10% immunoglobulin solution (Octagam 100 mg/mL,
Octapharma, Lachen, Switzerland). The following mouse anti-human antibodies were used (all from
BD Biosciences): CD14 Alexa 488 (Clone M5E2), CD56 Alexa 647 (Clone B159), CD16 PerCpCy™5-5
(Clone 3G8), CD45 V500 (Clone HI30), CD11b V540 (Clone ICRF44 (44)) and HLA-DR PE (Clone G46-6).
The staining procedure and gating strategy for identification of monocytes and monocyte subsets has
been previously described in detail [29,37], and all samples were analyzed using a 10-parameter BD
FACS Verse flow cytometer equipped with 404, 488, and 640 nm lasers.
Comparison of peripheral blood levels of neutrophils and total monocytes was based on
analyses using an accredited clinical hemocytometer (Laboratory for Clinical Biochemistry, Section for
Hematology, Haukeland University Hospital).
2.3. Statistical Analyses
We applied IBM SSP statistics 23 for all analyses. The Kruskal–Wallis test was used for comparison
when several groups were included in the analysis. The Wilcoxon’s rank sum test was used for
comparison of differences between two different groups of individuals, whereas the Wilcoxon’s test for
paired samples was used for statistical comparison of two different observations in the same patients.
p-values below 0.05 were regarded as statistically significant.
3. Results
3.1. The Pretransplant Status of Our Patients with Hematological Malignancies; Monocyte Subsets for Patients
in Complete Hematological Remission after Conventional Chemotherapy
Patients are usually treated with initial conventional chemotherapy to achieve disease control
(see Section 2.1) [1]. We analyzed the monocyte subset levels after 13 different chemotherapy cycles
in 11 patients (Table 1) who fulfilled the criteria of disease control/complete remission at the time of
sampling, and in addition they all had peripheral blood total monocyte counts within the normal range.
The results are presented in Figure 1. The monocyte subset levels showed a wider variation in the
patients than in the healthy controls, but for 11 of the 13 samples, the majority of circulating monocytes
(>80%) belonged to the classical monocyte subset. For the last two patients, classical monocytes
constituted <20% of total monocytes. When comparing the overall results, the percentages of classical,
intermediate, and nonclassical monocytes for the remission patients did not differ significantly from the
healthy controls. The two exceptional patients were patients 1 and 16 (Table 1). For five of the patients,
we also estimated the peripheral blood concentrations of the various monocyte subsets, and both
classical (p = 0.002), intermediate (p = 0.002), and nonclassical monocyte (p = 0.006) concentrations
were significantly decreased compared with the corresponding concentrations in the healthy controls.
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3.2. The Peripheral Blood Levels of Various Monocyte Subsets Show Wide Variation during the Period of Severe
Posttransplant Pancytopenia
The levels of circulating monocyte subsets during the period of severe posttransplant pancytopenia
were investigated for nine transplant recipients (Figure 1). Severe pancytopenia was then defined as
total peripheral blood leukocytes ≤ 0.3 × 109/L, neutrophils < 0.2 × 109/L, total monocytes < 0.1 × 109/L,
and dependency of regular platelet transfusions to keep the platelet count above 10–20 × 109/L. Two of
these patients had overly low peripheral blood leukocyte counts to allow for reliable estimation of
monocyte subset distribution (Table 1, patients 2 and 11). The two exceptional patients with detectable
but low (i.e., <3%) levels of classical monocytes were the two allotransplant recipients, patients 1 and
8. The other seven patients showed a distribution within the variation ranges of the normal controls.
Thus, the transplant recipients show a wider variation than the healthy controls in venous blood
monocyte subset levels during the period of severe posttransplant pancytopenia. The percentage of
intermediate monocytes was even significantly decreased compared with healthy controls (only the
seven patients with detectable levels included, p = 0.002), even though healthy controls also show
levels for this subset. By contrast, the percentages of classical and nonclassical monocytes did not differ
significantly from the healthy controls.
For two of the patients, we estimated the venous blood concentrations of the three monocyte
subsets and, as expected, both classical, intermediate, and nonclassical monocytes for these two
patients showed peripheral blood concentrations outside the corresponding variation ranges of the
healthy controls.
We investigated the peripheral blood levels of the three monocyte subsets for patients with
severe pancytopenia, as defined above, after conventional intensive antileukemic chemotherapy (seven
patients examined). These patients also showed a wide variation in their peripheral blood levels of both
classical (range < 0.01–100%), intermediate (range < 0.01–42%), and nonclassical monocytes (range
< 0.01–22%). Thus, a wide variation in peripheral blood levels during treatment-induced cytopenia
is observed not only for stem cell transplant recipients, but also for patients receiving conventional
intensive antileukemic chemotherapy.
3.3. Stem Cell Transplant Recipients Show Early Posttransplant Total Monocyte Reconstitution
Previous studies have demonstrated that stem cell recipients show early reconstitution of total
monocytes, and this is true for both allotransplant [18,19] and autotransplant recipients [20]. All our
stem cell transplant recipients showed early reconstitution with normalized levels of circulating
monocytes before the normalization of the neutrophil counts (Figure 2, Supplementary Table S2).
Furthermore, many of the recipients showed a posttransplant period of increased levels of circulating
monocytes; this could be observed for eight of our 12 stem cell transplanted patients, including
six out of the nine allotransplant recipients. The maximal total monocyte levels for our patients
were reached between day +21 and +35 posttransplant, increased levels were seen both for patients
receiving autologous and allogeneic stem cell transplantation, and the maximal levels varied between
1.41 × 109/L and 5.85 × 109/L (normal range 0.04–1.30 × 109/L).
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Figure 2. Monocyte and neutrophil reconstitution after conditioning therapy followed by stem cell
transplantation. All 11 stem cell transplant recipients (patients 9–11 received an autologous stem cell
graft) were included in this part of the study; the symbols for each of the patients are indicated to the
right in the figure. The upper part of the figure shows the first posttransplant day with normal total
monocyte cell counts (normal level 0.4–1.3 × 109/L; day 0 being the day of stem cell infusion) and the
number of additional days until normalized peripheral blood neutrophil counts (lower normal limit of
neutrophils 1.7 × 109/L). The lower part of the figure presents the peripheral blood concentrations of
total monocytes and neutrophils on the first day with normalized total monocyte counts in the blood.
All samples were collected between 07:00 and 08:30 a.m.
3.4. Early Posttransplant Monocyte Subset Regeneration after Stem Cell Transplantation
We investigated the posttransplant peripheral blood levels of the three monocyte subsets
during early regeneration when the total monocyte counts had reached normal levels (normal
range 0.04–1.3 × 109/L). Nine patients were tested 12–28 days p s transplant when monocyte cou ts
had normalized (median concentration 0.74 × 109/L, range 0.45–1.66 × 109/L). At the time of testing,
five of the patients were still neutropenic; the patients had median neutrophil levels of 1.6 × 109/L with
a variation range of 0.5–2.8 × 109/L (lower norm l limit 1.7 × 109/L). The levels of the three monocyte
subse s are pr s n ed in Figur 1. T majori y of circulati g monocytes early after posttransplant
reconstitution belonged to the classical monocyte subset for all patients (median 76%, range 58–100%),
but the variation range was wider for the regenerating patients than f r the hea thy contr ls. The levels
of both interm diate and non tes were below 20%. The percentages of classical
(decreased, p = 0.001), intermediate (increased, p = 0.001), and nonclassical monocytes (increased,
p = 0.003) for patie s showing hematological regeneration differed significantly from the healthy
controls. How ver, the variation between pati nts was maller during regeneration than for patients in
pretr nsplant remissi n.
We investigated th levels of circulating monocyte ubsets at various tim points both during
and soon aft r the eriod of severe posttransplant cytopenia for nine stem cell transplant recipients.
The results for thr e patients are presented in Figure 3. It can be seen that the perce tage of classical
mon cytes was initially decr ased, and could be very low bef e t increased after 2–4 weeks. It was
also observed at the intermediat monocytes constituted a minority during the whole period but
showed a wider variation range than the healthy controls, whereas he nonclassical monocytes sho ed
high/increased levels during the first week, but after 4 weeks, they were a small minority. All nine
patients showed a similar pattern for the classic mon cytes with initially low/decreased levels with a
later increase, until after 4 weeks, they consti uted a majori y of th circulating monocytes.
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Figure 3. Posttransplant peripheral blood levels of classical (A), intermediate (B), and nonclassical
monocytes (C) in three leukemia patients. The figure presents the levels for days +6, +13/+14, and day
+28 posttransplant for patients 1, 2, and 10 (see Table 1). These three time points after the stem cell
infusion correspond to severe cytopenia and early posttransplant hematological regeneration with
normalization of monocyte counts and, finally, also normalized neutrophil counts. The results are
presented as the percentage of each monocyte subset among total monocytes. The day of testing is
indicated on the x-axis; day 0 is the day of stem cell infusion.
For four of the patients, we estimated the peripheral blood concentrations of the three monocyte
subsets, and classical (p = 0.002), intermediate (p = 0.008), and nonclassical monocyte (p = 0.006)
concentrations differed significantly from the levels in the 18 healthy controls.
4. Discussion
Several observations suggest that monocytes are important for outcome after allogeneic stem cell
transplantation. Firstly, differences in the amounts of graft monocytes between younger and older
stem cell donors may contribute to the adverse prognosis when using older stem cell donors [38,39].
Secondly, monocytes seem important for the development of posttransplant tolerance [40]. Finally,
the monocyte-lymphocyte ratio seems to have a prognostic impact at least in haploidentical
transplantation [41]. In our present study, we therefore investigated the balance between classical,
intermediate, and nonclassical monocytes after stem cell transplantation in patients with high-risk
leukemia or MDS. To the best of our knowledge, this is the first study of early monocyte subset
reconstitution after stem cell transplantation for hematological malignancies. We observed very early
reconstitution of total monocytes, and also the dominating classical monocyte subset after intensive
conditioning therapy followed by stem cell transplantation.
In our present study, we focused on the early posttransplant period, i.e., the first 4 weeks after
stem cell reinfusion. This period is important for outcome after transplantation; this is illustrated
by the observations that both the type of conditioning therapy as well as the use of hematopoietic
growth factors during this period influence the risk of severe posttransplant complications [15].
We investigated a group of consecutive patients with high-risk hematological malignancies admitted to
our institution for intensive chemotherapy. All patients had hematological malignancies with adverse
prognoses, and received intensive chemotherapy, including stem cell transplantation for 11 of them.
We included all admitted patients without any selection, and for this reason, we investigated patients
with different diagnoses who had received different forms of pretransplant conditioning therapy.
However, all patients received peripheral blood mobilized stem cell grafts; most of them received
allografts (all from HLA-matched siblings) but a minority of our patients received autologous stem
cell grafts. The pattern of reconstitution seemed to be similar for allotransplant and autotransplant
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recipients, which is not surprising as autotransplanted patients received the same conditioning
chemotherapy as allotransplanted patients.
Our present study included a small number of patients, but our patients are relatively homogeneous.
We would also emphasize that our patient cohort represents a consecutive group of patients from a
defined geographical area during a defined time period. Thus, our patients should also be regarded
as unselected.
All transplant recipients included in our study had severe hematological malignancies, and they
initially received intensive conventional chemotherapy with the intention to induce complete
hematological remission. They all reached stable complete remission prior to transplantation.
Patients receiving such intensive conventional chemotherapy showed a similar wide variation in
monocyte subset levels during treatment-induced cytopenia to the patients with posttransplant
cytopenia, even though they had received repeated cycles of intensive consolidation treatment with
relatively short intervals after remission induction [1].
Previous studies have demonstrated that monocyte reconstitution (i.e., normalization of peripheral
blood monocyte levels) occurs relatively early after allogeneic stem cell transplantation [37], and this
was also true for all our allotransplant and autotransplant recipients. Normalization of the circulating
monocyte levels usually occurred before normalization of the neutrophil levels. Thus, even though our
study included relatively few patients, they should be regarded as representative because they show
the expected early normalization of both total monocyte and neutrophil peripheral blood levels.
We have previously investigated the levels of circulating monocyte subsets in myeloma patients
receiving autologous stem cell transplantation [29]. These myeloma patients differ from the patients
included in our present study as (i) they received different and less intensive pretransplant treatment
without remission induction; (ii) the intention of the transplantation is stabilization but not cure;
and (iii) they received less intensive conditioning therapy as well as growth factor treatment
posttransplant. The myeloma patients also showed early monocyte reconstitution, but displayed wider
variations in the monocyte subset levels both pretransplant and immediately after transplantation
during cytopenia. However, despite these differences, both patient groups showed early monocyte
reconstitution, and a majority of circulating monocytes show classical phenotypes within 4 weeks,
both for the majority of myeloma patients and all the present leukemia patients.
The CD14 and CD16 markers used for identification of monocyte subsets reflect the functional
heterogeneity of the three subsets because both these surface molecules initiate downstream
intracellular signaling that is involved in the regulation of important functional characteristics,
including proinflammatory and phagocytic activity [24,25]. Thus, our present results show that the
balance between functionally different monocyte subsets can be altered not only immediately before,
but also during the early posttransplant period (i.e., the first 4 weeks) when compared with later
after transplantation.
Several previous observations suggest that immunological events during the early posttransplant
period are important for outcomes after stem cell transplantation, especially allogeneic transplantation.
The effect of G-CSF therapy on outcome after allogeneic stem cell transplantation has been investigated
in two large studies. In the European study, G-CSF therapy was associated with decreased overall
survival due to increased non-relapse mortality (i.e., severe GVHD) [42], whereas in another study,
G-CSF therapy did not influence survival [43]. A major difference between the two studies was the
increased use of total body irradiation in the European study. An experimental study has previously
shown that total body irradiation is associated with an increased activation of dendritic cells, which can
also be differentiated from monocytes, and thereby increased proinflammatory alloreactivity [44].
Furthermore, the intensification of GVHD prophylaxis during the first one or two posttransplant
weeks with methotrexate or cyclophosphamide also demonstrates that immunological events early
posttransplant are important for outcome [45–47], and that this intensification may not only affect
the T-cells, but also directly influence the monocytes [48,49]. Taken together, all these observations
suggest that the altered balance between various monocyte subsets early after allotransplantation may
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be important for the later outcome. Other studies suggest that this may also be true for autologous
stem cell transplantation [50].
Our present study shows that patients with hematological malignancies have a wider variation in
the relative levels (i.e., percentage) of circulating monocyte subsets than healthy individuals during
periods of antileukemic therapy. However, this variation is reduced after stem cell transplantation
due to rapid posttransplant reconstitution of total and classic monocytes, although there is still
a wider variation between patients after transplantation. Previous studies have shown that later
posttransplant variations in monocyte subset are associated with outcome after transplantation [20,31].
Other investigators have observed that clinical events during the very early period after stem cell
transplantation are important for outcome/survival [15]. Future studies should therefore try to
clarify whether the early variations described in our present study are also associated with outcome
after transplantation, and if so, whether these early differences between patients may be used as
clinically relevant biomarkers and a basis for early interventions to improve outcome. These studies
should possibly also investigate the balance between remaining recipient and donor monocytes in
allotransplant recipients [44]. Finally, previous studies have demonstrated that the role of monocytes in
inflammation may be influenced by other leukocyte subsets, and the interactions between monocytes
and other normal leukocytes during the early posttransplant period also need to be investigated [51,52].
5. Conclusions
Our present data show that monocytes reconstitute early after stem cell transplantation for high-risk
leukemia and MDS patients. Our data also show a greater variation in the distribution of monocyte
subpopulations among patients during both pretransplant stable remission and posttransplant
pancytopenia, whereas the variation is less 4 weeks posttransplant, although still larger than for healthy
controls. Thus, our present studies show an expected normalization of total monocyte counts early
after stem cell transplantation, but our results also show that normalized total monocyte counts do not
mean a normalization of monocyte functions (i.e., normalization of the balance between functionally
different monocyte subsets).
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Abstract: Immunomodulatory drugs (IMiDs) are used in the treatment of hematological malignancies,
especially multiple myeloma. IMiDs have direct anticancer effects but also indirect effects via
cancer-supporting stromal cells. Monocytes are a stromal cell subset whose metabolism is modulated
by the microenvironment, and they communicate with neighboring cells through extracellular release
of soluble mediators. Toll-like receptor 4 (TLR4) is then a common regulator of monocyte metabolism
and mediator release. Our aim was to investigate IMiD effects on these two monocyte functions.
We compared effects of thalidomide, lenalidomide, and pomalidomide on in vitro cultured normal
monocytes. Cells were cultured in medium alone or activated by lipopolysaccharide (LPS), a TLR4
agonist. Metabolism was analyzed by the Seahorse XF 96 cell analyzer. Mediator release was
measured as culture supernatant levels. TLR4 was a regulator of both monocyte metabolism and
mediator release. All three IMiDs altered monocyte metabolism especially when cells were cultured
with LPS; this effect was strongest for lenalidomide that increased glycolysis. Monocytes showed a
broad soluble mediator release profile. IMiDs decreased TLR4-induced mediator release; this effect
was stronger for pomalidomide than for lenalidomide and especially thalidomide. To conclude,
IMiDs can alter the metabolism and cell–cell communication of normal monocytes, and despite their
common molecular target these effects differ among various IMiDs.
Keywords: monocytes; immunomodulatory drugs; cell metabolism; cytokines
1. Introduction
The immunomodulatory drugs (IMiDs) are widely used in the treatment of multiple myeloma and
are also considered for the treatment of other hematological malignancies [1]. Cereblon is a common
molecular target for IMiDs, and the drugs can have direct anticancer effects on malignant cells or
indirect effects mediated via cancer-supporting nonmalignant cells (e.g., antiangiogenic effects) [2].
Monocytes are important both for immunoregulation and for regulation of normal and malignant
hematopoiesis [3,4], and IMiD effects on monocytes may therefore be important both for their efficiency
and toxicity in anticancer treatment.
Monocytes undergo morphological, phenotypic, and functional changes in response to their
metabolic microenvironment [5]. Most circulating monocytes have a classical phenotype and their
metabolism can be altered by ligation of Toll-like receptor 4 (TLR4), e.g., by lipopolysaccharide (LPS) or
Molecules 2020, 25, 367; doi:10.3390/molecules25020367 www.mdpi.com/journal/molecules
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certain metabolites (e.g., oleic acid, palmitic acid), and the downstream NFκB activation following TLR4
ligation [6]. However, very high levels of TLR4 ligands may instead induce tolerance [7]. Cholesterol,
triglyceride-rich lipoproteins, low density lipoproteins (LDL), very low density lipoproteins (VLDL)
and high density lipoprotein (HDL) can also modulate the monocyte phenotype through non-TLR4
mechanisms and thereby alter the balance between pro- and anti-inflammatory effects [5–8]. Finally,
even dietary intake seems to influence the phenotypic characteristics of monocytes, including the
balance between pro- and anti-inflammatory effects [8]. Thus, monocyte functions are modulated by
the monocyte’s metabolic status/environment.
TLR4 receptors can be activated not only by microbial products but also by endogenous ligands
as described above [9,10]. TLR4 ligation can stimulate monocyte release of several cytokines [11,12]
and at the same time also activate a metabolic switch towards glycolysis leading to production of
metabolites that are important for the pentose–phosphate pathway, fatty acid synthesis, and amino
acid metabolism [8]. This relative block in the citric acid cycle will increase the availability of citric acid
and succinate with further modulation of phospholipid and cholesterol synthesis [13,14]. Thus, the
balance between glycolysis and oxidative phosphorylation is not only modulated by TLR4 ligands
but also by the metabolomic profile of the extracellular microenvironment [15], e.g., glutamine that
both feeds into the tricarboxylic acid cycle and also acts as a regulator of TLR4 responses [13,16].
These examples further illustrate the complex overlap/crosstalk between TLR4 signaling, metabolic
regulation, and extracellular mediator release.
Monocytes can influence the development of various malignancies through direct and indirect
effects [17], possibly also multiple myeloma. First, the balance between various leukocyte subsets in
peripheral blood seems to have a prognostic impact, and high neutrophil- or monocyte-to-lymphocyte
ratios at the time of diagnosis are associated with unfavorable clinicobiological features [18]. Secondly,
monocytes can modulate the cell surface molecular profile of the myeloma cells [19]. Third, activated
monocytes release cytokines that directly stimulate myeloma cell proliferation or indirectly facilitate
disease progression, e.g., through increased angiogenesis [20,21]. Finally, monocyte-derived dendritic
cells can present myeloma-associated antigens [22], whereas monocyte-derived myeloid-derived
suppressor cells have immunosuppressive effects [23]. Thus, monocytes may influence myeloma
development/progression and susceptibility to chemotherapy, but the final effects are difficult to predict.
The immunomodulatory drugs (IMiDs) thalidomide, lenalidomide, and pomalidomide are
widely used in myeloma treatment [24] and can inhibit TLR4/LPS-induced secretion of inflammatory
cytokines [25]. Cereblon is a common molecular target for these drugs, but their cereblon binding
as well as their clinical effects in myeloma treatment differ [2]. As described above there may be a
crosstalk between TLR4 signaling, metabolic modulation, and capacity of cytokine release in normal
monocytes. In this context we have compared the effects of these IMiDs on monocyte metabolism and
release of soluble mediators by normal monocytes.
As described above monocytes seem to support disease development in multiple myeloma [17],
but because monocytes are a part of the bone marrow stem cell niches they may also influence
the development and chemosensitivity of other hematological malignancies, e.g., through their
release of leukemia-supporting cytokines [4]. IMiDs are therefore considered for the treatment of
other hematological malignancies [2]. The aim of the present study was to use standardized in vitro
models to investigate how various IMiDs influence important phenotypic characteristics of normal
monocytes and whether these effects differ among various IMiDs that have cereblon as a common
molecular target [26]. Thus, monocytes are important in physiological immunoregulation as well as
in carcinogenesis, and our goal was to investigate IMiD effects on metabolic regulation and cytokine
release; two functional characteristics that seem to be important are the roles of normal monocytes in
both immunoregulation and carcinogenesis [8,17].
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2. Results
2.1. TLR4/LPS Activation Alters the Balance between Glycolysis and Oxidative Phosphorylation in the
Direction of Glycolysis
Monocytes derived from 10 healthy blood donors (4 males and 6 females; median age 33 years
with range 25–71 years) were incubated for four hours in medium with and without LPS; the cells
were thereafter incubated for one hour without CO2 before cell metabolism was analyzed. We first
investigated the basal mitochondrial metabolism (see Supplementary Figure S1 upper part) of the
monocytes; the balance between oxidative phosphorylation (oxygen consumption rate, OCR) and
glycolysis (i.e., extracellular acidification rate, ECAR) is presented as the OCR:ECAR ratio. The results
from a representative experiment are presented in Supplementary Figure S1 (lower part).
Preincubation for four hours with LPS 1 ng/mL decreased the OCR:ECAR ratio significantly,
compared with the medium control (Figures 1a and 2A). A similar effect on the OCR:ECAR ratio was also
seen when analyzing the maximal respiration period where LPS also decreased this ratio significantly
(Figures 1b and 2D). Thus, LPS altered the balance between glycolysis and oxidative phosphorylation
in the direction of glycolysis, but LPS did not alter the coupling efficiency (i.e., the efficiency of
mitochondrial ATP production) or spare respiratory capacity (i.e., showing how much of the respiratory
capacity was being used) (Figure 1c).
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or pomalidomide—in medium alone without LPS; and (iv) LPS in combination with either 
thalidomide, lenalidomide or pomalidomide. The figures show the results for (a) the OCR:ECAR ratio 
during the initial period of basal incubation; (b) the period of maximal respiration after addition of 
FCCP (Carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone; an uncoupling agent); and (c) the 
calculated spare respiratory capacity. The figure summarizes the results for 10 independent 
experiments testing monocytes from 10 healthy blood donors. The results are presented as median, 
box (i.e., the 25–75 percentiles) and whiskers (the 5–95 percentiles). The Wilcoxon test for paired 
samples was used for the statistical comparisons, and p-values < 0.05 were regarded as statistically 
significant. The significant comparisons are indicated in the figure (* p < 0.05, ** p < 0.01). 
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cell analyzer; a summary of the overall results. Normal mon cytes wer cultured in mediu al or
in the presence of LPS (lipopolysaccharide) 1 ng/mL, or IMiDs (immuno odulatory drugs) 5 µg/mL for
four hours before the oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were
determined. Each of the figures presents the OCR:ECAR ratio (diagrams (a,b)) or the spare respiratory
capacity (diagram (c)) for cultures prepared in (from the bottom to the top of each diagram) (i) medium
alone (ctr), (ii) LPS control, (iii) each of the IMiDs—thalidomide, lenalidomide, or pomalidomide—in
medium alone without LPS; and (iv) LPS in combination with either thalidomide, lenalidomide or
pomalidomide. The figures show the results for (a) the OCR:ECAR ratio during the initial period of
basal incubation; (b) the period of maximal respiration after addition of FCCP (Carbonyl cyanide-4
(trifluoromethoxy) phenylhydrazone; an uncoupling agent); and (c) the calculated spare respiratory
capacity. The figure summarizes the results for 10 independent experiments testing monocytes from 10
healthy blood donors. The results are presented as median, box (i.e., the 25–75 percentiles) and whiskers
(the 5–95 percentiles). The Wilcoxon test for paired samples was used for the statistical comparisons,
and p-values < 0.05 were regarded as statistically significant. The significant comparisons are indicated
in the figure (* p < 0.05, ** p < 0.01).
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were cultured with and without LPS 1 ng/mL and/or with and without IMiDs 5 µg/mL in the presence of
LPS. Metabolism was analyzed using the XF Mito Stress Test assay and the Seahorse XF 96 cell analyzer.
The figure presents the results for all statistically significant comparisons. The culture conditions that
were compared in each of the statistical analyses/diagrams are indicated on the x-axis, the OCR:ECAR
ratio is indicated on the y-axis and the corresponding p-values from the statistical analyses (Wilcoxon
test for paired samples) are indicated at the top of each diagram. We present the results from analysis
of basal (A–C) and maximal respiration (D–H). Each diagram compares the results for (i) cultures
prepared with medium alone versus LPS (A,D); (ii) cultures prepared with LPS without and with an
IMiD (B,F,G), and (iii) cultures prepared with two different IMiDs but otherwise with similar culture
conditions (E,H).
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2.2. IMiDs Differ in Their Effects on the Balance between Glycolysis and Oxidative Phosphorylation; Especially
Lenalidomide Increases Oxidative Phosphorylation
We first investigated whether thalidomide, lenalidomide, and pomalidomide altered monocyte
metabolism when cells from 10 healthy individuals were cultured in medium alone without TLR4/LPS
stimulation. The OCR:ECAR ratio was not significantly altered by any of the IMiDs when analyzing
the initial basal metabolism or the maximal respiration (Figure 1a,b).
We then investigated the effects of the three IMiDs on the OCR:ECAR ratio in the presence of
LPS/TLR4 ligation, i.e., an intervention that alters the metabolic balance in the direction of glycolysis
(see above). Lenalidomide caused a significant increase in this ratio when testing the cells under basal
conditions (Supplementary Figure S1 lower part, Figures 1a and 2B), but for 8 out of the 10 tested
individuals the ratio was still lower for the lenalidomide cultures than for the medium controls. The
lenalidomide levels were also significantly different from the thalidomide values (Figure 2C) but did
not differ significantly from pomalidomide (data not shown). Thus, lenalidomide was the only IMiD
that significantly altered monocyte metabolism and decreased the relative importance of glycolysis
(i.e., increased the OCR:ECAR ratio) in the presence of TLR4/LPS activation.
We also investigated the OCR:ECAR ratio during maximal respiration (see Figures 1–3). The ratio
was significantly higher for lenalidomide than for pomalidomide when testing normal monocytes
incubated in medium alone without LPS (Figure 2E). In the presence of LPS the IMiDs had different
effects on the OCR:ECAR ratio; lenalidomide caused a highly significant increase (Figure 2F) whereas
pomalidomide caused an increase of borderline significance (Figure 2G). The ratio was significantly
higher for lenalidomide than for thalidomide (Figure 2H) in the presence of LPS.
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(a–d) and with two different IMiDs (e).
None of the IMIDs had ignificant ff cts on the coupling efficiency (i.e., the efficiency of
mitochondrial ATP production, see Supplementary Figure S1) (data not shown).
2.3. IMiDs Have Different Effects on the Spare Respiratory Capacity of Normal Monocytes
We first investigated the effects of the three IMiDs on the spare respiratory capacity in the
absence of TLR4/LPS stimulation; none of the drugs then had any significant effect (Figure 1). We
also investigated the effects of the three IMiDs on the spare respiratory capacity in the presence of
TLR4/LPS stimulation (Figures 1 and 3). All three IMiDs altered this capacity significantly compared
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with the LPS control cultures (Figure 3a–c). Lenalidomide then caused a highly significant increase
(Figure 3b, p = 0.007), and this lenalidomide effect was significantly stronger than the increase caused
by thalidomide (Figure 3d) and the decrease caused by pomalidomide (Figure 3e). Thus, the differences
among IMiDs with regard to modulation of monocyte metabolism are not only reflected in OCR:ECAR
ratio but also in the spare respiratory capacity.
2.4. Healthy Individuals Differ in Their Spontaneous and TLR4/LPS-Induced Mediator Release
We investigated the spontaneous release of 14 soluble mediators for normal monocytes derived
from 15 healthy individuals (7 males and 8 females, median age 48 years with range 23–71 years).
Monocytes showed a spontaneous mediator release, but these levels were relatively low and varied
between patients (Supplementary Table S1, Figure 4).Molecules 2020, 25, x FOR PEER REVIEW 7 of 18 
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Figur 4. Analysis of mo ocyte cytokine release during in vit o cult re; a sum ary of the overall
results. Normal monocytes were cultured in medium alone or in the presence of LPS 1 ng/mL, or IMiD
5 µg/mL for 24 h before supernatants were harvested and the supernatant levels of the 14 soluble
mediators determined. Each of the diagrams/figures present the level for cultures prepared in (from
the bottom to the top of the figure) (i) medium alone (ctr), (ii) LPS + DMSO alone, (iii) each of
the IMiDs—thalidomide, lenalidomide or pomalidomide—in combination with either thalidomide,
lenalidomide, or pomalidomide. The diagrams show the results for each individual soluble mediator.
The results are presented as the median, box (i.e., 25–75 percentiles), and whiskers (5–95 percentiles).
The Wilcoxon test for paired samples was used for all statistical comparisons, and p-values < 0.05 were
regarded as statistically significant. All statistically significant comparisons are indicated in the figure
(* 0.01 < p < 0.05, ** p < 0.01, *** p < 0.001).
For seven of these individuals we also investigated the release in cultures prepared in medium
with LPS 1 ng/mL. As expected we observed a LPS-induced increased in soluble mediator release,
and the levels did not differ significantly when we compared cultures with LPS alone and cultures
with LPS + DMSO (i.e., the control cultures for the IMiD experiments) (data not shown). Thus, the
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TLR4/LPS-induced mediator response was maintained in the presence of the DMSO concentration used
in our IMiD experiments, and the LPS response is reflected in the difference between the spontaneous
levels presented in Supplementary Table S1 and the levels in the DMSO containing control cultures
presented in Table 1 (see also the overview in Supplementary Figure S2). Finally, LPS significantly
increased the levels for all soluble mediators except for CCL1 and CXCL10, and there were no significant
correlations between the spontaneous release for cultures prepared in medium alone and the LPS
cultures, except for IL10 (r-value 0.821, p-value 0.001) and MMP9 (r-value 0.621, p-value 0.018).
We did a hierarchical clustering analysis of the TLR4/LPS-induced mediator release for the 15
healthy individuals (Supplementary Figure S3). These results are presented as the relative responses,
i.e., the levels in LPS containing cultures versus the levels in control cultures prepared in medium
alone. The TLR4/LPS responsiveness differed among individuals, and a strong response was seen
especially for the lower six individuals (2, 10, 6, 7, 3, 1) that clustered together. We performed similar
analyses for thalidomide/lenalidomide/pomalidomide containing cultures, and these analyses showed
that similar variations among individuals in TLR4/LPS responsiveness (i.e., variations in absolute
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2.5. Thalidomide Shows a Weak, Lenalidomide an Intermediate, and Pomalidomide a Strong Inhibitory Effect on
the TLR4/LPS-Induced Release of Soluble Mediators by Normal Monocytes
The supernatant levels of 14 soluble mediators were compared for monocyte cultures prepared
in medium with DMSO (i.e., control cultures) and cultures prepared in medium with DMSO and 5
µg/mL of either thalidomide, lenalidomide, or pomalidomide (Figure 5), Supplementary Figure S2,
Table 1). All three IMiDs modulated TLR4/LPS-induced soluble mediator release by normal monocytes,
but the effects differed among the drugs. First, thalidomide caused a significant reduction for only
three mediators (CCL2, IL10, MMP9) and a highly significant effect was only seen for MMP9. Second,
lenalidomide caused a significant reduction for five mediators, but a highly significant effect was only
seen for CCL2. Third, pomalidomide caused a significant reduction for seven mediators and the effect
was generally stronger (i.e., lower p-values) for pomalidomide than for the other two IMiDs (Table 1,
Supplementary Figure S2). A generally stronger effect (i.e., lower concentrations) by pomalidomide
was also observed when comparing the absolute levels for cultures with LPS + pomalidomide versus
LPS + thalidomide/lenalidomide (Supplementary Table S2).
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Figure 5. The effects of IMiDs on TLR4/LPS-stimulated cytokine release by normal monocytes; a
hierarchical clustering analysis of the overall IMiD effects. The analysis was based on the relative
mediator level, i.e., level in IMiD-containing LPS cult res lative to the level in the corresponding LPS
stimulated IMiD-free control. Bef re the clustering analysis ll relative respons s for each mediator
were normaliz d t the m ian relativ response for all three IMiDs, i.e., they were normalized to
the edian relative r spo s of all 45 IMID responses for each mediator (3 IMiDs, 15 individuals).
Thus, green color thus means a relatively strong inhibitory effect. It can be se n that even for mediators
showing highly significant effects of IMiDs there was a con iderable variation among individuals with
regard to the effects of IMiDs.
We also did a hierarchical clustering analysis including all the drugs and all the mediators
(Figure 5). This analysis was based o the relative mediator levels in drug-containing cultures,
i.e., levels in IMiD cultures relative to the level in the corresponding LPS control culture. Each of these
relative responses for a mediator was next normalized to the median relative response for all three
IMiDs, i.e., the median relative response of the 45 IMID responses for each soluble mediator (3 drugs
times 15 individuals). It can be seen that even for mediators showing highly significant overall effects
of IMiDs there was a considerable variation among individuals with regard to the effect.
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Furthermore, weaker responses were often seen for the lower cluster including six patients, and all
these patients showed relatively strong TLR4/LPS responses (see Supplementary Figure S3). Thus, the
effect of IMiDs in the presence of TLR4/LPS stimulation seemed to depend on the LPS responsiveness,
and the IMiD effects were stronger for patients with a relatively weak TLR4/LPS responsiveness.
2.6. Lenalidomide and Pomalidomide Reduce TLR4/LPS-Induced Mediator Release by Normal Monocytes Also
at Concentrations Corresponding to Their Therapeutic Serum Levels
Thalidomide was tested at a concentration corresponding to its therapeutic serum level
(i.e., 5 µg/mL) in the previous experiments, whereas lenalidomide and pomalidomide in vivo levels
are lower than this. We therefore tested the effect of lenalidomide 500 ng/mL and pomalidomide
100 ng/mL on the TLR4/LPS-induced mediator release for five healthy donors, and both these IMiDs
could inhibit soluble mediator release even when tested at the lower concentrations corresponding to
their serum levels (uncorrected p-value of 0.031, Wilcoxon test for paired samples).
2.7. Pomalidomide Inhibits Soluble Mediator Release also in the Presence of Bortezomib
The effect of the proteasomal inhibitor bortezomib was tested for five healthy blood donors (two
males and three females, median age 63 years with range 21–66 years) when monocytes were cultured
in medium alone or in the presence of LPS. Bortezomib had minor and divergent effects when testing
monocytes cultured in medium alone (data not shown), whereas it caused an inhibition of CCL1
and CXCL10 for all five individuals when tested in the presence of LPS (Figure 6). Furthermore,
we tested whether the inhibitory effects of lenalidomide and pomalidomide on TLR4/LPS-induced
release by normal monocytes was maintained in the presence of bortezomib. An inhibitory effect of
pomalidomide was observed for a limited number of mediators also in the presence of bortezomib,
whereas lenalidomide had generally weaker and divergent effect (Figure 6).
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Figure 6. The effects of TLR4/LPS, bortezomib, and IMiDs on the release of soluble mediators by 
normal monocytes; a summary of the overall results for five healthy blood donors. We compared the 
mediator levels for (i) cultures prepared in medium with and without LPS 1 ng/mL; and (ii) DMSO 
containing control cultures with LPS alone versus cultures with LPS together with either lenalidomide 
500 ng/mL or pomalidomide 100 ng/mL (i.e., concentrations corresponding to the serum levels 
reached during myeloma treatment); and (iii) cultures with LPS + bortezomib versus cultures with 
LPS and bortezomib together with either lenalidomide or pomalidomide. The comparisons showing 
a similar decrease (i.e., at least 25% reduction) in the soluble mediator level for all five individuals 
included in the comparisons are indicated in grey; a decrease for all five individuals corresponds to 
an uncorrected p-value of 0.031 when using the Wilcoxon test for paired samples. 
3. Discussion 
Normal monocytes seem important both in immunoregulation and possibly also for 
carcinogenesis/leukemogegesis [1,17]. The aim of the present study was therefore to investigate 
whether monocyte functions are altered by IMiDs, a class of pharmacological agents that have 
cereblon as a common intracellular molecular target [2] and are considered for the treatment of 
various cancers, especially hematological malignancies [1,27,28]. Our main conclusion based on the 
present study is that IMiDs can alter both monocyte metabolism as well as cytokine release, and 
despite their common molecular target these pharmacological effects differ among IMiDs.  
Thalidomide and its derivatives lenalidomide and pomalidomide are used in the treatment of 
multiple myeloma [29–34]. The antimyeloma effect is probably due to both direct and indirect effects 
on the myeloma cells, including immunomodulation as well as anti-angiogenic, anti-inflammatory 
and direct antiproliferative effects [31,32,35]. These drugs are often combined with steroids and/or 
proteasome inhibitors [34] and can be used in frontline therapy [34]. The E3 ligase protein cereblon 
is a well-characterized molecular target of IMIDs [36,37], but animal studies suggest that IMiDs also 
have other intracellular targets [37]. The binding to cereblon modulates the stability of cereblon-
interacting molecules [36] and thereby promotes apoptosis by activating caspase-8 [38]. However, the 
clinical evidence suggests that there are important pharmacological differences among IMiDs, and 
resistance against one IMiD does not exclude a response to another IMiD [39]. In the present study 
we investigated how IMiDs differ in their effects on normal monocytes.  
TLR4 is expressed by human monocytes [11,12,40]. LPS is a TLR4 ligand that initiates the 
activation of several downstream intracellular pathways in monocytes, including NFκB, extracellular 
signal-regulated kinases (ERK) 1 and 2, c-Jun N-terminal kinase (JNK) and p38 pathways that activate 
several transcription factors [11,12]. The signaling leads to metabolic modulation and a well-
Figure 6. The effects of TLR4/LPS, bortezomib, and IMiDs on the release of soluble ediators by
nor al onocytes; a su ary of the overall results for five healthy blood donors. We co pared the
ediator levels for (i) cultures prepared in edium ith and ithout LPS 1 ng/ L; and ( i) S
containing control cultures ith LPS alone versus cultures with LPS together with either lenalidomide
500 or pomalidomide 100 ng/mL (i.e., concentrations corresponding to the serum levels reached
during myeloma treat ent); and (iii) cultures wi h LPS + bortezomib versus cultures wi h LPS and
bortezomib together with either lenalidomide or pomalidomide. The comparis ns showi g a similar
decrease (i.e., at least 25% reduction) in the soluble mediator lev l for al five individuals inclu ed in
the comparisons are indicated in grey; a decreas for all five individuals corresponds to an unc rrected
p-value of 0.031 when using the Wilcoxo test for paired samples.
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3. Discussion
Normal monocytes seem important both in immunoregulation and possibly also for
carcinogenesis/leukemogegesis [1,17]. The aim of the present study was therefore to investigate
whether monocyte functions are altered by IMiDs, a class of pharmacological agents that have cereblon
as a common intracellular molecular target [2] and are considered for the treatment of various cancers,
especially hematological malignancies [1,27,28]. Our main conclusion based on the present study is
that IMiDs can alter both monocyte metabolism as well as cytokine release, and despite their common
molecular target these pharmacological effects differ among IMiDs.
Thalidomide and its derivatives lenalidomide and pomalidomide are used in the treatment of
multiple myeloma [29–34]. The antimyeloma effect is probably due to both direct and indirect effects
on the myeloma cells, including immunomodulation as well as anti-angiogenic, anti-inflammatory
and direct antiproliferative effects [31,32,35]. These drugs are often combined with steroids and/or
proteasome inhibitors [34] and can be used in frontline therapy [34]. The E3 ligase protein cereblon is a
well-characterized molecular target of IMIDs [36,37], but animal studies suggest that IMiDs also have
other intracellular targets [37]. The binding to cereblon modulates the stability of cereblon-interacting
molecules [36] and thereby promotes apoptosis by activating caspase-8 [38]. However, the clinical
evidence suggests that there are important pharmacological differences among IMiDs, and resistance
against one IMiD does not exclude a response to another IMiD [39]. In the present study we investigated
how IMiDs differ in their effects on normal monocytes.
TLR4 is expressed by human monocytes [11,12,40]. LPS is a TLR4 ligand that initiates the
activation of several downstream intracellular pathways in monocytes, including NFκB, extracellular
signal-regulated kinases (ERK) 1 and 2, c-Jun N-terminal kinase (JNK) and p38 pathways that
activate several transcription factors [11,12]. The signaling leads to metabolic modulation and a
well-characterized cytokine release response including chemokines, TNFα, IL8/CXCL8, and members
of the IL1 family [41]. Furthermore, TLR4 binds microbial molecules as well as several host-derived
ligands, e.g., molecules derived from degradation of extracellular matrix molecules (e.g., hyaluronic
acid, heparin sulphate), heat shock proteins, fibrinogen, lipoproteins, and amyloid [9,10]. Thus, TLR4 is
both a cellular sensor of the extracellular microenvironment and a regulator of cellular communication.
In this context we investigated the effects of IMiDs on monocyte metabolism and cytokine release in
the presence of TLR4 activation.
We used highly standardized in vitro models for our comparison of pharmacological effects. The
same medium was used in all studies. This medium was supplemented with inactivated fetal calf
serum, and the monocytes were thereby exposed to lipids during culture. Stimulation of TLR4 by
lipids or lipoproteins may at least partly explain why monocytes show spontaneous release of several
soluble mediators during culture, even in the absence of TLR4 stimulation [42].
Our monocyte populations had a purity exceeding 83%, and a major part of the contaminating
cells were small lymphocytes. Furthermore, we cultured the cell for only 24 h, whereas lymphocyte
activation will often require a longer incubation time for cytokine release, even during mitogenic
stimulation [43]. For these reasons we regard our cytokine responses to be monocyte responses.
Thalidomide (molecular weight 358), lenalidomide (359), and pomalidomide (372) were tested
at a concentration of 5.0 µg/mL, and due to these minor differences in molecular weight their molar
levels in the cultures should in our opinion be regarded as comparable. However, despite comparable
molar levels the IMiDs differed in their pharmacological effects; lenalidomide showed a stronger effect
on monocyte metabolism, whereas pomalidomide had the most significant effect on soluble mediator
release. This last difference in their effects on cytokine release is probably not caused by different
effects on monocyte viability; if so, one would expect all mediators to be affected and not only certain
mediators, as we observed.
The concentration of 5 µg/mL was chosen because this is the systemic level reached during
thalidomide treatment of myeloma patients [44]. However, the systemic levels of lenalidomide and
pomalidomide are usually lower, and for this reason we also tested lenalidomide and pomalidomide
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at levels corresponding to their systemic levels reached during myeloma treatment (i.e., 500 and
100 ng/mL, respectively) [45–47]. These experiments showed that both lenalidomide and pomalidomide
reduced monocyte release of soluble mediators also when tested at these lower concentrations.
Our studies showed that LPS as expected altered monocyte metabolism in the direction of
glycolysis [41]. IMiDs could further modulate the metabolism of normal monocytes in the presence
of TLR/LPS stimulation, and lenalidomide had the strongest effects, with a significant increase in the
OCR:ECAR ratio (i.e., increased importance of glycolysis) and an increased spare respiratory capacity.
These observations were only made in the presence of TLR4/LPS stimulation but not when cells were
cultured in medium alone, an observation demonstrating that the differences between IMiDs with
regard to metabolic modulation depend on the biological context. Finally, even though lenalidomide
seems to have the strongest effect on metabolism, pomalidomide had the strongest effect on the
extracellular release of soluble mediators. Thus, the IMiD effects on these phenotypic characteristics
are probably mediated at least partly through different molecular mechanisms.
There was a considerable variation among individuals with regard to the levels of the various
soluble mediators, and a possible explanation for this could be immunogenetic differences between
cell donors. Single nucleotide polymorphisms (SNPs) exist both for NKκB and TLR4 signaling [48–53],
and certain SNPs seem to be clinically relevant and are associated with differences in regulation of
monocyte activation. First, certain polymorphisms have been associated with cancer risk, and this is
possibly due to a genotypic influence on intracellular signaling [50,52]. Second, the risk and/or severity
of infections have also been associated with such genetic variants [49,53]. Finally, immunogenetic
characteristics may be important for the role of monocytes in the development of inflammations [51,53].
Both clinical and experimental studies suggest that differences in monocyte cytokine responsiveness
are important for the associations between immunogenetic differences and severity of infections [53],
but differences in TLR4 expression levels may also contribute [48]. In this context it is not surprising
that we detect a considerable variation among healthy individuals in the cytokine responsiveness of
normal monocytes to TLR4 ligation.
Proteasome inhibitors are also widely used in the treatment of multiple myeloma [27]. These
drugs inhibit the NFκB pathway, one of the pathways also activated by TLR4 [9], and may thereby be
able to reduce the release of NFκB-regulated soluble mediators [54]. Proteasome inhibitors and IMiDs
can be combined in myeloma treatment [27]. The proteasome inhibitor bortezomib had relatively weak
and divergent effects on the mediator release by normal monocytes and inhibited TLR4/LPS-induced
release only for a few mediators. However, bortezomib seemed to modulate the inhibitory effects of
IMiDs on the mediator release, and this was true especially for lenalidomide, whereas several effects of
pomalidomide were maintained also in the presence of bortezomib.
Infections are a major cause of morbidity and mortality in myeloma patients, and immunosuppressive
effects of IMiDs may contribute to the risk of infections [55]. Advanced myeloma is associated with
dysregulation of several immunocompetent cells [29], including monocytes [18,56–62]. The effects of IMiDs
on monocyte mediator release will influence communication between immunocompetent cells and possibly
contribute to the risk of infections. Myeloma patients receiving antimyeloma therapy seem to have a
quantitative monocyte defect [63] and our present results suggest that these patient also have a qualitative
effect, but in our opinion the myeloma-associated B-cell defect is probably most important for the increased
risk of infections [64].
Our present in vitro studies suggest that various IMiDs alter the metabolic regulation and the
immunomodulatory functions of normal monocytes, but for several reasons our results should be
interpreted with great care. First, additional clinical studies are needed to clarify whether these
effects are relevant in vivo. Second, normal monocytes consist of different subsets with different
immunoregulatory functions [17,65], and it is not known whether IMiDs have similar effects on
different monocyte subsets. Third, it is not known whether circulating normal monocytes derived
from cancer patients, especially allotransplant recipients [63,65], show similar pharmacological effects
compared with monocytes from healthy individuals, or whether the IMiD effects are similar for
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young/middle-aged/elderly patients. Finally, we have only investigated IMiDs in combination with the
proteasome inhibitor bortezomib; additional combinations used for treatment of multiple myeloma [27]
as well as for other hematological malignancies [28] also need to be investigated.
Based on our present experimental studies we conclude that IMiDs modulate metabolism and
communication of normal monocytes, and despite their common molecular target [2] these effects
differ among IMiDs. These pharmacological in vivo effects may be relevant for immunoregulatory
as well as cancer-supporting effects of normal monocytes [1,17], and future clinical studies should
therefore try to clarify whether these effects are also important in vivo.
4. Materials and Methods
4.1. Cell Donors
Normal monocytes were derived from healthy blood donors. In accordance with the approved
routines at the Blood Bank, Haukeland University Hospital peripheral venous blood samples were
donated after written informed consent. The project was approved by the Regional Ethics Committee
(REK VEST 2013/635, 2017/305).
4.2. Reagents
A stock solution of lipopolysaccharide (LPS) from Escherichia coli (#L2654-1MG; Merck KGaA,
Darmstadt, Germany) was dissolved in medium (1 mg/mL) and stored at −80 ◦C. LPS was used
at a concentration of 1 ng/mL based on titration experiments using monocytes in the Seahorse
assay. Bortezomib (#5043140001; Merck KGaA) was dissolved in medium and used at a final
concentration of 25 nM; this concentration can inhibit in vitro constitutive chemokine release by
myeloid cells [54]. Stock solutions of thalidomide 12 µg/mL (#14610), lenalidomide 16 µg/mL (#14643),
and pomalidomide 15 µg/mL (#19877; all from Cayman Chemicals, Ann Abor, MI) were prepared
in DMSO (D2650-5X5ML, Merck KGaA), aliquoted, and stored at −80 ◦C. DMSO reached a final
concentration of 0.55 mg/mL (corresponding to 0.055%) in the experiments. The molecular weights for
the IMiDs are thalidomide (C13H10N2O4) 258, lenalidomide (C13H13N3O3) 259, and pomalidomide
(C13H11N3O4) 273 (see Supplementary Figure S4). The IMiDs were used at a final concentration of
5 µg/mL; this concentration corresponds to the systemic levels reached in vivo during thalidomide
treatment of myeloma patients [44] (for molar concentrations, see Supplementary Figure S4).
4.3. Preparation of Enriched Normal Monocytes
Monocytes were isolated from buffy coats that were diluted 1:1 with phosphate-buffered saline
(PBS), and peripheral blood mononuclear cells (PBMC) were then isolated by density gradient
separation (Lymphoprep™, NycoMed, Oslo Norway; density 1.077 g/mL; centrifugation 800 G/30 min).
The PBMC were washed twice in PBS, resuspended in 5 mL RPMI 1640 medium (#R7509, Merck KGaA)
and overlaid 4 mL Percoll solution (P4937, Merck KGaA) [66]. After centrifugation (500 G, 30 min,
room temperature) monocytes were harvested, washed, resuspended in 30 mL PBS and counted by a
TC20™ Automated Cell Counter (BIO-RAD, Oslo, Norway).
The cells were thereafter centrifuged and resuspended (107 cells/40 µL in the recommended
buffer for the Pan Human Monocyte Isolation Kit (#130-096-537; MACS Miltenyi Biotec, Bergisch
Gladbach, Germany) and the separation procedure performed strictly according to the manufacturer’s
recommendations. Briefly, the LS column (#130-042-401, MACS Miltenyi Biotec), and the 30 µm
preseparation filter (#130-041-407, MACS Miltenyi Biotec) were prepared according to the instructions.
Cells were incubated with the FcR-block and Pan Monocyte Biotin–Antibody Cocktail for 5 min
at a concentration of 10 µl per 107 cells; an additional 40 µL of buffer per 107 cells was thereafter
added, followed by 20 µl Anti-Biotin MicroBeads per 107 cells. The cell suspension was thereafter
incubated for 10 min before buffer was added, the cells were centrifuged and resuspended in buffer at
a concentration of 108 cells/0.5 mL. Thereafter 0.5 mL of the cell suspension was added to the pre-filter
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and the suspension was run through the column and collected. The column was subsequently washed
with 3 mL buffer that was collected together with the monocytes. The collected cells were centrifuged
and reconstituted in 50 mL PBS before counting. Flow cytometric analysis of isolated cell populations
showed at least 83% monocytes (median 89.5%, range 83.4–95.3%); the majority of contaminating
cells being small lymphocytes. The monocytes included a median of 84% classical (range 76–90%),
5% (range 4.1–9.3%) intermediate, and 9% (range 4.8–18.4%) nonclassical monocytes. The monocytes
were centrifuged and resuspended in RPMI 1640 supplemented with 10% fetal calf serum (FCS) and
penicillin/streptomycin (1.25 x 106 cells/mL), and 200 µl were distributed to each culture well. After
30 min of preincubation at 37 ◦C the cells were used in the experiments.
4.4. Analysis of Monocyte Metabolism
In vitro culture of enriched monocytes. Monocytes were incubated for four hours in medium with
and without IMIDs/LPS before the medium was changed. Thereafter the cells were incubated for
one hour without CO2 before analysis by the Seahorse XF 96 cell analyzer. No significant difference
was detected for control cultures (with or without LPS) with and without DMSO. Pilot experiments
compared the effects of IMiDs after 2, 4, and 24 h of in vitro culture; the effects of IMiDs were strongest
after four hours and this incubation time was used for all experiments.
Extracellular flux assays. The XF Mito Stress Test Kit (#103,325-100 and #103,015-100; Agilent
Technologies, Inc., CA) was used strictly according to the manufacturer’s instructions. Briefly, assay
medium was prepared by supplementing XF Base Medium minimal DMED (#102,353-100; Agilent
Technologies) with glucose 10 mM (#103,577-100, Agilent Technologies), pyruvate 1 mM (S8,636-100 mL,
Merck KGaA), and glutamine at 2 mM (#103,575, Agilent Technologies); the pH was adjusted to 7.4
with NaOH. Cells were washed twice in assay medium before being resuspended in 180 µL medium
and incubated (humidified atmosphere, 37 ◦C, without CO2) for 60 min. The cartridges that had
been hydrated according to manufacturer instructions one day earlier, were prepared with the drugs
for injections, i.e., oligomycin 2 µM, carbonyl cyanide-p-trifluoromethox-yphenyl-hydrazon (FFCP,
a protonophore) 1 µM, and rotenone/antimycin A 0.5 µM (all solutions prepared in assay medium).
The extracellular flux assays were performed; subsequently the assay medium was discarded and the
plate stored at −80 ◦C for at least 24 h before the amount of protein was measured (see below). All
assays were prepared with 6–8 parallels.
The oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were estimated
by a Seahorse XF 96 cell analyzer. The spare reservoir capacity and coupling efficiency was calculated
by XF Cell Mito Stress Test Excel Template. The definitions of the parameters used in the metabolic
analyses can be seen in Supplementary Figure S1 (upper part).
Estimation of total cell proteins. The Pierce™ BCA Protein Assay Kit (#23,225; Thermo Scientific™,
Waltham, MA, USA) was used for normalization of data and performed strictly accordingly to
manufacturer’s instructions. A total of 10 µl of standard samples was added to each well together with
200 µl of working reagent. After 30 s on a plate shaker and 30 min incubation 150 µl was transferred to
a new plate and read at 595 nm by a iMark™Microplate Absorbance Reader (Bio-Rad laboratories,
Oslo, Norway).
4.5. Analysis of TLR4/LPS Induced Cytokine Release
Enriched normal monocytes were cultured in RPMI 1640 medium (#R8758-1L; Merck KGaA)
supplemented with 10% inactivated fetal calf serum (#S181B-500; Biowest, Nuaillé, France) and
penicillin-streptomycin (#MS00AO100H; Biowest). Cultures were prepared in Agilent Seahorse XF95
cell culture microtiter (96-well) plates with each well containing 250,000 monocytes in 200 µl medium.
LPS 1 ng/mL was added together with the drugs, cultures were thereafter incubated (37 ◦C, humidified
atmosphere, 5% CO2) for 24 h before supernatants were harvested. The supernatants were stored
frozen at −20 ◦C until analyzed.
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Supernatant levels of soluble mediators were determined by Luminex high performance assays
(Biotechne, Abingdon, UK) and included CCL1, CCL7, CXCL10, IL-8, MMP-9, CCL2, CCL4, CXCL1,
IL-1β, and IL-10. ELISA assays (Biotechne) were used to determine levels of CCL3, IL1RA, IL6, and
TNF-α. All assays were performed strictly accordingly to the manufacturer’s instructions; the assays
were performed in duplicates and differences between duplicates were generally <10%.
4.6. Statistical Analysis
The Wilcoxon rank sum test and the Wilcoxon test for paired samples were used for statistical
analyses and p-values < 0.05 were regarded as statistically significant.
Supplementary Materials: The following are available online, Table S1: The spontaneous release of
soluble mediators, an overview; Table S2. The effects of thalidomide, lenalidomide, and pomalidomide on
TLR4/LPS-induced release of soluble mediators by normal monocytes derived from healthy individuals; a
comparison of the effects of the three pharmacological agents; Figure S1: Analysis of monocyte metabolism
using The XF Mito Stress Test assay and the Seahorse XF 96 cell analyzer; an overview of the Seahorse assay
(upper part) and the results from a representative experiment (lower part); Figure S2: The effects of TLR4/LPS
activation and IMiDs on the release of soluble mediators by normal monocytes; a summary of the results for
15 healthy blood donors presented in Table 1 in the article; and Figure S3: A hierarchical clustering analysis of
the TLR4/LPS-induced stimulation of soluble mediator release by normal monocytes. Figure S4: The chemical
structure of the three IMiDs investigated (thalidomide, lenalidomide, and pomalidomide), their molecular weights,
and the molar concentrations corresponding to 5 µg/mL.
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